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Abstract 
Organic co-crystals are a class of promising materials in industries such as 
pharmaceuticals and energy industry. The work described in this thesis is the result of 
studying a series of organic co-crystals, which are synthesized by several different 
crystallization methods, and includes structures determined by single-crystal X-ray 
diffraction and powder X-ray diffraction. 
Chapter 1 is a general introduction to organic co-crystals and the phenomenon of 
polymorphism in organic crystalline materials. The importance of intermolecular 
interactions such as hydrogen bonding and π-π stacking interactions for the design of 
organic co-crystals are also highlighted. 
Chapter 2 describes the experimental techniques which have been used for 
studying organic co-crystals. These include co-crystallization methods and 
characterization methods such as single-crystal X-ray diffraction, powder X-ray 
diffraction, thermal analysis techniques and solid-state nuclear magnetic resonance. 
Chapter 3 reports two novel polymorphic co-crystal systems of trimesic acid 
(TMA) and tert-butylamine (TBA) with different stoichiometric ratios and analyses the 
crystal structures of the two polymorphic systems. 
Apart from the phenomenon of polymorphism of co-crystals of TMA and TBA, 
the structural diversity of other co-crystals of TMA and TBA are discussed in Chapter 4. 
In this chapter, all co-crystals of TMA and TBA are classified into four families based 
on the stoichiometric ratio between TMA and TBA, and the structural features of each 
family are investigated from the view point of hydrogen bonding with graph set notation. 
Chapters 5 and 6 demonstrate the processes of structure determination of co-
crystals of TMA and ʟ-arginine (Chapter 5) and the co-crystal of pillar[5]quinone and 
1,1,2,2-tetrachloroethane (Chapter 6) from powder X-ray diffraction data. 
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Chapter 1 Introduction 
1.1 Organic Co-Crystals 
The subject of organic co-crystals is not a new research direction, having been 
studied for over one hundred years. Originally, due to the lack of relevant knowledge of 
the intermolecular interactions and their effects on crystal formation, organic co-crystals 
were discovered primarily by chance. With passing time, more and more organic co-
crystals were synthesized and scientists gradually noticed that intermolecular 
interactions, especially hydrogen bonding, play a key role in the formation of organic 
co-crystals. In recent decades, due to its potential applications in the pharmaceutical 
industry, a great deal of attention has been attracted towards organic co-crystals 
research and, thus, the number of reported organic co-crystals has increased 
dramatically. 
1.1.1 The Definition of a Co-Crystal 
Although the area of co-crystals is flourishing, the issue of nomenclature for co-
crystals is not settled. Up to now, many papers and patents concerning co-crystals have 
been published and reported, and the number is still rising very quickly every year. 
However, the precise definition of co-crystals has been a controversial issue in the 
scientific community. Nevertheless, in general, the term co-crystal (also written as 
cocrystal) has, by common consent, been used to describe multi-component crystals. 
Currently, it is very difficult to know exactly when the term co-crystals came into 
use. However, in 2003, Desiraju[1] wrote an article insisting that the term co-crystals is 
ambiguous and suggesting that the term should be discarded; on the other hand, at the 
same time, Dunitz[2] argued that, although the term co-crystals is not well-defined, the 
term should be retained in consideration of its popularity and difficulty to displace. 
Then, in 2005, Aakeröy and Salmon,[3] while not providing a new definition of co-
crystals, listed some rules for co-crystals, such as that co-crystals can only be composed 
of neutral molecular species, only those compounds formed from reactants that are 
solids under ambient conditions can be considered as co-crystals, and that the amounts 
of components of co-crystals should be definite. Obviously, these rules greatly narrow 
down the definition of co-crystals and a large number of multi-component crystals are 
excluded, such as all crystals containing ions, all hydrates and solvates and many 
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inclusion compounds. Although some researchers [4-7] accepted one or all these rules 
and used them as the definition of co-crystals, not all researchers agree with these rules. 
For example, Bond[8] states that the requirement that all components are solids under 
ambient conditions is “contrived and inappropriate” and presents some compelling 
examples, such as the n-alkyl carboxylic acids (from formic acid up to tridecanoic acid) 
which form a series of two-component crystals with pyrazine. This series is obviously 
continuous. However, the members of the series from formic acid up to nonanoic acid 
are all liquids under ambient conditions, while those from decanoic acid and above are 
solids. Therefore, it is not appropriate to call the early members of this series solvates, 
while calling decanoic acid/pyrazine (and those with longer acids) a co-crystal. In 
addition, Bond also insisted that, due to the popularity of the term co-crystal and in 
order to avoid the scientific offence, researchers should use co-crystal only as “a 
synonym for multi-component molecular crystal”. 
Now, let us turn our attention to industry. Medications need to receive regulatory 
approval by governments. The European Medicines Agency (EMA) is the agency 
responsible for the scientific evaluation of medicines used in the European Union. So 
far, there is no guidance or definitions for co-crystals to be found on EMA’s website 
and only one pharmaceutical co-crystal drug, tramadol (hydrochloride)/celecoxib 
(EMEA-001279-PIP01-12), was approved by EMA in 2012. The UK equivalent to the 
EMA is the Medicines and Healthcare Products Regulatory Agency (MHRA). No 
information about co-crystals is to be found on their websites. 
With the rapid development of pharmaceutical co-crystals and in response to the 
need for regulatory guidance, the United States Food and Drug Administration (FDA) in 
December 2011 released draft guidance concerning the classification of pharmaceutical 
co-crystals of active pharmaceutical ingredients (APIs) and one of the main subjects of 
the draft guidance was the definition of co-crystals.[9] Subsequently, in February 2012, 
the Indo-U.S. Bilateral Meeting was held in India. Over 70 industrial and academic 
researchers from the US and India discussed the FDA guidance draft and the results of 
this discussion were summarised and published in April 2012.[10] According to this 
perspective, after discussing the FDA guidance draft, the participants in the meeting all 
strongly agreed that the term co-crystal needed to be defined more broadly. They 
proposed the following definition: “co-crystals are solids that are crystalline single 
phase materials composed of two or more different molecular and/or ionic compounds 
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generally in a stoichiometric ratio”. This definition includes solvates and hydrates but 
excludes many inclusion compounds. A year later, in April 2013, the FDA released the 
formal Guidance for Industry[11]: Regulatory Classification of Pharmaceutical Co-
Crystals. In that formal guidance, the FDA proposed the definition of co-crystals as 
“crystalline materials composed of two or more molecules within the same crystal 
lattice”. From that definition, we can see that the definition of co-crystal is also broadly 
defined to some extent. The components can be solid or liquid at room temperature. 
According to this view, it covers many types of compounds, including hydrates, 
solvates and inclusion compounds. 
However, this definition requires that the components in co-crystals should exist 
in their neutral states and interact via non-ionic interactions. In general, all definitions 
agree that both salts and co-crystals are multi-component crystals, but this does not 
mean a salt is a co-crystal. 
Conventionally, the way to determine if a multi-component crystal containing an 
organic acid and organic base is a salt or co-crystal depends on the position of the 
proton, i.e., it depends on whether proton transfer has occurred from the acid to the base 
or not. If the proton is attached to the base, proton transfer has occurred and the crystal 
is a salt. If the proton remains on the acid, no proton transfer has occurred and the 
material is a co-crystal. In general, the acid ionization constant, pKa, is employed for 
predicting solid-form molecular ionization states.[12-17] For larger values of ΔpKa 
(greater than 3) (where ΔpKa = pKa (base) – pKa (acid)) the acid and base will form a 
salt whereas for smaller values of ΔpKa (less than 0), they will form a co-crystal. 
However, in the range 0 < ΔpKa < 3, the acid and the base may form a salt, a co-crystal 
or a disordered crystal with partial proton transfer, depending on the specific packing 
environment. In the third case, in which the position of the acidic proton is not located 
on a specific molecule, how can we assign the multi-component crystal as a salt or a co-
crystal? 
In addition, in some cases, multi-component crystals can neither be classified as a 
salt or a co-crystal under the new definition of FDA. For example, in the course of 
studying fluconazole co-crystals with di-carboxylic acids, Kastelic and co-workers[18] 
synthesized three multi-component crystals, one containing a neutral maleic acid 
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molecule, an ionized maleic acid molecule and an ionized fluconazole molecule in the 
asymmetric unit. Is this a salt or a co-crystal? 
Although the final definition of co-crystal is still not settled, it is clear that the 
term co-crystal should be defined more broadly. Personally, in my thesis, the term of 
co-crystal refers to solids that are crystalline materials composed of two or more 
components in the same crystal structure, where the components may be neutral, ionic, 
atomic or molecular. 
1.1.2 The Developments of Organic Co-Crystals 
There are tens of thousands of papers relating to co-crystals and the number is still 
increasing rapidly. To the best of our knowledge, in 1844, German chemist Friedrich 
Wöhler published a paper concerning quinhydrone, which may be the earliest reported 
organic co-crystal.[19] The components of quinhydrone are 1,4-benzoquinone and 
hydroquinone in a 1:1 molar ratio. However, at that time, single-crystal X-ray 
diffraction had not been invented and chemists were not sure what types of 
intermolecular interactions existed. Even so, from then on, chemists began to synthesize 
all types of organic co-crystals by all kinds of methods. 
In the 20th century, a large number of organic co-crystals were synthesized and 
published. Originally, these co-crystals were often reported by chance, and almost all of 
these organic co-crystals contained aromatic compounds. Initially, chemists considered 
that π-π stacking interactions may be the necessary driving force between components 
in the formation of co-crystals but, with passing time, more and more co-crystals 
without aromatic components were synthesized and knowledge of the formation 
mechanisms of co-crystals accumulated gradually. Researchers realized that π-π 
stacking interactions are not necessary for the formation of many types of co-crystals. 
Other intermolecular interactions, especially hydrogen bonding, play a more important 
role in the formation of co-crystals and chemists now consider that intermolecular 
interactions can be viewed as a useful tool for the design of co-crystals.[20,21] 
After entering the 21st century, the field of co-crystals research has become more 
and more important. Due to its potential applications in improving the physicochemical 
properties of drug products, there has been enormous interest in pharmaceutical co-
crystals as a research area, with hundreds of publications relating to pharmaceutical co-
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crystals reported annually.[7,22] I will give more details about pharmaceutical co-crystals 
in the next section. 
Although pharmaceutical co-crystals have attracted extensive attention in the last 
ten years, we should realize that the subject of co-crystals research is not new and has 
already been the subject of research for more than 100 years. Apart from the 
pharmaceutical industry, other industries such as dyes and pigments,[23,24] organic 
nonlinear optical materials,[25-30] and biological research[31-34] have also studied co-
crystals for a long time and used co-crystals for commercial purposes. It is not hard to 
imagine that, in the future, an increasing number of co-crystal products will appear on 
the market. 
1.1.3 Applications of Organic Co-Crystals in Pharmaceuticals 
In the pharmaceuticals industry, every year many active pharmaceutical 
compounds are eliminated from further development due to poor solubility, poor 
dissolution rate or poor stability, rather than toxicity or lack of efficacy. In order to 
improve or overcome these weaknesses of drug candidates, a series of techniques have 
been used by pharmaceutical scientists. In general, the conventional approaches to 
enhancing the physical or chemical properties of active pharmaceutical ingredients 
(APIs) include the use of salt forms, hydrates, solvates and polymorphs. These methods 
have been shown to be successful to some extent, but scientists still attempt to 
investigate new and better ways for improving drug quality. Over the last decades, 
pharmaceutical co-crystals have become a promising and interesting approach for 
enhancing the quality of drugs during drug development. 
Pharmaceutical co-crystals are composed of an API (the main component) and 
other component(s), called coformers or excipients. Pharmaceutical co-crystals can 
offer great opportunities to improve the bioavailability of the API. In principle, by using 
coformers co-crystallized with APIs, the aim is to change the structure and composition 
of the drug and, thus, to greatly influence the biopharmaceutical properties of the drug 
rather than the efficacy of the drug. As mentioned before, the main idea of 
pharmaceutical co-crystals is to adjust the physiochemical properties of the solid form 
in which the API is administered, including melting point, solubility, dissolution rate 
and stability. All these properties have been studied extensively by chemists. For 
example, Stanton and Bak synthesized ten co-crystals of API AMG517 (an insoluble 
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small molecule VR 1 antagonist) with a series of coformers, and then compared their 
melting points with the API and their corresponding coformers. The result showed that 
all the melting points of these co-crystals fell between the melting point of API 
AMG517 and their corresponding coformers.[15,35] 
Among the physiochemical properties, solubility is a key parameter. Many drug 
candidates are discarded due to their low solubility. Shiraki and co-workers synthesized 
two novel co-crystals, exemestane (the API) with maleic acid and megestrol (the API) 
with saccharin. The results showed that co-crystallization improved initial dissolution 
rates compared to the respective pure crystals.[36] Bruni and co-workers prepared two 
new co-crystals of acyclovir/glutaric acid and acyclovir/fumaric acid to improve the 
solubility of acyclovir and its dissolution properties. The experiments showed that, 
compared to pure acyclovir, the water solubility of the acyclovir/glutaric acid was not 
improved, while for acyclovir/fumaric acid it was slightly increased. In the case of 
dissolution rates, both of these co-crystals dissolved much faster compared with pure 
acyclovir.[37] 
Stability of drugs is also an important issue for the pharmaceutical industry. In 
general, four aspects of stability need to be considered: relative humidity stress, thermal 
stress, chemical stability and solution stability.[38] Different aspects of stability need to 
be tested depending on the specific substance. In the case of co-crystals, researchers 
usually focus on solution stability, since dissociation of the co-crystals may result in 
precipitation of the single component crystal or a hydrate. For example, a 2:1 co-crystal 
of caffeine/oxalic acid was found to be stable at all relative humidities up to 98% RH 
for seven weeks and the co-crystal maintains its physical form for two days when it is 
slurried in water at room temperature.[39] In another example, Jung and co-workers 
reported two co-crystals of adefovir dipivoxil with suberic acid and succinic acid; both 
co-crystals displayed superior thermal stability compared to pure adefovir dipivoxil.[40] 
Due to the rapidly increasing number of pharmaceutical co-crystals, a series of 
reviews in this subject have been published giving more detailed examples about their 
physicochemical properties compared with the corresponding pure crystals.[7,22,38,41] 
Through a large amount of research, it has been found that pharmaceutical co-crystals 
are not only able to offer potential enhancements in solubility, dissolution rate and 
physical stability, but may also enhance other properties of drugs, including flowability 
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or compressibility.[42] According to the scientific literature, the development of this area 
has grown explosively, and a large number of literature reviews concentrated on 
pharmaceutical co-crystals from different perspectives and aspects have been 
published.[5,38,41,43-50] Owing to its popularity, there is no doubt that the number will 
continue to grow. These articles provide detailed and systematic overviews of 
pharmaceutical co-crystals, and also present and discuss almost all crucial issues of 
pharmaceutical co-crystals. 
From these articles, we can understand and learn about the development of co-
crystals, the importance of pharmaceutical co-crystals, and some very useful strategies 
for design and synthesis of pharmaceutical co-crystals. For example, we may take 
advantage of intermolecular interactions including hydrogen bonding and π-π stacking 
for the design of pharmaceutical co-crystals, and we also should realize that there is no 
general strategy for improving the physicochemical properties of all APIs. Thus each 
API must be investigated case by case. The basic preparation methods of 
pharmaceutical co-crystals, [41,45] including solution methods and solid-state grinding 
methods are summarized. The improved physicochemical properties of pharmaceutical 
co-crystals, including melting point, solubility, dissolution rate, stability, bioavailability, 
etc., are described in detail. The characterization techniques for pharmaceutical co-
crystals such as X-ray diffraction methods (single-crystal and powder XRD methods), 
spectroscopy techniques (infrared and nuclear magnetic resonance spectroscopy), 
thermal analysis (DSC and TGA), etc., are also mentioned, and plenty of 
pharmaceutical co-crystal examples are presented in these articles. In addition, the 
potential influence and growing trend of pharmaceutical co-crystals are also discussed. 
1.1.4 Design of Co-Crystals 
In general, there are many strategies for co-crystal design in the literature. 
However, these strategies are almost all based on empirical observations and the 
mechanism of co-crystal formation is not fully understood. Therefore, the design 
strategies for co-crystals are still being explored. As we all know, intermolecular 
interactions between components control the formation of co-crystals and, thus, the 
resulting co-crystal may have certain new physical properties that differ from the 
properties of the pure crystals of each component. In order to design and prepare co-
crystals to our requirement and benefit, comprehensive understanding of the 
intermolecular interactions in the co-crystals is essential. In general, in the process of 
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formation of organic co-crystals, intermolecular interactions are the driving force and 
the final co-crystals structure is controlled by these intermolecular interactions. Among 
these intermolecular interactions, hydrogen bonding and π-π stacking are among the 
most common influential intermolecular interactions in the process of formation of 
organic co-crystals. 
1.1.5 Hydrogen-Bonding Interactions 
Hydrogen bonding is the predominant interaction in the design of organic co-
crystals and, thus, having good understanding of hydrogen bonding is vital in crystal 
engineering. According to the latest definition of hydrogen bonding recommended by 
IUPAC in 2011,[51] a hydrogen bond is “an attractive interaction between a hydrogen 
atom from a molecule or molecular fragment X–H in which X is more electronegative 
than H, and an atom or a group of atoms in the same or a different molecule, in which 
there is evidence of bond formation.” The hydrogen-bonding interaction between water 
molecules is the prototype of all hydrogen bonds. Owing to the big difference in electro-
negativity between the O and the H atoms, the O–H bonds of each water molecule are 
polar. Thus, the distance between two neighbouring water molecules (referring to the 
distance of the O–H···O hydrogen bond) is shorter than the sum of the van der Waals 
radii for the O and H atoms. Therefore, a hydrogen bond forms. Today, a typical 
hydrogen bond is described as X–H···Y–Z, where the three dots denote the hydrogen 
bonding, X–H represents the hydrogen bond donor and Y represents the hydrogen bond 
acceptor. Y may be an atom, or part of an anion or a molecule. 
The hydrogen bond was discovered almost 100 years ago and has been a subject 
for research ever since.[52] However, because of its importance for chemistry, it is a vital 
subject which deserves further research. Due to the short contact distances and specific 
directionalities associated with hydrogen bonding, it can easily be recognized in crystal 
structures. Moreover, hydrogen bonding is a vital tool in crystal engineering. Strong 
hydrogen bonding, such as O–H···O, N–H···O or O–H···N, is very common and 
important in organic solids but, in addition, weak hydrogen bonding, including  
C–H···O,[53] C–H···N, and N–H···π,[54] is also significant in organic crystal structures. 
In order to describe hydrogen-bonding interactions more easily, a straightforward 
method is required. Etter and co-workers [55,56] created a graph-set system for describing 
hydrogen-bonding patterns. 
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Figure 1.1. Hydrogen-bonding ring of the benzoic acid dimer. 
Generally, in order to make the graph-set method applicable to many different 
kinds of systems, a straightforward approach has been developed using four main types 
of motif: chains (C), dimers or other finite set (D), rings (R), and intramolecular 
hydrogen bonds (S). In each motif, the numbers of donors and acceptors are assigned as 
subscripts and superscripts, respectively, and the number of atoms in the pattern is 
indicated in parentheses. For example, the hydrogen-bonding interaction between a 
benzoic acid dimer can be described by graph set )8(
2
2R (see Figure 1.1). Due to its 
simplicity, the graph-set approach has been widely accepted and used by researchers to 
describe hydrogen bond patterns. 
At the same time, some empirical but very useful guidelines have also been 
proposed for the design of hydrogen-bonded crystals. [56] There are three general rules: 
1. All good proton donors and acceptors are used in hydrogen bonding; 
2. Six-membered ring intramolecular hydrogen bonds form in preference to 
intermolecular hydrogen bonds; 
3. The strongest hydrogen-bond donors and acceptors that remain after the 
formation of intramolecular hydrogen bonds form intermolecular hydrogen bonds 
to one another. 
Apart from these three general rules, some specific hydrogen bonding rules are also 
summarized by Etter.[56] By using these guidelines, it might be possible to design co-
crystals with a certain degree of accuracy. Even so, it is still essential not only to 
understand the structure of individual molecules, but also to be able to exploit the 
hydrogen bonding rules skilfully. 
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Figure 1.2. Homomeric (I and II) and heteromeric (III) hydrogen-bonding dimers. 
For example, since carboxylic acids and suitable N-containing compounds such as 
amides have self-complementary hydrogen-bond donor and acceptor groups, they can 
form homomeric hydrogen-bonding dimers (Figures 1.2 I and 1.2 II, homomeric 
hydrogen-bonding dimers) in their pure crystal structures through C=O···H–O and 
C=N···H–O hydrogen bonds, respectively. If we use suitable combinations of 
carboxylic acids and N-containing compounds as components for assembly of co-
crystals, they can instead interact to form heteromeric systems (Figure 1.2 III, 
heteromeric system) rather than homomeric systems. In fact, studies of a series of this 
type of co-crystals (acid-base type) have proven to be extremely successful.[57-61] In all 
these cases, the two components form heteromeric systems as expected and the resulting 
hydrogen-bonding pattern is very common and clear. The preference to form 
heteromeric systems is partly because the forces between the two acid-base components 
are stronger than those in each homomeric system.[62] 
It is worth noting that, although the use of empirical hydrogen bonding rules can 
be very helpful in the design of co-crystals, prediction of the structure of co-crystals is 
still difficult. In the last couple of decades, with the development of computational 
chemistry, researchers developed several new algorithms and mathematical models [63-70] 
to predict crystal structure. Combined with the statistical analysis of hydrogen bonding 
in the Cambridge Structural Database (CSD), researchers use computer programs to 
predict hydrogen bonding in crystal structures leading to prediction of single component 
crystal and co-crystal structures. Although, progress in this field has led to more and 
more successful predictions, the challenge of crystal structure prediction is far from 
solved and needs further substantial investigation. 
1.1.6 π-π Stacking Interactions 
As mentioned above, hydrogen bonding is not the only important type of 
intermolecular interaction in organic co-crystals, and the π-π stacking interaction is also 
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significant. The reason why π-π stacking interactions are important in organic co-
crystals is that many organic co-crystals contain phenyl rings. Therefore, π-π 
interactions may have influences on molecular arrangement of these crystal 
structures.[71] In addition, π-π stacking interactions are widespread in the natural world, 
such as the structures of DNA, RNA, peptides and proteins. 
The π-π stacking interactions (also called aromatic interactions) refer to the 
intermolecular interactions between molecules containing aromatic fragments.[72,73] In 
general, π-π stacking interactions are composed of van der Waals interactions and 
electrostatic forces, but the relative contribution of these components are complicated, 
depending on the nature of the aromatic rings involved and their geometries.[74] It is not 
easy to propose straightforward rules as for hydrogen bonding. Even so, several basic 
geometries of π-π stacking interactions are attractive, and are commonly observed. In 
consideration of the electron distribution and their shapes, these π-π stacking 
interactions can be summarized into three types: (I) parallel type, (II) parallel offset type 
and (III) T-shaped (edge-to-face) type (Figure 1.3).[75,76] 
As an example of the parallel (also called face-to-face) type, the 1:1 co-crystal of 
benzene/hexafluorobenzene is an ideal example.[77] The structure of this co-crystal 
contains stacks of alternating benzene and hexafluorobenzene molecules and this 
parallel stacking arrangement of benzene and hexafluorobenzene maximises the 
electrostatic interaction energy.[78,79] Offset type π-π stacking interaction is widespread 
in proteins and DNA; this arrangement can minimise electron repulsion and maximise 
the attraction between adjacent aromatic rings. Edge-to-face type π-π stacking 
interactions describe the T-shaped, perpendicular arrangement of adjacent aromatic 
molecules, often involving CH··· π interactions, which is found in the crystal structure 
of benzene. 
 
Figure 1.3. Three types of π-π stacking interactions. 
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In addition, π-π stacking interactions in organic co-crystals can be affected by 
different substituents. An electron donating substituent (e.g., –NH2, –NR2, –OH) will 
increase the electron density on the aromatic ring, consequently increasing the electron 
repulsion. An electron withdrawing substituent (e.g., –NO2, –CF3, –CN) has the 
opposite effect. Therefore, when two aromatic molecules are polarized, like 
polarizations repel but unlike polarizations attract. 
1.1.7 Other Intermolecular Interactions 
Apart from hydrogen bonding and π-π stacking interactions, other intermolecular 
interactions such as halogen bonding interactions [80,81] have also been used in the 
design of co-crystals. In addition, many co-crystal structures are controlled by not just 
one type of intermolecular interaction (for example, hydrogen bonding) but secondary 
interactions such as π-π stacking or halogen bonding also play an important role in 
assembling their structures.[82] On the whole, the strategies for design and preparation of 
co-crystals are still being investigated and crystal structural prediction remains a far-
away goal. 
1.2 Polymorphism of Organic Crystals 
Polymorphism is a very interesting solid-state phenomenon. The phenomenon of 
polymorphism in organic crystals was discovered in 1832, when Wöhler and Liebig 
reported two polymorphs of benzamide[83]. As single-crystal X-ray diffraction was not 
available at that time, scientists had no idea about these two polymorphic structures. In 
1936, Robertson determined the crystal structure of α-resorcinol using single-crystal 
X-ray diffraction. Then, in 1938, Robertson and Ubbelohde [84] discovered a new form 
of resorcinol (β) and determined the structure, representing the first time that detailed 
structural information about polymorphism had been established. Subsequently, many 
more new polymorphs of organic compounds were published. About half a century ago, 
driven in part by regulatory issues in the pharmaceutical industry, scientists gradually 
recognized the importance of polymorphism. In the pharmaceutical industry, the 
differences in the structures of polymorphs of a given API result in different physical 
properties, such as solubility, melting point, stability, etc. As a consequence, the 
polymorphic form affects the quality of the drug. Therefore, all polymorphic forms of a 
given drug must be identified. In most cases, pharmaceutical companies would chose 
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the most stable form of the API as the designed product, because the most stable form 
would be reliable and robust during the course of drug manufacture. 
With the passing of time, many APIs and drugs turn out to have more than one 
form.[85-91] For aspirin, also known as acetylsalicylic acid, the first form was reported in 
1964,[92] while a new form was reported in 2005.[93] Nowadays, apart from the 
pharmaceutical industry, polymorphism has been studied extensively and has found 
wide potential applications in many research areas, such as crystal engineering, which 
attempts to understand the intermolecular interactions of organic crystals [94,95] and other 
industries, such as dyes and pigments.[96] From the literature, we can see that the 
number of papers concerning polymorphism is numerous and increases dramatically 
every year. 
1.2.1 The Definition of Polymorphism 
Similar to the definition of co-crystals, the precise definition of polymorphism is 
also disputable. From the literature, we can find several different definitions of 
polymorph. An early and well-known definition given by McCrone in his book “Physics 
and Chemistry of the Organic Solid State” in 1965 is: “A polymorph is a solid 
crystalline phase of a given compound resulting from the possibility of at least two 
different arrangements of the molecules of that compound in the solid state”. 
Subsequently, different definitions have arisen in the literature [97,98]. In 1987, Sharma 
suggested[97] that polymorphism means “different crystal forms, belonging to the same 
or different crystal systems, in which identical units of the same element or identical 
units of the same compound, or identical ionic formulas or identical repeating units are 
packed differently”. In 2007, Gavezzotti proposed a definition of polymorphism with 
three key points: “polymorphs are a set of crystals (a) with identical chemical 
composition, (b) made of molecules with the same molecular connectivity but allowing 
for different conformations by rotation about single bonds, and (c) with distinctly 
different three-dimensional translational periodic symmetry operations”. 
According to the latest definition of polymorphism from the guidance of the U.S. 
FDA in 2013, polymorphism means “the different crystal forms of the same chemical 
compounds or substance; this may include solvation or hydration products (also known 
as pseudo-polymorphs or solvatomorphs) and amorphous forms.” This definition is 
quite similar to the definition proposed by European Medicines Agency (EMA) in 
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2005.[99] EMA defined polymorphism as “the occurrence of different crystalline forms 
of the same drug substance; this may include solvation or hydration products (also 
known as pseudopolymorphs) and amorphous forms.” Obviously, both the FDA and the 
EMA define the term polymorphism in a broad sense. However, the term pseudo-
polymorph may confuse. Thus, it is better not to use the term pseudo-polymorph but 
instead to use terms such as solvate or hydrate. Excluding solvates, hydrates and 
amorphous solids allowed by the FDA and the EMA definitions of polymorphism, 
generally polymorphism is defined in a more rigorous manner to include only a set of 
materials with identical chemical composition (as in the definition of Gavezzotti 
discussed above). 
When different conformers of the same molecule pack in different crystal forms, it 
is called conformational polymorphism. In general, organic molecules with multiple 
flexible torsional angles (single bond torsions) can exhibit several possible 
conformations, and therefore have a greater chance of exhibiting conformational 
polymorphism.[85,100-102] For example, aripiprazole (Figure 1.4), used as an antipsychotic 
drug, was approved by the U.S. FDA for schizophrenia in 2002 and the EMA in 2004. 
Up to now, six polymorphs of aripiprazole have been reported.[85] The molecular 
structure of aripiprazole has seven freely rotatable bonds, which can explain why 
aripiprazole is such a rich conformational polymorphic system. Another reason may be 
that there are many different functional groups in aripiprazole molecule. Therefore, 
various hydrogen-bond donor and acceptor groups are able to be utilized in different 
crystal forms; thus, the variety of possible molecular conformations and hydrogen 
bonding schemes lead to a wide variety of plausible crystal packing arrangements.[103] 
Apart from conformational polymorphism, in other cases, all components have the 
same or almost the same conformation but, owing to different spatial arrangements of 
these components (resulting from different intermolecular interactions), different crystal 
 
Figure 1.4. The structure of aripiprazole. 
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forms arise. The nomenclature of polymorphs does not follow a specific rule, and labels 
such as I, II, III… or α, β, γ… are often used to assign the different polymorphs. 
1.2.2 The Different Properties of Polymorphs 
Since different polymorphs have different physicochemical properties, scientists 
attempt to understand the structure-property relationships in polymorphs of the same 
substance. As time goes on, more and more knowledge in this regard is accumulated but 
the mechanism of polymorphism is still not fully understood and still remain mysterious 
in certain aspects.[104] In terms of thermodynamics, the relationship between two 
polymorphs can be enantiotropic or monotropic, depending on their relative stability as 
a function of temperature and pressure. 
For a monotropic relationship between two polymorphs (Figure 1.5, left), the 
stable and the metastable polymorphs can coexist only as a result of kinetic stability, 
and the transformation from the metastable polymorph to the stable polymorph is 
irreversible. On the other hand, for an enantiotropic relationship between two 
polymorphs (Figure 1.5, right), the transformation between the two polymorphs is 
reversible below their melting points by means of heating and cooling. Thus, over a 
certain temperature range, just one polymorph is stable, the other polymorph being 
unstable and will transform to the stable form. 
It is not hard to image that the polymorphic form with the lower free energy is 
more stable than the form with higher free energy. In both systems (monotropic system 
and enantiotropic system), the metastable polymorph is unstable and should transform 
to the stable form. The life-time of the metastable polymorph depends on the rate of 
transformation into the stable form. In practice, the rates of transformation may range 
 
Figure 1.5. Types of polymorphism (monotropic and enantiotropic relationships). 
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from rapid to extremely slow, depending on the nature of the molecular structures, and 
there are no general rules for all polymorphic systems. 
As mentioned above, when external conditions such as temperature or pressure 
are changed, polymorphic transformations can occur. Therefore, it is possible to 
distinguish between monotropic and enantiotropic systems by using thermal analytical 
techniques, such as Differential Scanning Calorimetry (DSC), to help us understand the 
relationship between polymorphs. In addition, DSC is also used to measure the melting 
points and the transformation temperature between different polymorphic forms. 
As an example, we consider paracetamol (Figure 1.6), also called acetaminophen. 
According to the literature, there are three polymorphs of paracetamol, numbered I, II 
and III. The crystal structure of each polymorph has been determined.[105,106] Form I is 
stable at room temperature but has poor compressibility, while form II exhibits good 
compressibility but is not easy to isolate. Form III was reported to exist in 1982 but it is 
only recently determined (2009). That crystal structure was determined using high 
quality powder X-ray diffraction data by Perrin and co-workers.[107] Researchers have 
attempted to understand the relationships between the three polymorphs by DSC.[108,109] 
First of all, heating form I (the commercially available form) to 190 °C (the melting 
point of form I is 170 °C) followed by rapid cooling to 25 °C, produces an amorphous 
form. Heating the amorphous form to about 75 °C results in the formation of form III 
(form III can only prepared by this method). Further heating to around 140 °C causes 
form III to transform to form II and finally melts at 159 °C. From the results of DSC 
experiments,[108,109] the relationships among these three polymorphs is that form I is the 
most stable form and it is monotropic with respect to forms II and III; forms II and III 
are enantiotropically related, with the transition temperature at 140 °C. 
 
Figure 1.6. The structure of paracetamol. 
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1.2.3 Polymorphism in the Process of Crystallization from Solution 
For a long time, it was quite difficult to understand why one polymorph is formed 
under certain conditions from solution, rather than another form. After long-term and 
detailed research work, scientists concluded that the preferential formation of a given 
polymorph under a particular set of experimental conditions depends largely on kinetic 
factors and the mechanism of the crystallization process.[110,111] In principle, the 
crystallization process of polymorphic systems involves three aspects: nucleation, 
crystal growth and the transformation from less stable forms to more stable forms. The 
processes of nucleation and crystal growth are controlled by kinetic factors. First of all, 
components aggregate into small clusters. These small clusters are unstable and are able 
to disperse into atoms, ions or molecules again; thus, at this stage, the process is 
reversible. As time goes on, these clusters become stable nuclei. Once the nuclei exceed 
a critical size, they finally grow into crystals. Therefore, the arrangement of components 
in the first batch of stable nuclei plays a key role in dictating the crystal structure (and 
hence the polymorph) of the crystal formed finally. 
In general, all conditions involved in a specific crystallization process may affect 
the formation of specific polymorphs. These conditions include solvent effects,[112-114] 
additives, [115,116] temperature or pH values [117] as well as the crystallization methods. 
1.2.4 Characterizations of Polymorphs 
When a given compound has two or more polymorphs, the relationship among the 
different forms can be established using a combination of characterization techniques. 
Apart from DSC mentioned above, other analytical techniques used extensively are 
single-crystal X-ray diffraction (SCXRD), powder X-ray diffraction (PXRD), solid-
state NMR, hot stage microscopy, etc. 
SCXRD is the more powerful tool for polymorphic characterization as it can 
provide complete 3D structural information and atomic positions. However, sometimes 
it is not easy to obtain suitable single crystals for this technique. In such cases, PXRD 
becomes the alternative tool. PXRD is not only used for phase identification of different 
polymorphs but, nowadays, it is also used for structure determination. The details in this 
regard are given in chapter 2. Spectroscopic techniques, such as solid-state NMR, are 
very useful for characterization of polymorphs and can be used to study the different 
chemical environments of the nuclei in different polymorphs. In addition, hot stage 
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microscopy is used to determine the phase transition temperature (if one exists) and help 
to identify the changes in crystal shape. It should be noted that the techniques listed 
above are only a few the methods used for characterizing polymorphs. As technology 
evolves, new techniques will emerge in the future. 
1.2.5 The Polymorphism in Co-Crystals 
There is no doubt that, just like singe-component crystals, co-crystals are also able 
to exhibit polymorphism, i.e., different packing arrangements but with the same 
composition in the crystal structures. The phenomenon of polymorphism in single-
component crystals has been recognized and studied for a long time and research in this 
regard is still ongoing. However, recently the subject of co-crystals has seized the 
attention of a great number of chemists. Few polymorphic co-crystal systems have been 
reported in the literature compared to single-component crystals and research on 
polymorphism in the case of co-crystals is still at a relatively early stage. 
As discussed above, polymorphism is an important issue in the pharmaceutical 
industry in relation to human safety. Generally, drug products need to receive regulatory 
approval for only one particular crystal form or a specified polymorph by the relevant 
government agency in different countries (such as FDA in the U.S., Medicines and 
Healthcare Products Regulatory Agency (MHRA) in the U.K., or the European 
Medicines Agency for EU). If a new drug can exist in different solid forms that differ in 
their physicochemical properties (which, consequently, would affect the drug product 
performance or stability), then the appropriate solid form must be specified. Therefore, 
in the pharmaceutical industry, lots of money and time are being spent on this aspect 
every year. Similarly, polymorphism of co-crystals is also a crucial issue, if 
pharmaceutical co-crystals are to reach the pharmaceutical market. However, only 
recently, pharmaceutical researchers recognized the importance of co-crystals, and 
investigations regarding polymorphism of co-crystals are less frequent. Therefore, 
understanding the details of polymorphism of co-crystals and systematic studies 
regarding co-crystals are still evolving. 
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To date, only limited examples of polymorphic co-crystal systems have been 
reported in the literature. For example, Braga and co-workers reported a 1:1 co-crystal 
system of 4,4’-bipyridine and pimelic acid, which has three polymorphs.[118] Forms I 
and II both convert into form III at high temperature, with forms II and III being the 
thermodynamically stable forms at room temperature and high temperature, respectively. 
Moreover, based on the results from X-ray diffraction and solid-state NMR data, they 
concluded that no proton transfer takes place from the acid to the base. Halasz and co-
workers discovered another 1:1 co-crystal system of 4,4’-bipyridine and 4-oxopimelic 
acid, which has two conformational polymorphs.[119] Form I was obtained by 
crystallization from ethanol, while form II was obtained from methanol. Form II can 
transform to form I by heating or by mechanochemical methods. 
Ethenzamide (Figure 1.7), an analgesic drug, is used for the relief of fever, 
headaches and other minor pains. However, due to its poor water solubility, it is mainly 
used in combination with other ingredients, such as paracetamol, aspirin, caffeine and 
ibuprofen, etc. In order to improve its solubility in water and other physicochemical 
properties, several co-crystals of ethenzamide have been synthesized. Among these co-
crystals, some exhibit polymorphism. For example, a 1:1 co-crystal of ethenzamide and 
gentisic acid has been reported by Aitipamula and co-workers, which has three 
polymorphs.[120] Form I was obtained by solution crystallization or solid-state grinding, 
while forms II and III were obtained only by solution crystallization. Forms II and III 
convert into form I by solid-state grinding. Apart from this co-crystal system, 1:1 co-
crystal systems of ethenzamide with saccharin,[121] 3,5-dinitrobenzoic acid [122] and 
ethylmalonic acid [123] exhibit two polymorphs in each case. 
 
Figure 1.7. The structure of ethenzamide. 
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Another interesting example of a pharmaceutical substance which exhibits 
polymorphism in co-crystal systems is carbamazepine (Figure 1.8). For example, the 
1:1 co-crystals of carbamazepine with nicotinamide,[124] saccharin[124] and 
isonicotinamide[125] have two polymorphs in each case, and a 2:1 co-crystal of 
carbamazepine/malonic acid has two polymorphs.[126] Other pharmaceutical co-crystals 
also exhibit polymorphism.[127-130] There is no doubt that, with the development of co-
crystals, the number of polymorphic co-crystal systems will increase over time. 
In practice, the process of searching for all different solid forms of a given 
compound is called polymorph screening. In principle, a comprehensive polymorph 
screening process is attempted to search for every solid form that can be prepared 
experimentally. In such a screening process, the number of preparation strategies should 
be as high as possible. However, due to limited budget and the current preparation 
strategies, no polymorph screening process can guarantee that all polymorphs of a given 
substance have been found. In fact, the process is still mainly based on a trial-and-error, 
case-by-case approach. There is no general method for finding all possible forms of a 
given molecule. As can be imagined, this process is often extremely time-consuming. 
Due to the importance of polymorphism, scientists are attempting to develop 
models by using computer techniques to help predict the full range of polymorphs that 
can be formed by a given molecule. In the last decades, many theoretical approaches 
have been proposed and some successes were achieved.[101,131-136] These results are 
encouraging but, in the long run, there is still a lot of work needed to be done in order to 
achieve this goal. 
 
Figure 1.8. The structure of carbamazepine. 
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1.3 The Purpose of the Thesis 
As mentioned above, co-crystals have great potential applications in the 
pharmaceutical industry and a substantial amount of research has been done on this area. 
However, in practice, there are few commercial pharmaceutical co-crystals that have 
been approved for use in the pharmaceutical market. Therefore, this area still requires 
further investigation before co-crystals are able to be treated as a reliable technology in 
the pharmaceutical industry. In addition, polymorphism is an important issue in the 
pharmaceutical industry, as different polymorphs of a given API may affect the quality 
of the new drug product. During the development of a new drug, in order to ensure the 
required product quality, pharmaceutical companies have to spend substantial amounts 
of money and time to identify all polymorphic forms of the new drug. In the course of 
investigating pharmaceutical co-crystals, few polymorphic systems have been reported 
(as mentioned above), therefore, if pharmaceutical co-crystals are to be able to reach the 
market, understanding the details of polymorphism of pharmaceutical co-crystals is 
quite significant. 
At present, most research on pharmaceutical co-crystals is related to a specific 
API, such as aspirin, paracetamol, or carbamazepine. That is to say, research on 
pharmaceutical co-crystals is still on a case by case basis. There is no general or 
systematic method for studying pharmaceutical co-crystals. Since the number of APIs is 
increasing every year and many substances can be used as coformers or excipients, there 
is no doubt that studying pharmaceutical co-crystals is extremely time-consuming. It is 
necessary to develop general and systematic approaches for studying pharmaceutical co-
crystals. Among these API compounds, a number of commonly used drugs are aromatic 
compounds containing carboxylic acid functional groups, such as ibuprofen, aspirin, 
ketoprofen, etc. Through carboxylic acid groups, molecules of these drugs can co-
crystalize with other excipients via hydrogen bonding.  
Based on the importance of these drugs, we have attempted to develop a general 
co-crystallization strategy involving aromatic compounds containing carboxylic acid 
functional groups (trimesic acid) with two organic compounds containing amine 
functional groups (tert-butylamine and ʟ-arginine), in order to investigate and 
demonstrate the structural diversity of these type of pharmaceutical co-crystals (in 
which one component is an API containing an aromatic ring and carboxylic acid 
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functional groups). We also used different co-crystallization conditions, including 
different solvents and different stoichiometric relationships between the components 
and different co-crystallization methods, to investigate the polymorphism in these co-
crystal systems very comprehensively. 
From the view point of crystal engineering, in the course of studying co-crystals, 
carboxylic acids and suitable N-containing compounds such as amides have been 
extensively investigated and the resulting co-crystals can form heteromeric systems 
with hydrogen-bonding patterns. Organic amines (NH2R) are compounds with 
functional groups that contain a basic nitrogen atom with an electron lone pair. 
Obviously, amines also belong to N-containing compounds and can be used as 
hydrogen-bonding acceptors with carboxylic acids. In our present work, we focus on 
co-crystals of trimesic acid (TMA) with tert-butylamine (TBA) and co-crystals of 
trimesic acid with ʟ-arginine, both of which are examples of carboxylic acid-amine 
heteromeric systems. 
TMA is an important aromatic carboxylic acid and has attracted much attention 
because of its interesting structure. The TMA molecule has three carboxylic acid groups 
and can exist in the solid state in four different forms (corresponding to different levels 
of deprotonantion: H3TMA, H2TMA
–, HTMA2– and TMA3–). Therefore, the structural 
diversity of co-crystals containing TMA is very interesting in our research, particularly 
with regard to the phenomenon of polymorphism. In Chapter 3, we present two 
polymorphic co-crystals of TMA and TBA. One is a solvated polymorphic system with 
2:5:3 ratio of TMA, TBA and methanol; the other is a non-solvated polymorphic system 
with 2:3 ratio of TMA and TBA. Apart from these two polymorphic systems of TMA 
and TBA, we also discovered a series of solvates and hydrates of TMA and TBA with 
different ratios by using a series of solvents and crystallization methods. We discuss the 
structural diversity of the co-crystals of TMA and TBA in more detail in Chapter 4. In 
Chapter 5, we report and discuss the structures of co-crystals of TMA and ʟ-arginine. 
In addition, grinding methods have recently become a popular method for 
preparing pharmaceutical co-crystals; therefore, determining crystal structures directly 
from powder X-ray diffraction data has become a more important technique for 
characterization of co-crystals. Pillar[5]quinone is a potential molecule for molecular 
recognition and supramolecular host-guest chemistry. However, due to the fact that 
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large single-crystals of pillar[5]quinone cannot be prepared, the structure of 
pillar[5]quinone has not yet been reported. Therefore, in Chapter 6, we determined the 
structure of the co-crystal of pillar[5]quinone and 1,1,2,2-tetrachloroethane (solvent) 
directly from powder X-ray diffraction data. 
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Chapter 2 Experimental Techniques 
2.1 Co-Crystallization Methods 
Co-crystallization is the process of simultaneous crystallization of more than one 
component together into one crystal structure. According to the literature, there are a 
range of methods for the preparation of organic co-crystals. In general, the most 
common preparation methods are based on solution-state crystallization [137-140] and 
solid-state grinding.[50,141,142] 
Solution methods are the simplest and commonest ways to prepare organic co-
crystals and are easy to scale up for manufacturing in industry. In addition, co-crystals 
suitable for single-crystal X-ray diffraction can only be prepared through solution 
crystallization methods. Therefore, in the course of studying co-crystals, solution 
methods are the preferred way of synthesizing organic co-crystals. However, solution 
methods also have disadvantages. First, all components need to be suitably soluble in 
one solvent or mixture of solvents. Second, if the difference in solubility of the different 
components is large, the different components may crystallize separately. Third, in 
some cases, organic solvent molecules have been incorporated into crystal structures 
which causes crystals to be unstable at room temperature. Last, but not least, the 
processes of solution crystallization may be time-consuming and not 
environmentally-friendly. 
Grinding methods are the alternative way to prepare organic co-crystals. These 
methods do not require the components to be soluble and, due to the absence of solvent 
or the use of only small amounts of solvent (so called liquid-assisted grinding), these 
methods are much more “green”. Grinding methods are also generally quicker than 
solution methods. In addition, solid-state grinding may provide a way to synthesize new 
co-crystals which cannot be obtained by solution methods.[143] 
Some researchers have attempted to prepare co-crystals containing the same 
components by both of these methods in order to compare the results.[121,144-149] These 
studies show that, in some cases, co-crystals obtained by grinding methods are the same 
as those from solution methods.[146,148] However, some co-crystals can only be obtained 
from one of the two methods.[121,147,148] For example, Aitipamula and co-workers[121] 
reported two polymorphs of the 1:1 co-crystal of ethenzamide and saccharin. Both 
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polymorphs could be obtained by slow evaporation from different solvents (methanol 
and acetonitrile). However, metastable form II was the only product from both neat 
grinding and solvent-assisted grinding. In other cases, co-crystals synthesized from the 
two methods are quite different.[145,149] For example, Trask and co-workers[149] 
attempted to synthesize co-crystals of caffeine with formic acid, acetic acid and 
trifluoroacetic acid via solid-state grinding and solution methods. Their results showed 
that, although some co-crystals can result from both methods, the co-crystals obtained 
from each method may have different stoichiometries. Furthermore, different co-crystal 
polymorphs can be obtained from each method. Therefore, in the course of studying co-
crystals, employing more than one experimental method may result in the formation of 
a wider diversity of new co-crystals. 
As research on organic co-crystals continues, apart from these two main methods, 
many other preparation techniques are emerging, such as the anti-solvent method,[150,151] 
reaction method,[152] co-crystallization assisted by ultrasound,[153,154] supercritical fluid 
method,[155,156] sublimation method,[128] slurry method,[157,158] and other strategies.[159-161] 
2.1.1 Co-Crystallization from Solution 
As mentioned above, the formation of co-crystals based on solution crystallization 
is very important. In general, solution methods for growing co-crystals mainly include 
slow evaporation and slow cooling. In order to grow co-crystals from solution 
successfully, we not only need to understand the intermolecular interactions among the 
components but, we also need to comprehend the co-crystallization process. In practice, 
the process of growing co-crystals from solution is quite complicated and many 
variables need to be considered in the process. 
According to the classical view of crystal growth theory, the crystallization 
process from solution consists of two steps: nucleation and crystal growth.[162,163] First, 
at constant temperature and pressure, a number of small nuclei form from the 
components (ions and/or molecules). These nuclei are unstable and are able to disperse 
into their individual components again. As the solvent evaporates, these nuclei become 
stable and attain a critical size. Thus, the first, nucleation step is achieved. The next step 
is crystal growth. In this second stage, nuclei begin to grow and ultimately become the 
final crystals. This stage is affected by the nature of the solvent and any additives 
present. 
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In practice, preparing co-crystals of new components is based on experience. No 
general recipe exists. Therefore, a large number of different experimental conditions 
need to be tested for every system. Before trying to synthesize co-crystals from new 
materials, there are several important points to be aware of: 
1. Pure materials should be used whenever possible as the impurities may 
affects the crystal growth. 
2. The crystals obtained from solution do not necessarily contain all the 
solute components that are present in the solution. Thus, the crystals may 
contain just one component or may be a solvate of one component. 
3. The process of co-crystallization may last over days, weeks or even 
months, so it is important to be patient and not to disturb the set up. 
4. It is much better to leave the crystals in the liquor from which they have 
grown, particularly if there are solvent molecules incorporated into the 
crystal structures, as they may deteriorate on being removed from the 
mother liquor. 
Slow evaporation is the simplest and the most important solution method for 
growing co-crystals. The process is to prepare a saturated or nearly saturated solution of 
all the components in a vial with a suitable solvent or mixture of solvents, then allow 
the solvent to evaporate undisturbed. Many co-crystals have been synthesized 
successfully by this method.[138,139,164-166] 
As for crystallization of a single-component crystal, solvent selection is an 
important issue in the process of co-crystallization. Ideally, if all components have 
similar, moderate solubility in a specific solvent or mixture of solvents, then 1:1 co-
crystals can be formed when equal molar components are dissolved in the solvent(s).[137] 
At present, the role of solvent in the formation of co-crystals is not fully understood. In 
some cases, changing the solvent will change the intermolecular interactions and cause 
different co-crystals to form. For example, in the course of studying co-crystals of 
4-oxopimelic acid and 4,4-bipyridine, Halasz and co-workers[119] obtained two 
conformational polymorphs of a co-crystal with 1:1 molar ratio just by using different 
solvents (methanol and ethanol). 
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However, in some cases, slow evaporation of solvent may not lead to the 
formation of co-crystals. Instead, something else, such as a single-component crystal, a 
single-component solvate, a new polymorph of one component or mixtures of 
single-component crystal(s) and the co-crystal may form.[137,167,168] For example, 
Wenger and Bernstein[167] attempted to co-crystallize asparagine or glutamine with 
oxalic acid. Unexpectedly, they obtained two new hydrates of oxalic acid instead of co-
crystals. In such cases, it is better to use non-equivalent component concentrations or to 
change the solvent system or even to try another co-crystallization method. In addition, 
co-crystals with the same components but different stoichiometries may be formed from 
different crystallization conditions (such as different solvents or different 
concentrations).[169,170] 
Slow cooling is the most widely used scale-up crystallization method in the 
pharmaceutical industry. If co-crystals can be prepared by cooling crystallization, the 
same equipment used for conventional cooling crystallization can also be used for co-
crystal crystallization. In theory, this method works well by following the rule: soluble 
hot and insoluble cold. This method for co-crystallization is carried out by preparing a 
saturated (or near saturated) solution of all components at a higher temperature, then 
slowly reducing the temperature. Some co-crystals have been prepared successfully by 
this method.[31,42,171-175] For example, Zhang and co-workers[171] reported a 2:1 co-
crystal of theophylline and oxalic acid by cooling crystallization in a 
chloroform/methanol mixture (4:1, v:v). Sheikh and co-workers[176] demonstrated a 
generic, scalable, slow-cooling crystallization methodology for co-crystallization of 
carbamazepine/nicotinamide as a model system. This example shows that some 
techniques and equipment commonly used in single-component crystallization can also 
be used to control the process of co-crystallization with the desired benefits. 
2.1.2 Co-Crystallization from Solid-State Grinding 
The solid-state grinding method is not a new method for preparing co-crystals. In 
fact, the first reported organic co-crystal, quinhydrone, was obtained using solid-state 
grinding by Friedrich Wöhler in 1844[177]. In the past few decades, preparing co-crystals 
via grinding methods has become a more important topic due to the fact that these 
methods require no solvent or only a small amount of solvent compared to solution 
crystallization methods. As the process of producing drug products by solution methods 
in the pharmaceutical industry consumes a large amount of solvent and energy, leading 
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to environmental problems in the long run, scientists are trying to find new ways to 
improve this situation. Grinding methods are viewed as an effective and “green” way to 
prepare pharmaceutical co-crystals. In general, grinding methods include “neat” 
grinding (in the absence of solvent) and solvent-assisted grinding (in the presence of a 
small amount of solvent). 
Neat grinding, also called dry grinding, consists of mixing two or more 
components together and grinding them manually, using a mortar and pestle, or 
mechanically, using an electrical mill, without any solvent. To date, many co-crystals 
have been successfully prepared by neat grinding.[121,142,178,179] 
However, the mechanism of neat grinding remains poorly understood. Several 
mechanisms have been proposed for the process of neat grinding.[50,141,180] One of the 
recognized mechanisms is that neat grinding co-crystallization acts through molecular 
diffusion between the components. This mechanism requires that the components 
exhibit significant vapour pressures in the solid state. This mechanism was first 
proposed by Rastogi and co-workers in 1963[181] when they investigated the mechanism 
of the co-crystallization of hydrocarbons (naphthalene, phenanthrene and anthracene) 
with picric acid by neat grinding. In further studies, Rastogi and co-workers[182,183] 
monitored the reaction rates of co-crystals of picric acid with different aromatic 
compounds, further suggesting that both vapour and surface diffusion are important for 
the formation of these co-crystals. The role of grinding in these systems is to enhance 
the rate of surface diffusion of components and to make fresh reactive surfaces available. 
Solvent-assisted grinding, also called liquid-assisted grinding or solvent-drop 
grinding, requires small amounts of an appropriate solvent added to the grinding 
mixture during grinding. Originally, the purpose of adding a small amount of solvent 
was to enhance the rate of co-crystal formation.[184] Therefore, the choice of solvent is 
important. It is required that at least a small portion of the original components can 
dissolve in the chosen solvent. Soon, it was found that the presence of a small amount 
of solvent, apart from increasing the rate of co-crystallization, could also provide 
benefits such as higher yield, higher crystallinity and control of the polymorphic 
outcome of co-crystallization.[185] One example is the co-crystallization of meloxicam 
with succinic and maleic acids,[186] which can be easily prepared by solvent-assisted 
grinding. Compared to the slow evaporation method, only a small amount of solvent is 
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used. If this method can be used widely for the preparation of pharmaceutical co-
crystals, it would become much more efficient and environmentally friendly, and can 
save significant amounts of money and energy for pharmaceutical companies. 
In general, in the course of liquid-assisted grinding, the liquid has a catalytic role. 
However, there is still no general explanation for the mechanism of solvent-assisted 
grinding and it varies from case to case. In some cases, the solvent is just a medium for 
molecular diffusion. In others, researchers suggest that the nature of the solvent may 
have a profound effect on the formation of the co-crystal. However, co-crystals prepared 
from neat grinding or solvent-assisted grinding are normally microcrystalline and are 
too small for structure determination by single-crystal X-ray diffraction. Sometimes, if 
we obtain microcrystals from grinding method, which cannot be crystallized directly 
from solution methods, then it is possible, using these microcrystals as seeds, to obtain 
large-size co-crystals by crystallization from solution.[149] In addition, due to the 
remarkable advances of the powder X-ray diffraction technique in recent years, we can 
employ the powder X-ray diffraction method to determine the crystal structure from the 
powder samples obtained directly from the grinding method.[187,188] Of course, structure 
determination from powder XRD data is enhanced by using information from other 
techniques, such as solid-state NMR. Even so, structure determination directly from 
powder XRD date remains more difficult compared to single-crystal X-ray diffraction 
methods. 
2.1.3 Other Methods for Co-Crystallization 
Since pharmaceutical co-crystals have attracted extensive attention in recent years, 
many new methods have appeared for pharmaceutical co-crystallization. For example, 
vapour diffusion is a good method for co-crystallization. It requires that all components 
have moderate solubility in one solvent and low solubility in another (the anti-solvent). 
Vapour diffusion is carried out by dissolving all components in the moderate solvent in 
a small glass bottle, which is placed inside a larger glass bottle that contains a small 
volume of the anti-solvent. The larger glass bottle is then sealed. Vapour from the 
anti-solvent will diffuse into the solution slowly, inducing crystals to grow in the 
solution. This method requires that the anti-solvent is more volatile than the solvent. For 
example, in this work, we used this method to prepare two polymorphs of a co-crystal 
system[189] composed of trimesic acid (TMA), tert-butylamine (TBA) and methanol 
with the stoichiometry TMA2TBA5·(MeOH)3. 
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In the pharmaceutical industry, anti-solvent crystallization is an efficient way to 
control the particle size distribution of drug substances. Lee and co-workers [150,151] used 
anti-solvent crystallization to prepare co-crystals of saccharin with indomethacin and 
carbamazepine. In theory, the process is similar to vapour diffusion. The anti-solvent 
co-crystallization process is carried out by dissolving all components (saccharin with 
indomethacin or saccharin with carbamazepine) in methanol, then slowly adding 
purified water (the anti-solvent) to the solution using a peristaltic pump at room 
temperature over a period of about half an hour. 
In practice, it is not possible to predict which method will work for a specific co-
crystal system. If one method does not work or does not produce suitable crystals, 
adjusting the crystallization conditions such as the choice of solvents, temperature or 
method may be required. In general, the more crystallization conditions and methods 
that are used, the greater the potential to produce different new co-crystals or 
polymorphs. For example, Fucke and co-workers[174] reported, in the course of a study 
of piroxicam co-crystals, the formation of 46 co-crystals by using 20 different acids as 
co-crystal formers, five solvents and six crystallization techniques. 
2.2 Characterization Methods for Co-Crystals 
The goal of co-crystal characterization is to understand the physicochemical and 
crystallographic properties of the co-crystals. In general, co-crystals can be 
characterized by a wide variety of techniques, including single-crystal X-ray diffraction 
(SCXRD), powder X-ray diffraction (PXRD), differential scanning calorimetry (DSC), 
thermogravimetric analysis (TGA) and solid-state nuclear magnetic resonance 
(SSNMR).[190] As for single-component crystals, single-crystal X-ray diffraction is still 
the basic and best method for determining the crystal structure of co-crystals at the 
atomic level. However, it is not always easy to produce suitable, high-quality co-
crystals for single-crystal X-ray diffraction, especially for co-crystals formed through 
grinding methods. 
Originally, powder X-ray diffraction was just a tool used for phase identification 
of crystalline materials. Powder X-ray diffraction requires a small amount of powder. 
The data are much easier to record and it is also more convenient to identify phases 
from a recorded powder XRD pattern than using single-crystal XRD. In the case of co-
crystals, from a recorded powder X-ray diffraction pattern, it is also easy to distinguish 
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whether a new co-crystal phase has been formed or not, owing to the fact that each 
compound has its own distinct powder XRD pattern. In addition, with the rapid 
development of powder X-ray diffraction techniques, using powder X-ray diffraction 
data for structure determination has become more and more routine.[191,192] 
Apart from X-ray diffraction techniques, other methods of characterization also 
are available for co-crystals. DSC is a commonly used thermal method for determining 
the melting points, phase transitions and other properties of co-crystals. High-resolution 
solid-state NMR is another powerful technique for characterization of co-crystals. It is 
non-destructive and only requires a small amount of powder. It can provide detailed 
structural information about co-crystals and therefore it can be advantageous to use 
information from solid-state NMR to confirm details when carrying out structure 
determination from powder XRD data. 
2.2.1 Single-Crystal X-ray Diffraction 
A crystal is a solid material composed of atoms, ions or molecules that exhibit 
long range periodic order in three dimensions. X-ray diffraction is a powerful method 
for determination of crystal structure of crystalline materials, which involves 
determination of the unit cell parameters (the unit cell axis lengths a, b and c and the 
unit cell angles α, β and γ) and the atomic content of the unit cell [described by the 
atomic coordinates (x1, y1, z1), (x2, y2, z2), ··· (xn, yn, zn)]. 
There is no doubt that single-crystal X-ray diffraction is the most unambiguous 
method for characterizing the structure of co-crystals at the atomic level, yielding 
detailed three-dimensional information such as bond lengths, bond angles and geometric 
properties of intermolecular interaction. If good single crystals can be prepared, 
single-crystal X-ray diffraction is the first choice for structure determination. 
In 1895, German physicist Wilhelm Conrad Röntgen discovered X-rays. 
Subsequently, scientists began to explore the properties and applications of X-rays. 
X-rays are electromagnetic radiation of wavelength between ca. 1 Å to 100 Å, which is 
of similar order of magnitude to the periodic repeat distances in crystalline materials. 
This means that crystals can be used as a diffraction grating to scatter X-rays. In 1912, 
diffraction of X-rays by crystals was first observed, giving birth to X-ray diffraction and 
X-ray crystallography. In the same year, Sir W. L. Bragg developed Bragg’s Law to 
explain the interference pattern of X-rays scattered by crystals.[193] In 1914, the first 
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structure (sodium chloride) was determined by single-crystal X-ray diffraction. After 
that, more and more structures of inorganic and organic compounds were solved by 
single-crystal X-ray diffraction. As a consequence, single-crystal X-ray diffraction has 
allowed scientists to better understand the three-dimensional structure of materials and 
intermolecular interactions in solid materials. 
An X-ray diffraction measurement is based on constructive interference of 
monochromatic X-rays. Therefore, first of all, monochromatic X-rays are required. 
Usually, X-rays are produced by an X-ray tube. In the vacuum tube, a hot cathode 
(usually tungsten) releases electrons and these electrons were accelerated to a high 
velocity by a high voltage. These electrons then strike the anode (usually Cu or Mo), 
creating the X-rays. These continuous X-rays are then passed through a crystal 
monochromator, set to reflect one particular wavelength required for X-ray diffraction 
research. 
Synchrotron radiation is another widely used X-rays source for X-ray diffraction 
research. A synchrotron is a type of particle accelerator. In a synchrotron, electrons are 
accelerated to a high speed close to the speed of light, and are then maintained at 
constant energy in a circular trajectory by a bending magnetic field. These higher 
intensity X-rays then pass through a crystal monochromator set to reflect the particular 
wavelength required. Compared to X-rays created from X-ray tubes, the X-rays 
generated by synchrotron radiation possess higher intensity and a broader spectrum. 
Therefore, researchers can select the specific wavelength required for their experiment. 
In addition, diffraction patterns obtained from synchrotron radiation have significantly 
higher resolution and improved signal-to-noise. 
When monochromatic X-rays strike a crystal sample, the X-rays are scattered by 
their interaction with the electrons, producing constructive interference if the geometry 
of the scattering process satisfies Bragg’s Law: 
  sin2 hkldn  . (2.1) 
Here, the variable dhkl is the spacing between adjacent atomic layers for the lattice 
planes hkl in a crystal. For example, in the case of monoclinic system: 
 


 222
2
2
2
22
2
2 sin
cos2
sinsin
1
ac
hl
c
l
b
k
a
h
dhkl
 , (2.2) 
 33 
Where, θ is the incident angle, n is the order of reflection (an integer), and λ is the 
wavelength of the beam. Bragg’s Law is the fundamental equation of X-ray diffraction 
and provides a simple and convenient statement of the geometry of X-ray diffraction by 
crystals. The simplified derivation process of Bragg’s law can been seen in Figure 2.1. 
For constructive interference, the path difference between the waves scattered by 
electrons from adjacent lattice planes must be equal to an integer number of 
wavelengths, i.e. 
 Path difference = BDCBn  . (2.3) 
According to the geometrical relationship shown in Figure 2.1, we can infer that 
 sin2 hkldBDBC  . (2.4) 
Therefore, we can produce the equation of Bragg’s law. 
The aim of crystal structure determination is to determine the density of electrons 
(ρ(r)) in the crystal (where r is a vector in the unit cell), and to use the electron density 
map to calculate the actual real structure of the crystal. In order to create an electron 
density map, two pieces of information are needed: the amplitude and phase of the 
scattered X-rays. These two pieces of information can be expressed by a complex 
number, called the structure factor F(H). The relationship between structure factor 
(reciprocal space vectors) and electron density (direct space vectors) can be illustrated 
by a mathematical operation called the Fourier transform, as follows: 
 
Figure 2.1. The simplified derivation process of Bragg’s Law 
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Here, H is the position vector in reciprocal space for the diffraction maximum (hkl) (i.e., 
H = h a* + k b* + l c*), and a*, b* and c* are the unit cell vectors in reciprocal space, 
while r is a position vector in direct space (i.e., r = x a + y b + z c), and a, b and c are 
the unit cell vectors in direct space. |F(H)| is the amplitude and α(H) is the phase angle 
of the scattered X-ray corresponding to the diffraction maximum (hkl). The integration 
is performed over all vectors r in the unit cell. 
Unfortunately, in an X-ray diffraction measurement, only the intensities of 
scattered X-ray beams are measured, which is related to the structure factor amplitude 
|F(H)| (the intensities are proportional to the squares of the amplitudes). However, 
information on the phase angles cannot be obtained from experimental measurements. 
This is called the phase problem, which is the major problem in crystal structure 
determination. Since the diffraction pattern is the Fourier transform of the electron 
density, the electron density is the inverse Fourier transform of the diffraction pattern. 
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where V is the volume of the unit cell, and the summation is over all vectors H. Thus, 
without the information about the phases, the inverse Fourier transform (Equation 2.6) 
cannot be performed. Researchers have developed several methods to recover 
information on the phases. The Patterson method and direct methods are the two major 
methods for recovering the phases in structure solution in small-molecule single-crystal 
X-ray diffraction data analysis. 
The Patterson method was introduced in 1934.[194] As mentioned above, if we 
carry out an inverse Fourier transform of the structure factors (requiring both amplitudes 
and phases), we get the electron density map. However, if we carry out an inverse 
Fourier transform of the intensities from the measured data, the resulting map we get is 
called a Patterson map and is a map of the vectors between atoms. Using the Patterson 
method, it is possible to work out the positions of the atoms for small structures. If there 
are n atoms in the unit cell of the crystal, then there are n2 interatomic vectors in the 
pattern map. Therefore, if n becomes larger, it is very difficult to solve the structure by 
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the Patterson method. In practice, it is mostly used for simple structures or structures 
containing a few ‘heavy’ atoms (i.e., atoms with high atomic numbers) as the Patterson 
map is dominated by the vectors between heavy atoms. 
Due to the development of computer techniques, direct methods have become the 
most useful strategy for solving crystal structures.[195] Direct methods are mathematical 
methods to solve the phase problem that rely on the reasonable assumption that the 
electron density in the unit cell should be zero or positive everywhere in the unit cell. 
This creates certain relationships between the phases of sets of structure factors. These 
relationships can be used to deduce possible values for the phases. In general, direct 
methods employ such relationships with no previous knowledge about the crystal 
structure to solve the crystal structures. It is almost a trial and error process and often 
described as a “black box”, because the process is automated by computers. In addition, 
the final structure from the direct methods calculation or Patterson method is only an 
initial approximation of the true structure and requires further refinement. 
Space groups with screw axes, glide planes or centring result in diffraction 
patterns with certain reflections “missing” (i.e., the structure factor is zero). These are 
called systematic absences or systematic extinctions. The combination of the symmetry 
of the reciprocal lattice and the presence or absence of certain types of reflections is 
used to determine the space group of the crystal lattice. In a single-crystal X-ray 
diffraction experiment, the identification of systematic absences is done automatically 
by the data collection software on the diffractometer. However, during the process of 
crystal structure determination from powder X-ray diffraction data, in some cases, the 
systematic absences are not sufficiently decisive to differentiate between alternative 
space groups (for example, P21 and P2/m). 
In general, single-crystal X-ray diffraction experiments involve three steps: 
1. Growing a high quality single crystal large enough and with no significant 
cracks. Preferably, the size of crystal should be in the range 0.2 - 0.4 mm in 
the three directions of space because excessively small crystals are not 
suitable for single-crystal X-ray diffraction. 
2. Collecting the X-ray diffraction data. First, a suitable crystal is fixed on the tip 
of a thin glass fibre using glue or in a loop including specific oil (for low 
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temperature experiments), which is then mounted on a goniometer head. The 
crystal is rotated through various angles with respect to the X-ray beam, 
producing a diffraction pattern. It is necessary to know the stability of the 
crystal. If the crystal is sensitive to air (mainly water) or unstable (solvate 
crystals) then special treatment is required. For example, if a crystal is 
sensitive to air, it can be sealed in a glass capillary. The glass is amorphous 
and thus does not affect the diffraction pattern. If the crystal is solvated and 
unstable at room temperature, we can collect the data at low temperature. In 
addition, data collection at low temperature can reduce the atomic mobility 
and thus enhance the diffraction intensities. Data is usually collected between 
3° and 40° (2θ) and the process takes several hours, depending on the sample 
and the diffractometer. Usually, it is possible to determine the unit cell 
parameters from the first few images. 
3. The 2D diffraction patterns are converted into a 3D model of the electron 
density by Fourier transformation. In this step, first of all, corrections of the 
measured intensities should be carried out. A common correction is the 
Lorentz-polarization correction. The Lorentz factor is related to the instrument 
geometry, whilst the polarization factor is due to the fact that the reflected X-
rays are partially polarized. Another correction is for the absorption of X-rays 
by the crystal, particularly for crystals containing heavy atoms, since heavy 
atoms can strongly absorb X-rays. After corrections, the phase problem should 
be solved by direct methods or Patterson methods. 
In the process of solving the phase problem, the structural model obtained is only 
approximate and has to be refined. Refinement is carried out by optimizing the fit 
between the observed and calculated intensities in the diffraction pattern. The 
refinement process includes adjustment of the positions of atoms and of anisotropic 
displacement parameters. When the following conditions are achieved, then the 
refinement is considered finished: a) the value of R-factor (R, Equation 2.7) and the 
weighted R-factor (Rw, Equation 2.8) are small enough. A value of R less than 5% is 
considered indicative of a good refined structure and high quality samples will result in 
R less than 2.5%. Rw is similar to R and the value of Rw is always higher than R. The 
R-factors are defined as 
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where |Fo| is the observed structure factor amplitude, |Fc| is the calculated structure 
factor amplitude and w is a weighting factor. b) The structural model is chemically 
reasonable. c) The estimated standard deviations for all parameters are sufficiently small. 
In practice, in the process of determining a small-molecule single crystal structure, the 
most widely used software for structure solution and refinement are SHELXS and 
SHELXL,[196] and these are called via the WinGX user interface.[197] Once the structure 
is refined, a standard file (CIF: crystal information file) containing all the information of 
the structure is created. 
2.2.2 Powder X-ray Diffraction 
Conventionally, powder X-ray diffraction is used as a rapid tool for phase 
identification of a crystalline material and if the sample is a mixture of more than one 
phase, in principle, all phases present can be identified due to each crystalline material 
having its own unique powder pattern. However, with recent developments of powder 
X-ray diffraction techniques, we can also use powder X-ray diffraction data for 
structure determination,[191] often combined with other techniques, such as 
high-resolution solid-state NMR. 
Before carrying out structure determination from powder XRD data, a high 
quality powder XRD pattern should be recorded. There are two main ways to obtain 
high quality powder XRD data: conventional laboratory powder X-ray diffractometers 
and synchrotron X-ray diffractometers. Under normal conditions, powder XRD data 
obtained from a conventional laboratory powder X-ray diffractometer is already good 
enough for structure determination. However, in some cases, there are significant 
advantages to using synchrotron X-ray powder diffraction data. For example, 
sometimes, powder patterns recorded on conventional powder X-ray diffractometers 
suffer from peak overlap, a big issue for determination of unit cell parameters (see 
below). In contrast, the data recorded from a synchrotron source with higher resolution 
may make it possible to determine the unit-cell parameters successfully.[191,198] In 
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general, there are three stages for determination of crystal structures from powder X-ray 
diffraction data: [199-201] unit cell determination and space group assignment, structure 
solution and structure refinement. 
The first stage is unit cell determination, also called “indexing”. The process is 
carried out by using programs for automatic indexing, including: TREOR,[202] ITO,[203] 
or DICVOL,[204] which are incorporated into the program CRYSFIRE.[205] In practice, 
we use more than one program for indexing because these programs employ different 
methods for indexing and usually offer several different, possible sets of unit-cell 
parameters for a given set of powder XRD data. Normally, we pick out about 20 
individual, non-overlapped peaks at low angles for indexing. The peaks in the high 
angle region cannot be trusted in this process due to extensive overlap.[206] Indexing is a 
very important step. If the correct unit cell cannot be found, then we cannot proceed to 
the next stage. 
If the unit cell parameters have been determined, then the next task is the space 
group assignment. We use the program CHEKCELL[207] to assist in space group 
identification. Using the unit cell parameters obtained from indexing, the program 
CHEKCELL gives some suggested space groups. In the next stage, we use Le Bail 
profile fitting[208] to check all of these options in order to obtain the right space group, 
using the GSAS [209] software and its graphical user interface editor EXPGUI.[210] The 
Le Bail method fits the complete experimental powder XRD data by refinement of 
variables that include peak positions (including unit cell parameters and zero-point shift 
parameter), peak widths, peak shapes, background intensity distribution, and peak 
intensities. In the Le Bail fitting procedure, no structural model is used and the aim is to 
obtain reliable values of the variables that describe different features of the powder 
diffraction profile. In this case, the intensity data extracted from the powder XRD 
pattern are not used in the structure solution process. Instead, the determined values of 
variables that describe the features of the powder diffraction profile are required in 
order to construct the calculated powder diffraction pattern for the trial structure. In this 
stage, comparison of the experimental data with the calculated data is assessed by the 
whole-profile figure-of-merit, Rwp, which is defined as below (Equation 2.9). Following 
Le Bail fitting, the space group can be assigned by identifying the conditions for 
systematic absences in the intensity data. If the space group cannot be assigned uniquely, 
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structure solution calculations (the next stage) should be carried out in parallel for each 
of the possible space groups. 
Before performing structure solution, the contents of the asymmetric unit must be 
established. By consideration of the unit cell volume, space group and density, the 
contents of the asymmetric unit can be established theoretically. High-resolution solid-
state NMR can also be helpful for this purpose; for example, in some cases, solid-state 
13C NMR spectroscopy can be used to determine the number of independent molecules 
within the asymmetric unit. 
The purpose of structure solution is to obtain a best approximation to the true 
structure. In this stage, we use the direct-space strategy for structure solution,[191] carried 
out using a genetic algorithm (GA) method[201,211,212] incorporated in the program 
EAGER.[195] The quality of trial structures is assessed by comparison between the 
calculated powder XRD pattern for the trial structure and the experimental powder XRD 
pattern. This comparison requires an appropriate R-factor. In our method, we use the 
weighted powder profile R-factor (Rwp), which is defined as 
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where yi is the intensity of the ith point in the experimental powder pattern, yci is the 
intensity of the ith point in the calculated powder pattern, and wi is a weight factor for 
the ith point (wi = 1/yi). 
In EAGER, a number of trial structures are initially generated randomly, defined 
by a set of structural variables. Each molecule is defined by its position in the unit cell 
(three coordinates), orientation with respect to the unit cell (three angles) and torsion 
angles. There are 6 + n variables for each molecule in the asymmetric unit, where n is 
the number of torsion angles. These trial structures evolve subject to rules and 
operations (mating, mutation and natural selection). The quality of each trial structure is 
assessed by comparing the calculated powder XRD pattern of each trial structure with 
the experimental powder XRD pattern as discussed above. New structures are generated 
by mating and mutation. In mating, a number of pairs of structures (“parents”) are 
selected and new structures (“offspring”) are generated by swapping structural 
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information between the two parents. In mutation, some structures are selected from the 
population and random changes are made to parts of their structure to create mutant 
structures. In the course of natural selection, only the structures with lowest Rwp are 
allowed to pass from one generation to the next generation. After a sufficiently large 
number of generations, a best trial structural solution will be generated in the population 
and this structure should be close to the true crystal structure. Therefore, this structure is 
taken as the starting structural model for the next stage of the structure determination 
process. A schematic flowchart illustrating the procedure for evolution of the population 
from one generation to the next generation in the genetic algorithm technique for 
structure solution is shown in Figure 2.2. 
 
Figure 2.2. Flow chart representing the evolution of the population from one 
generation (j) to the next generation (j + 1) in the genetic algorithm (GA) for powder 
structure solution. 
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The structure with lowest Rwp in the final generation of the GA calculation is used 
as the starting structural model for Rietveld refinement,[213] which is carried out using 
the GSAS program. If the structural model from the structure solution calculation is a 
good approximation to the true structure, then a good quality structure may be obtained 
by Rietveld refinement. In Rietveld refinement, the atomic positions and atomic 
displacement parameters are adjusted. Thus, the constraints of planes (such as aromatic 
planes), bond lengths and bond angles are relaxed during Rietveld refinement. In terms 
of displacement parameters, Uiso values are refined and all atoms within the same 
molecule are generally set to the same value. For hydrogen atoms, the Uiso value is 
usually set to a value of 1.2 times that for the non-H atoms. In addition, if some 
molecules are considered to be disordered, the site occupancy can also be refined. 
During Rietveld refinement, the R-factor Rwp is used to assess the quality of fit between 
the experimental and calculated powder XRD patterns. In practice, Rietveld refinement 
may suffer from problems of instability. Therefore, it is necessary to use certain 
geometric restraints based on standard molecular geometries to ensure stable 
convergence of the refinement calculation. In addition, difference Fourier maps can be 
used in order to help Rietveld refinement and to check the correctness of the refined 
structural model. In general, the final structural parameters obtained from powder XRD 
data are not as accurate as structural parameters obtained from single-crystal XRD data. 
However, it is good enough for us to understand the arrangement of atoms and 
molecules in the crystal structure and the intermolecular interactions (such as hydrogen 
bonding). 
In addition, structure solution will succeed only if the powder XRD pattern 
contains reliable information on the peak intensities. However, the existence of 
preferred orientation can significantly change the peak intensities and thus hinder the 
determination of the crystal structure from powder XRD data. When the crystallites are 
oriented preferentially in certain directions instead of randomly, preferred orientation 
arises. When the crystal shape is strongly anisotropic, such as long needles or flat plates, 
preferred orientation can be very severe. Since structure solution using the direct-space 
method starts with no knowledge of the correct structural model, the existence of 
preferred orientation can impose severe limitations on searching for an approximately 
correct structural model from scratch. Therefore, we need to address this problem 
during structure solution. The existence of preferred orientation can be detected by 
measuring the powder XRD pattern of the same sample in different types of sample 
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holder (e.g., capillary versus flat sample) or different measurement geometries (e.g., 
reflection versus transmission). If the sample exhibits preferred orientation, we need to 
re-prepare the sample in order to make sure that the sample is free of preferred 
orientation. Methods including repacking in a different sample holder (often the effects 
of preferred orientation are less severe using capillary than flat tape), regrinding 
(appropriate grinding can make the crystal morphology as isotropic as possible), 
recrystallization or mixing the powder sample with an amorphous material, such as 
starch.[214] When a sample without preferred orientation or only slight preferred 
orientation is obtained, it is used to record high quality powder XRD data for structure 
determination. 
2.2.3 Thermal Analysis 
Thermal analysis methods are well-known and commonly used techniques in 
many areas, such as pharmaceuticals, polymers, etc.[215] Differential scanning 
calorimetry (DSC) and thermogravimetric analysis (TGA) are the most commonly used 
and are distinguished from each other by the property measured: heat difference and the 
change in mass, respectively. 
DSC investigates how the heat capacity of a material changes as the function of 
temperature under a controlled atmosphere. This information allows phase transitions 
(e.g., melting, glass transition, crystallization or decomposition) to be identified. DSC 
experiments are carried out in a chamber which consists of a sample holder and a 
reference holder. Usually, the sample is sealed inside a small aluminium pan and the 
reference is an empty pan and cover. The difference in heat flow to the sample and the 
reference is recorded as a function of temperature. Both the sample and reference are 
maintained at the same temperature throughout the experiment. The result of a DSC 
experiment is a plot of heat flux versus time or temperature. In DSC data, each peak 
corresponds to a specific thermal process, see Figure 2.3. 
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In general, in a DSC experiment, when the sample goes through a transformation, 
for example phase transition, more heat or less heat will need to flow to it to maintain 
the same temperature as the reference. Whether less heat or more heat flows to the 
sample will depend on whether the process is exothermic or endothermic. For example, 
when a sample melts, it requires more heat flowing into it, because melting is an 
endothermic phase transition. Similarly, when a sample undergoes an exothermic 
processes, such as crystallization, move heat is required. In addition, the glass transition 
is a very important property for amorphous materials. This process introduces a change 
in heat capacity and appears as a step change with respect to the baseline. By observing 
the difference in heat flow between the sample and reference, DSC can measure the 
amount of heat absorbed or released qualitatively and quantitatively. In order to obtain 
good data, we note that, in general, increasing the sample weight and/or increasing the 
rate of heating/cooling will increase the signal sensitivity, while lower sample weight 
and/or lower heating/cooling rates will increase the resolution. 
TGA is a method that measures the mass change of a sample as a function of 
temperature under a controlled atmosphere. TGA is an extremely powerful thermal 
technique which can be used for studying several processes, including desorption, 
dehydration, decomposition, sublimation, etc. For example, in a decomposition TGA 
experiment, as the temperature increases, the components of the sample are gradually 
decomposed at different temperatures and the weight percentage of each resulting mass 
change can be precisely measured. Mass loss or percentage mass loss can be plotted as a 
 
Figure 2.3. A schematic DSC pattern with typical thermal processes. 
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function of temperature. From the TGA plot, we can analyse the decomposition 
behaviour of a given sample, see Figure 2.4. 
2.2.4 Solid-State NMR 
Solid-state NMR (SSNMR) is a powerful tool for characterization of solid 
materials and can provide detailed structural information due to the presence of 
anisotropic (directionally dependent) interactions. Anisotropic interactions have a 
substantial influence on the behaviour of nuclear spins. These interactions can be 
detected by solid-state NMR. However, in order to get high-resolution solid-state NMR 
spectra, a number of techniques/equipment are needed, including high-power 1H 
decoupling, magic-angle spinning (MAS) and cross polarization (CP). In general, 
high-resolution SSNMR can provide the same type of information as that available from 
solution NMR.[216] 
In solid-state NMR, nuclei in different chemical environments can give rise to 
different chemical shifts in the spectra and the position of these chemical shifts can be 
used to identify the structure of molecules. This kind of information is very useful in 
conjunction with determination of structure from powder XRD data. In practice, 
chemical shifts of nuclei are reported using δ values, which are usually expressed in 
parts per million (ppm). δ is defined as: 
 610


s
TMSo


 . (2.10) 
 
Figure 2.4. A schematic TGA pattern illustrating partial mass loss (e.g., desolvation) 
followed by sample decomposition. 
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Here, vo is the detected frequency, vTMS is the detected frequency of a reference 
substance (usually tetramethylsilane, (TMS)) and vs is the operating frequency of the 
spectrometer for the given type of Nucleus. The electron density, electronegativity of 
neighbouring groups and anisotropic induced magnetic field effects are the most 
important factors for influencing the value of the chemical shift. In general, electron 
density shields a nucleus from the external field, resulting in the chemical shift moving 
to an up-field position (lower δ value). A nucleus neighbouring an electronegative atom 
(such as I, Br, Cl, F) will have a reduced electron density and thus the chemical shift 
will move downfield (higher δ value). Electrons in π systems will interact with the 
external field which induces a magnetic field that causes anisotropy. The anisotropic 
induced magnetic field effects can be either shielded (lower δ value) or de-shielded 
(higher δ value), depending on the position of the nucleus. 
From the number of the peaks in a 13C SSNMR spectrum, in some cases, we can 
determine how many crystallographically distinct carbon atoms are present in the solid 
material and, thus, obtain information about the number of independent molecules in the 
asymmetric unit. In addition, for organic co-crystals composed of a carboxylic acid with 
organic base, powder X-ray diffraction cannot unambiguously determine whether 
proton transfer occurs from the acid to the base. 13C SSNMR chemical shift analysis can 
help determine the protonation situation and hydrogen-bonding state of carboxylic acid 
and carboxylate groups.[217] 
SSNMR can also be used to study molecular motions in solid materials using, for 
example, the CP/MAS experiment with dipolar dephasing. The aim of this kind of 
experiment is to simplify the high-resolution spectrum by removing signals that derive 
from any carbon atoms directly bonded to hydrogen (assuming a 13C SSNMR 
experiment and the molecule is static). Thus, if a molecule contains carbon atoms 
directly bonded to hydrogen and the molecule is static, the peaks corresponding to these 
carbon atoms are absent in the spectrum recorded with dipolar dephasing compared to 
the spectrum recorded without dipolar dephasing. On the other hand, a molecule 
containing carbon atoms directly bonded to hydrogen that are mobile, or for a molecule 
containing carbon atoms not directly bonded to hydrogen (static or mobile), dipolar 
dephasing does not affect the intensity of the solid-state NMR signal. The basis of this 
experiment is simple: prepare sample as normal with CP (i.e., applying a 90° pulse to 
the 1H channel of the spectrometer, then a spin-lock pulse is applied to the 1H channel 
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and a contact pulse is applied to the 13C channel in order to allow transference of 
magnetization from 1H to 13C nuclei (CP)). Then turn decoupling off (for 1H channel), 
wait for an appropriate time (dipolar dephasing delay), decoupling on (for 1H channel), 
acquiring the signal for the 13C channel while performing 1H decoupling to remove 
hetero-nuclear dipolar coupling. While the decoupling is turned off, the signal from any 
static carbon atoms strongly dipolar coupled to hydrogen will dephase faster than the 
signal derived from carbon atoms without coupling to hydrogen or mobile carbon atoms. 
If we choose the dipolar dephasing delay carefully, we can fully remove the signal from 
static carbon atoms that are directly bonded to hydrogen. Therefore, the resulting 
spectrum contains only signals from carbon atoms that are not directly bonded to 
hydrogen or mobile carbon atoms. 
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Chapter 3 Polymorphism of Co-Crystals of Trimesic 
Acid and tert-Butylamine 
3.1 Introduction 
Crystal engineering [218,219] of co-crystals concerns the design and synthesis of 
new molecular co-crystals with desired physicochemical properties based on the 
structure of the component molecules. The physicochemical properties of crystalline 
materials are influenced by the molecular arrangement in the crystal structure and the 
molecular arrangement is normally controlled by intermolecular interactions. Therefore, 
understanding intermolecular interactions in co-crystals is highly important. Among 
these intermolecular interactions,[220] hydrogen bonding, π-π stacking and van der Waals 
forces are the most influential. In particular, hydrogen bonding, due to its directionality 
and strength, is the most important tool for controlling the formation of organic co-
crystals. Despite many successful co-crystallizations, it remains difficult to predict the 
crystal structure completely in advance, as the mechanism of co-crystallization is not 
fully understood. This is especially pertinent for organic co-crystals prepared by 
grinding methods.[221] Therefore, the field of crystal engineering still attracts many 
researchers. 
Polymorphism is a very common phenomenon in nature. Due to different 
polymorphs having different physicochemical properties, it has potential applications in 
many industries, such as pharmaceuticals, dyes and pigments. In general, polymorphism 
is quite frequent in single-component crystals but, polymorphism in co-crystals and 
solvates is still a relatively rare phenomenon. In recent years, due to the subject of co-
crystals becoming more and more important, research in polymorphism of co-crystals 
has gradually seized the attention of chemists and some polymorphic co-crystal systems 
have been reported in the literature.[118-120] In order to understand the details of 
polymorphism of co-crystals, research in this regard is still evolving. 
Although it is very difficult to predict co-crystal structure in advance, selecting 
organic molecules with specific functional groups for preparing co-crystals with desired 
hydrogen bonding motifs may be possible. For example, organic compounds containing 
carboxylic acid functional groups have received significant attention due to their 
potential as hydrogen-bond donors to a variety of organic bases containing suitable N 
atoms which can act as hydrogen-bond acceptor, such as amides, pyridine and its 
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derivatives.[57,60,61] Organic amines can also be used as a hydrogen bond acceptor with a 
carboxylic acid as the donor. Recently, the carboxylic acid-amine heteromeric system 
has drawn much attention.[222-224] In this chapter, we will present two novel polymorphic 
co-crystal systems containing acid-amine heteromers and analyse their crystal structures 
in terms of hydrogen bonding. 
Trimesic acid (TMA), also known as benzene-1,3,5-tricarboxylic acid, is an 
important aromatic compound. It has attracted much attention because of its interesting 
molecular structure (Figure 3.1). TMA is a planar molecule with three carboxylic acid 
groups equally arranged around the benzene ring. It can exist in four forms in the solid 
state, depending on the degree of deprotonantion. For example, in the co-crystal of 
TMA and acetic acid,[225] TMA molecules exist in the form of neutral H3TMA 
molecules, while in the co-crystal of TMA and N,N-dicyclohexylamine[226], TMA 
molecules are totally deprotonated and exist in the form of TMA3– anions. The crystal 
structure of α-trimesic acid (the commercially available form) was determined by 
Duchamp and Marsh in 1969.[227] The basic motif of the α-TMA structure is a 
hydrogen-bonded, two-dimensional honeycomb (hexagonal) network. The main 
intermolecular interactions comprise the carboxylic acid dimer motif (graph set  822R ), 
arrangement of TMA molecules in a plane and interacting via this motif leads to a 
cavity of diameter of ~ 14 Å (Figure 3.2). However, these networks are not packed in a 
parallel, planar manner but as pleats with dihedral angles of about 70°. For the 
consideration of close packing, there is a triple concatenation of each network, leading 
to a triple interpenetration of each hexagonal hole. As TMA molecules can construct 
such honeycomb networks, they are often used as building blocks in the synthesis of 
hydrogen-bonded organic co-crystals [228-230] or metal-organic frameworks.[231-233] 
Tert-butylamine (TBA) (Figure 3.3) is an organic primary amine with a pKa of 10.68, 
 
Figure 3.1. The molecular structure of trimesic acid (TMA). 
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indicating that it will exist almost always in the form of tert-butylammonium cations 
when interacting with carboxylic acid groups in aqueous solution or organic solvents. 
The geometry of the resulting tert-butylammonium cations is very interesting, as it can 
possesses a three-fold axis through the N–C bond with three identical N–H bonds that 
can act as strong hydrogen-bond donors. Therefore, it is possible to form geometrically 
well-defined hydrogen-bonding motifs. In addition, due to the steric effect of the tert-
butyl group, the tert-butylammonium cation can only link with carboxylate groups 
through N–H···O hydrogen bonds when it co-crystallizes with carboxylic acids. As a 
whole, it is fascinating to investigate the co-crystal structures of TMA with TBA. 
 
Figure 3.3. The molecular structure of tert-butylamine (TBA). 
 
Figure 3.2. The basic motif of the hydrogen-bonded hexagonal network in the 
crystal structure of α-TMA. 
 
 50 
In the field of co-crystals, as mentioned before, the existence of polymorphism is 
not a common occurrence. However, molecules that possess multiple functional groups 
appear to be more likely to form polymorphs, because different hydrogen-bonding 
arrangements may arise between these functional groups in different polymorphs. In 
addition, molecules with several degrees of torsional freedom are also more prone to 
exhibit polymorphism due to the opportunity to exist in different conformers. The TMA 
molecule possesses three carboxylic acid groups with three torsional angles. Therefore, 
we expected that polymorphism might appear in organic co-crystals that containing the 
TMA molecule. In the course of studying co-crystals of TMA and TBA, we discovered 
that TMA and TBA form a series of co-crystals with different ratios, by using a series of 
solvents combined with different crystallization methods and different ratios of TMA 
and TBA in the crystallization solution. The resulting structural diversity of co-crystals 
of TMA and TBA in our research is very interesting, particularly with regard to the 
phenomenon of polymorphism. In this chapter, we present two novel polymorphic co-
crystal systems of TMA and TBA. One is a solvated polymorphic system (with 2:5:3 
ratio of TMA, TBA and methanol), which is particularly novel in having a large number 
of independent components in the asymmetric unit.[189] The other is a polymorphic co-
crystal system with a 2:3 ratio of TMA and TBA. The other co-crystal structures of 
TMA and TBA discovered in this work are presented in the next chapter. 
3.2 Polymorphism in Co-Crystals of TMA2TMA5·(MeOH)3 
In crystallographic and structural chemistry, the number of independent molecules 
in the asymmetric unit is denoted by the parameter Z' and structures with high Z' 
(Z' = 2 to 4) are relatively common for systems with low symmetry, but structures with 
a value of Z' of more than four are extremely rare.[234] In recent years, the discovery of 
polymorphic systems with large numbers of independent molecules in the asymmetric 
unit has been become an interesting subject.[234-236] In our present work, we report the 
polymorphism of co-crystals of TMA2TBA5·(MeOH)3. The crystal structure of each 
polymorph is composed of ten independent molecules in the asymmetric unit. In the 
literature concerning polymorphic systems, there are very few examples comprising ten 
or more independent molecules in the asymmetric unit[237-239] and very few examples of 
co-crystals composed of three or more independent organic molecules. Therefore, 
polymorphism of co-crystals of TMA2TBA5·(MeOH)3 reported here can be considered 
very rare and interesting. 
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3.2.1 Synthesis and Structure Determination 
The two polymorphs (denoted forms I and II) of TMA2TBA5·(MeOH)3 were 
prepared by vapour diffusion of anti-solvent into a solution of TMA and TBA in 
methanol. Vapour diffusion of acetone into a methanol solution containing TMA and 
TBA (TMA:TBA = 2:5, molar ratio in solution) at ambient temperature resulted, after a 
few days, in single crystals of form I. Vapour diffusion of ethanol into a methanol 
solution containing TMA and TBA (TMA:TBA = 2:5, molar ratio in solution) at 
ambient temperature resulted, after a few days, in single crystals of form II. The 
crystallization procedure to produce form II yielded monophasic samples, whereas our 
procedure to produce form I was frequently found to yield the concomitant formation of 
small amounts of form II. 
 Single-crystal X-ray diffraction data were collected at 150 K on a Nonius Kappa 
CCD diffractometer equipped with a molybdenum tube source (λ = 0.71073 Å). The 
crystal structures were solved (by direct methods) by SHELXS and refined using 
SHELXL.[196] Refinement of non-hydrogen atoms was carried out using anisotropic 
displacement parameters. All hydrogen atoms were located in difference Fourier maps 
and were added to the structural model according to idealized geometries. Refinement 
of hydrogen atoms was carried out using a riding model, with isotropic displacement 
parameter equal to 1.2 or 1.5 times the equivalent isotropic displacement parameter of 
the atom to which the hydrogen atom is bonded. Powder X-ray diffraction data were 
recorded on a Bruker D8 instrument (CuKα1; Ge monochromated; transmission 
geometry). Differential scanning calorimetry (DSC) data were measured on a TA 
Instruments Q100 using sealed aluminium pans and cooling rates between 1 and 20 °C 
min–1 under the N2 atmosphere. 
3.2.2 Structural Analysis and Discussion 
The crystallographic parameters of the two polymorphs of TMA2TBA5·(MeOH)3, 
which have been determined from single-crystal X-ray diffraction, are summarized in 
Table 3.1 and the crystal structures of forms I and II are shown in Figures 3.4 and 3.5, 
respectively. In both forms of TMA2TBA5·(MeOH)3, the asymmetric unit comprises ten 
independent molecules: five HTBA+ cations, one HTMA2– anion, one TMA3– anion and 
three methanol molecules. For clarity, in this thesis, the abbreviations TMA and TBA in 
general refer to trimesic acid and tert-butylamine, respectively, without reference to the 
degree of protonation/deprotonantion. To indicate specifically the degree of 
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protonation/deprotonantion, we use TMA3–, HTMA2–, H2TMA
– and H3TMA to 
represent the different degrees of deprotonantion of TMA and we use HTBA+ to 
represent the protonated TBA cation. 
Table 3.1 The crystallographic parameters of forms I and II of 
TMA2TBA5·(MeOH)3 
 Form I Form II 
Space Group P1¯ P1¯ 
Temperature (K) 150 (2) 150 (2) 
a/(Å) 10.3251(3) 10.2893(2) 
b/(Å) 15.4590(4) 15.5312(2) 
c/(Å) 17.7519(5) 17.6113(3) 
α/(°) 69.964(2) 92.3960(10) 
β/(°) 86.592(2) 106.2330(10) 
γ/(°) 78.556(2) 100.9840(10) 
V/(Å3) 2608.96(13) 2639.14(8) 
Z 2 2 
R1/(%) 4.88 5.39 
Rw2/(%) 11.44 12.93 
Table 3.2 The lattice parameters for the transformed unit cells of forms I and II of 
TMA2TBA5·(MeOH)3 
 Form I Form II 
Space Group P1¯ P1¯ 
a'/(Å) 20.2219(5) 20.1986(2) 
b'/(Å) 19.9987(6) 21.7294(2) 
c'/(Å) 10.3251(3) 10.2893(3) 
α'/(°) 62.385(2) 83.640(1) 
β'/(°) 48.527(2) 49.011(1) 
γ'/(°) 85.268(2) 113.437(1) 
Z 2 2 
From the crystal structures of forms I and II, (see Figures 3.4a and 3.5a), we can 
see that, for each polymorph, the crystal structure comprises single hydrogen-bonded 
sheets with the planes of the TMA3– and HTMA2– anions lying in the plane of the sheet 
and the –N+H3 groups of the HTBA+ cations and the OH groups of the methanol 
molecules lying close to this plane as a result of intermolecular interactions (hydrogen 
bonding). The tert-butyl groups (TBA) and methyl groups (methanol) project outward 
from the sheets. For clarity, the three methyl groups of each tert-butyl group are omitted 
in the figures. The green dashed lines represent hydrogen bonds. 
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In order to compare these two polymorphic structures in more detail, we define a 
transformed unit cell (a', b' c') for each polymorph. The transformation relationship for 
form I is shown Equation 3.1 and for form II in Equation 3.2: 
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Figure 3.4. Crystal structure of form I of the co-crystal of TMA2TBA5·(MeOH)3, viewed 
(a) perpendicular and (b) parallel to the plane of the hydrogen-bonded sheets. In (a), a 
single sheet is shown and the tert-butyl groups of the HTBA+ cations are omitted for 
clarity. In (b), the green arrow indicates the hydrogen-bonded sheet and the orange 
arrow indicates the aliphatic region containing the methyl and tert-butyl groups. 
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Specifically, in the transformed unit cell, the a'-axis is parallel to the hydrogen-
bonded ribbon motif that is common to forms I and II, the b'-axis is defined such that 
the a'b'-plane is parallel to the plane of the hydrogen-bonded sheet and the c'-axis is the 
periodic repeat vector between adjacent hydrogen-bonded sheets. The transformed unit 
cells (a', b', c') are shown in the plots of the crystal structures of form I (Figure 3.4) and 
form II (Figure 3.5). The lattice parameters for the transformed unit cells are 
summarized in Table 3.2. 
 
Figure 3.4. Crystal structure of form I of the co-crystal of TMA2TBA5·(MeOH)3, viewed 
(a) perpendicular and (b) parallel to the plane of the hydrogen-bonded sheets. In (a), a 
single sheet is shown and the tert-butyl groups of the HTBA+ cations are omitted for 
clarity. The unit cell shown is the transformed unit cell (a', b', c') defined in the text. In 
(b), the green arrow indicates the hydrogen-bonded sheet and the orange arrow 
indicates the aliphatic region containing the methyl and tert-butyl groups. 
 
Figure 3.5. Crystal structure of form II of the co-crystal of TMA2TBA5·(MeOH)3, 
viewed (a) perpendicular and (b) parallel to the plane of the hydrogen-bonded sheets. 
In (a), a single sheet is shown and the tert-butyl groups of the HTBA+ cations are 
omitted for clarity. The unit cell shown is the transformed unit cell (a', b', c') defined in 
the text. In (b), the green arrow indicates the hydrogen-bonded sheet and the orange 
arrow indicates the aliphatic region containing the methyl and tert-butyl groups. 
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From the crystal structures of forms I and II (Figures 3.4 and Figure 3.5), it is 
clear that there are both similar aspects and significant differences between these two 
structures, highlighted in particular by the overlay of the two structures in Figure 3.6. 
Specifically, within the sheets, forms I and II share a common hydrogen-bonded ribbon 
motif (parallel to the a'-axis of the transformed unit cell in each case), which runs 
horizontally in Figures 3.4a and 3.5a and is indicated as the region between the two 
dashed lines and marked by the red arrow (the symmetry related ribbon, generated by a 
crystallographic inversion centre, is indicated by the blue arrow in Figures 3.4a and 
3.5a). From Figures 3.4b and 3.5b, we can see that the hydrogen-bonded sheets are 
stacked in a very similar manner that brings the tert-butyl groups and methyl groups 
together at the interface between adjacent sheets, with a similar perpendicular distance 
between the sheets in each polymorph (form I, 6.47 Å; form II, 6.55 Å). 
In terms of HTMA2– and TMA3– anions, the ribbon motif parallel to the a'-axis 
involves an alternation of the HTMA2– and TMA3– anions along the ribbon. Within the 
TMA3–···HTMA2–···TMA3– repeat unit of these ribbons (periodic repeat distance along 
the ribbon: form I, a' = 20.22 Å; form II, a' = 20.22 Å), one TMA3–/HTMA2– pair are 
linked by a direct O–H···O hydrogen bond involving the –COOH group of the HTMA2– 
anion and one of the –COO– groups of the TMA3– anion, and the other two O atoms of 
these groups are bridged by an O···H–N–H···O hydrogen-bonding arrangement with an 
intervening –N+H3 group. Thus, this set of hydrogen bonds gives rise to a cyclic graph 
set  1033R .
[55,56] The other HTMA2–/TMA3– pair in the ribbon motif are linked by the 
interaction of a –COO– group from each of these anions with two intervening –N+H3 
groups, which gives rise to a cyclic graph set  1034R . The primary difference between 
the structures of these two polymorphs lies in the relative disposition of adjacent 
ribbons of this type within the sheet and the nature of the hydrogen bonding between 
adjacent ribbons (Figure 3.6a, created by Dr Colan E. Hughes using the computer 
program Mathematica, constructed by aligning the a'-axes of forms I and II parallel to 
each other and by orienting the a'b'-planes of forms I and II parallel to each other) and 
some of these differences are highlighted by the yellow circles. 
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The hydrogen bonding involves the –N+H3 groups of HTBA+ cations and the OH 
groups of methanol molecules located in the region between adjacent ribbons. 
In terms of the HTBA+ cations, for both polymorphs, all three N–H bonds in each 
independent HTBA+ cation are used as donors in N–H···O hydrogen bonding to O 
atoms of the HTMA2– anion, the TMA3– anion or methanol molecules. With the 
exception of one specific N–H bond in form II (which forms a bifurcated hydrogen-
bonding arrangement involving the two O atoms of a –COO– group of the TMA3– 
anion), all N–H···O hydrogen bonds involve a single O atom as the acceptor. In terms 
of methanol molecules, for each polymorph, the O–H bond in each independent 
methanol molecule is used both (i) as the donor in an O–H···O hydrogen bond with an 
O atom of the HTMA2– anion or the TMA3– anion as the acceptor and (ii) as the 
 
Figure 3.6a. Overlay of the crystal structure of form I (cyan) and form II (magenta). 
The unit cell shown in each case is the transformed unit cell (a', b', c') defined in the 
text. The tert-butyl groups of the HTBA+ are omitted for clarity. 
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acceptor in an N–H···O hydrogen bond with an N–H bond of an HTBA+ cation as the 
donor. 
In order to understand the relationships between these two polymorphs, we used 
DSC to investigate their relative stabilities as a function of temperature. However, we 
observed no transformations at room temperature or low temperature (down to –100 °C) 
for either polymorph. However, on standing in an ambient atmosphere, both 
polymorphs are highly susceptible to loss of methanol, resulting in the same crystalline 
phase in each case (Figure 3.6b). However, crystal structure determination of this new 
desolvated phase from powder X-ray diffraction data has not yet been successful. 
3.3 Polymorphism of Co-Crystals of TMA2TBA3 
As mentioned above and elsewhere (section 3.1), formation of carboxylic acid 
dimer interactions with the graph set  822R  can yield an extensively hydrogen-bonded 
hexagonal network, as observed in the α-TMA crystal structure (Figure 3.2). Due to the 
low density, this kind of hexagonal network has potential as the structural basis of 
porous materials, the applications of which may be of particular interest. Similar 
extended hexagonal networks of TMA have also been found in co-crystals containing 
TMA molecules. However, due to the principle of close packing and space filling, 
interpenetration usually occurs in order to stabilize the structure.[229,240,241] However, it 
is also possible to avoid interpenetration by co-crystallizing TMA with a suitable 
 
Figure 3.6b. Powder X-ray diffraction pattern of the product on desolvation of  form I 
(red) and form II (black) of co-crystal of TMA2TBA5·(MeOH)3 
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molecule.[242-245] Here, we report two polymorphic structures of co-crystals of 
TMA2TBA3, both containing non-interpenetrated hydrogen-bonded hexagonal networks. 
3.3.1 Synthesis and Structure Determination 
The two polymorphs (denoted forms I and II) of TMA2TBA3 were prepared by 
vapour diffusion of anti-solvent into a solution of TMA and TBA in methanol. Vapour 
diffusion of ethanol or acetone into a methanol solution containing TMA and TBA 
(TMA:TBA = 2:3, molar ratio in solution) at ambient temperature resulted, after a few 
days, in single crystals of form I. Vapour diffusion of acetonitrile into a methanol 
solution containing TMA and TBA (TMA:TBA = 2:2.5, molar ratio in solution) at 
ambient temperature resulted, after a few days, in a mixture of crystals of form II and a 
second phase. The second phase was a methanol solvate with an asymmetric unit 
composed of two TMA molecules, two TBA molecules and one methanol molecule. We 
cannot distinguish this phase from form II by crystal shape or size. We left the mixture 
of crystals on the lab bench. After about two weeks, all the crystals of the methanol 
solvate became a white powder, allowing us to identify single crystals of form II of 
TMA2TBA3. 
Single-crystal X-ray diffraction data were collected at 150 K on a Nonius Kappa 
CCD diffractometer equipped with a molybdenum tube source (λ = 0.71073 Å). The 
crystal structures were solved (by direct methods) by SHELXS and refined using 
SHELXL.[196] Refinement of non-hydrogen atoms was carried out using anisotropic 
displacement parameters. All hydrogen atoms were located in difference Fourier maps 
and were added to the structural model according to idealized geometries. Refinement 
of hydrogen atoms was carried out using a riding model, with isotropic displacement 
parameter equal to 1.2 or 1.5 times the equivalent isotropic displacement parameter of 
the atom to which the hydrogen atom is bonded. In addition, The H atoms of certain 
carboxylic acids are disordered and the refinement of each those H atoms are refined 
over two sites with totally occupancy equal to 1. 
3.3.2 Structural Analysis and Discussion 
The crystallographic parameters of the two polymorphs of TMA2TBA3, which 
have been determined from single-crystal X-ray diffraction, are summarized in Table 
3.3 and the crystal structures of forms I and II are shown in Figures 3.7 and 3.8, 
respectively. In the case of form I, the space group is R3c, belonging to the 
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rhombohedral crystal system. This space group possesses high symmetry. Therefore, the 
asymmetric unit is composed of one independent HTBA+ cation and two independent 
(H3TMA)1/3 units (denoted as TMA1 and TMA2). The H atoms of the carboxylic acids 
of TMA1 and TMA2 are disordered over two sites with occupancies 0.29 and 0.71. 
Thus, this is equal to only one carboxylic acid group deprotonated, the charge 
between HTBA+ cations and two independent (H3TMA)1/3 units is balanced. Form II 
crystallizes in the triclinic system with space group P1¯ and an asymmetric unit 
comprising of five independent molecules: three independent HTBA+ cations and two 
independent H3TMA molecules (denoted as TMA3 and TMA4). The H atoms of the 
three carboxylic acids of TMA3 and TMA4 are disordered over two sites with the 
occupancies 0.36 and 0.64, 0.29 and 0.71, and 0.35 and 0.65. This is equal to three 
carboxylic acid groups of each two TMA molecules protonated, thus the charge is 
balanced in the asymmetric unit. 
Table 3.3 The crystallographic parameters of forms I and II of TMA2TBA3 
 Form I Form II 
Space Group R3c P1¯ 
Temperature (K) 296 (2) 296 (2) 
a/(Å) 16.7282(7) 7.3526(3) 
b/(Å) 16.7282(7) 16.2289(6) 
c/(Å) 21.1828(6) 16.4533(6) 
α/(°) 90 118.901(4) 
β/(°) 90 92.246(3) 
γ/(°) 120 95.790(3) 
V/(Å3) 5133.5(5) 1701.26(13) 
Z 18 2 
R1/(%) 4.21 5.17 
Rw2/(%) 8.88 15.21 
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As shown in Figures 3.7 and 3.8, for each polymorph, the crystal structure 
comprises non-interpenetrated hydrogen-bonded hexagonal networks. In the case of 
form I, the crystal structure comprises two-dimensional sheets of hydrogen-bonded 
hexagonal networks with a cavity of diameter of ca.16.7 Å and all the sheets are packed 
parallel to the ab-plane, which runs in the plane of the paper in Figure 3.7b. Within each 
sheet, the three TMA1 molecules and three TMA2 molecules are linked alternately to 
each other and thus form a planar hexagonal ring. The rings of TMA1 and TMA2 lie in 
the plane of the sheet, while the –N+H3 groups of the HTBA+ cations lie close to this 
plane linked by hydrogen bonding. 
 
Figure 3.7. (a) Hydrogen-bonding patterns of the hexagonal network in the flat sheets 
in the crystal structure of form I of co-crystal of TMA2TBA3, and (b) the complete 
crystal structure of form I. 
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For form II, the three TMA3 molecules and three TMA4 molecules are also 
alternately linked to each other to form hexagonal networks with the same size. 
However, the planes of the TMA3 and TMA4 molecules do not lie in the same plane. 
Therefore, the network is not planar but is instead corrugated; the –N+H3 groups of the 
HTBA+ cations also lie close to these corrugated sheets and are linked to TMA1 and 
TMA2 by hydrogen bonding. 
From Figures 3.7a and 3.8a, we can see that for both forms, each hexagonal ring 
is linked to six HTBA+ cations through N–H···O hydrogen-bonding arrangements. Thus, 
seemingly, there are six HTBA+ cations occupying each hexagonal ring. However, it is 
 
Figure 3.8. (a) Hydrogen-bonding patterns of the hexagonal network in the corrugated 
sheets in the crystal structure of form II of co-crystal of TMA2TBA3. (b) The complete 
crystal structure of form II. 
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not the true situation. As shown in Figures 3.9a and 3.9b, for both forms, within each 
hexagonal ring, there are only three HTBA+ cations occupying the centre of each 
hexagonal ring and the other three HTBA+ cations are linked to this hexagonal ring 
through hydrogen bond and are occupying the centre of the next hexagonal ring. In 
addition, for form I, the tert-butyl groups of all three HTBA+ cations point below the 
plane of the hexagonal ring. For form II, the tert-butyl group of one HTBA+ cation 
points below the plane of the hexagonal ring and the remaining tert-butyl groups of two 
HTBA+ cations point above the plane of the hexagonal ring. 
In terms of the TMA molecules, for each polymorph, there is only one type of 
cyclic hydrogen-bonding arrangement, corresponding to cyclic graph set  833R . 
Specifically, for form I, due to its high symmetry, within every hexagonal ring, all 
TMA1/TMA2 pairs are identical. Each TMA1/TMA2 pair is linked by a direct O–H···O 
hydrogen bond involving one –COOH group of TMA1 and one –COOH group of 
TMA2. In this hydrogen bond, the O···O distance is 2.52 Å and the two H atoms 
between these two O atoms are disordered over two sites with occupancies 0.71 and 
0.29. Therefore, we can consider that there is just one H atom shared between these two 
O atoms. The TMA1/TMA2 pair is also bridged by an O···H–N–H···O hydrogen-
bonding arrangement with an intervening –N+H3 group of TBA. This set of hydrogen 
bonds gives rise to the cyclic graph set  833R . However, in the case of form II, due to the 
 
Figure 3.9. (a) Three HTBA+ cations occupying each hexagonal ring in form I of 
TMA2TBA3. (b) Three HTBA
+ cations occupying each hexagonal ring in form II of 
TMA2TBA3. The HTBA
+ cations are displayed in space-filling model. 
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lower symmetry, within every hexagonal ring, the TMA3/TMA4 pairs are not exactly 
the same. There are three types of TMA3/TMA4 pair. In the three pairs, the O···O 
distances are 2.49 Å, 2.51 Å and 2.52 Å, respectively. In each O–H···O hydrogen bond, 
the H atom is disordered over two sites with occupancies 0.71 and 029, 0.65 and 0.35, 
and 0.64 and 0.36 (for the three pairs of TMA molecule). As in form I, there is just one 
H atom between each two O atoms. In a similar way as in form I, the TMA3/TMA4 pair 
is also bridged by an O···H–N–H···O hydrogen-bonding arrangement with an 
intervening –N+H3 group of TBA and thus forms the graph set  833R . 
In addition, for form I, all O atoms of TMA molecules are used as hydrogen-bond 
acceptors. However, in form II, all O atoms of TMA4 are used as hydrogen-bond 
acceptors to form hydrogen bonds but, three O atoms of TMA3 are used as 
hydrogen-bond acceptors and the other three O atoms of TMA3 do not form any 
hydrogen bonds. In order to compare the hexagonal rings formed in the two polymorphs, 
these are overlaid in Figure 3.10 (this figure was created by Dr Colan E. Hughes using 
the computer program Mathematica). From Figure 3.10, we can see that the sizes of 
these two hexagonal rings are almost the same, the primary difference is the relative 
disposition of carboxylic acid or carboxylate groups of each TMA molecule. 
In terms of the HTBA+ cations, for each polymorph, all three N–H bonds in each 
independent HTBA+ cation are used as donors in N–H···O hydrogen bonds, linked with 
O atoms of TMA molecules as the acceptor. In each polymorph, two N–H bonds are 
linked to a TMA1/TMA2 pair (form I) or a TMA3/TMA4 pair (form II) to form graph 
set  833R . Another N–H bond is linked to a TMA2 molecule (in form I) or a TMA4 
molecule (in form II) in the adjacent layer, linking all hexagonal networks together. In 
 
Figure 3.10. Overlay of the hexagonal ring in form I (cyan) and form II (magenta).  
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addition, from the structure of form I, we can see that there are six individual layers of 
the hexagonal network along the c-axis in every unit cell. According to the symmetric 
relationship and symmetry operations, when the molecules of one layer are translated by 
⅔a along the a-axis, then translated by ⅓b along the b-axis, followed by reflection in 
the ab-plane, we get a second layer of the hydrogen-bonded network (Figure 3.11). The 
same symmetry operation generates the other layers. In form II, there are two 
corrugated hexagonal networks (along the a-axis) in every unit cell, the second network 
generated by the crystallographic inversion centre. 
3.4 Summary 
Two polymorphic co-crystal systems containing TMA and TBA have been 
presented in this chapter. In the case of co-crystals of TMA2TBA5·(MeOH)3, the crystal 
structures of the two polymorphs both possess quite similar parallel 2D sheets but, the 
hydrogen-bonding pattern within these sheets shows subtle (but significant) differences. 
In the case of co-crystals of TMA2TBA3, despite the TMA molecules being partially 
deprotonated, both polymorphs still retain hexagonal networks and, due to the presence 
of TBA molecules, the hexagonal networks within both polymorphs are 
non-interpenetrated. However the network in form I is planar and while the network in 
form II is corrugated. 
 
Figure 3.11. Overlay of the hexagonal network layers (first layer: green; second layer: 
orange) in the crystal structure of form I of co-crystal of TMA2TBA3. 
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Chapter 4 Structural Analysis of Families of 
Co-Crystals of Trimesic Acid and tert-Butylamine 
4.1 Introduction 
The structural diversity of organic co-crystals is a very interesting phenomenon 
and has become a hot issue in recent years. In 1969, Duchamp and Marsh[246] 
determined the crystal structure of trimesic acid (TMA) and showed that TMA 
molecules can form hexagonal networks with triple interpenetration. This observation 
provided the basis for the design of organic porous materials and, since then, the TMA 
molecule has attracted considerable attention in crystal engineering. In the field of 
organic co-crystals, due to its symmetric molecular structure and its capability to form 
homo-dimers and hetero-dimers with a variety of functional groups (such as 
alcohols[247], carboxylic acids[225,241], pyridines[230,240,248] and organic amines[226,249]), 
trimesic acid has been widely studied and a wide range of organic co-crystals containing 
TMA molecules or deprotonated forms of TMA have been synthesized. It has been 
reported that organic co-crystals containing TMA molecules or deprotonated TMA 
anions are able to form a series of one-dimensional (1D), two-dimensional (2D) and 
three-dimensional (3D) frameworks, such as extended hexagonal networks with[240,248] 
or without[249] interpenetration. These interesting frameworks have shown versatile 
hydrogen-bonding patterns between carboxylic acid or carboxylate groups of pairs of 
TMA molecules, such as (Figure 4.1) typical acid-acid head-to-head  822R , single-
bridged  1033R  and double-bridged  12
4
4R  dimer motif patterns. 
Incorporation of solvent molecules,[250] such as methanol and water molecule,[251] 
into crystal structures is a wide-spread phenomenon in organic co-crystals. In such cases, 
the solvent molecules can usually be regarded as a nuisance because the presence of 
solvent molecules can render the crystals unstable. However, in some cases, the 
presence of solvent molecules is the key factor for successful crystallization. Solvent 
molecules in crystal structures may act as hydrogen-bond acceptors or donors to form 
three-dimensional networks and/or act as space fillers to stabilize channels or cavities 
within crystal structures. In addition to their value in fundamental academic study, 
solvates also have practical applications in industry, such as in the pharmaceutical 
industry. In many cases, a solvate of a given active pharmaceutical ingredient (API) 
may be chosen as the final commercial product if it is sufficiently stable and improves 
 66 
the quality of the API. Specifically, about three-quarters of APIs can form hydrate 
crystal structures. The water molecule is very small and can often be accommodated at 
many positions in the crystal structure, partly as a result of the versatility of the water 
molecule to act both as a hydrogen bond donor and as a hydrogen bond acceptor. In 
addition, water is almost always present in the atmosphere, and in some cases it is quite 
easy for ambient water molecules to be incorporated into a crystal structure. 
In the course of studying co-crystals of TMA and TBA, we discovered a series of 
co-crystals with different stoichiometries. The resulting structures contain diverse and 
interesting types of hydrogen-bonded networks, such as single-layered sheets, 
corrugated sheets, double-layered sheets and brick-wall networks. Most of these 
structures are solvates. In fact, incorporating solvent molecules into the crystal 
structures has been found to be quite common for this family of materials. It has been 
suggested[252] that the probability of forming a hydrate is particularly high when the 
components possess charged groups or polar groups, such as carbonyl (C=O), hydroxyl 
(OH) and primary amine (N–H) groups, which is exactly the case in the system of co-
crystals of TMA and TBA. In these structures, the solvent molecules (alcohol or water) 
act as a “glue” via intermolecular hydrogen-bonding interactions between TMA and 
TBA molecules to form three-dimensional networks and/or as space fillers in order to 
stabilize empty channels or cavities formed by the TMA and TBA molecules. 
 
Figure 4.1. Three common hydrogen-bonding motifs between two carboxylic acid or 
carboxylate groups. (I) Typical head-to-head )8(
2
2R , (II) single-bridged )10(
3
3R  and (III) 
double-bridged )12(
4
4R . 
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It is well known that the goal of crystal engineering is to design and predict 
crystal structures based on knowledge of the molecular structures and the preferred 
modes of intermolecular interaction between the components. However, this task can be 
very complicated and far from predictable. However, “supramolecular synthons” based 
on hydrogen bonds can simplify this task to some extent, and this concept has been used 
extensively to facilitate the design of crystal structures. In order to identify common 
“synthons” that appear in the family of organic co-crystals of TMA and TBA, in this 
chapter we classify all the co-crystal structures of TMA and TBA into four families in 
accordance with their stoichiometry (TMA:TBA = 2:1, 1:1, 1:2 and 1:3) and then 
analyse the structural features of each family of co-crystals from the view point of 
hydrogen bonding with graph set notation, especially, concentrating on the hydrogen-
bonding patterns between carboxylic acid or carboxylate groups of pairs of TMA 
molecules. 
4.2 Structural Diversity of Solvatomorphs of TMA2TBA1 
As mentioned above, water is all around us, and the formation of hydrate co-
crystals is quite common. In the course of studying co-crystals of TMA and TBA, when 
the TMA:TBA stoichiometry is 2:1, we obtained four different types of hydrate (tri-
hydrate, di-hydrate, mono-hydrate and hemi-hydrate), one methanol solvate and one 
anhydrous form by using different crystallization conditions and different crystallization 
methods. To the best of our knowledge, the existence of four different types of hydrate 
in the same family of organic co-crystals with the same stoichiometry is very rare. 
4.2.1 Synthesis and Structure Determination 
The crystallization process to form the tri-hydrate TMA2TBA1·(H2O)3 involved 
slow evaporation of a solution containing TMA and TBA (TMA:TBA = 2:1, molar ratio) 
in ethanol at room temperature. After a few days, the solution dried out, resulting in a 
white powder. Recrystallization of the powder in mixtures of ethanol and water 
(ethanol:water = 1:1, volume ratio), occasionally gave, after a few days, single crystals 
of the tri-hydrate. However, this process was quite difficult to reproduce. In the vast 
majority of cases, single crystals of the di-hydrate were obtained. Furthermore, single 
crystals of the tri-hydrate cannot be prepared directly by using ethanol and water as the 
crystallization solvent, as this results in the formation of di-hydrate single crystals. 
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The crystallization processes to form the di-hydrate TMA2TBA1·(H2O)2 were as 
follows: (i) slow evaporation of a solution containing TMA and TBA (TMA:TBA = 2:1, 
molar ratio) in ethanol and water (ethanol:water = 3:1, 2:1, 1:1, 1:2 or 1:3, volume ratio) 
at room temperature; after a few days, single crystals of the di-hydrate were obtained; (ii) 
1 mmol TBA dissolved in 10 ml water in a glass bottle, then slowly added this solution 
into 10 ml methanol solution containing TMA (1 mmol) at ambient temperature; the 
solution was then allowed to slowly evaporate, and after a few days single crystals of 
the di-hydrate were obtained; (iii) slow evaporation of a solution containing TMA and 
TBA (TMA:TBA = 2:1, molar ratio) in methanol and water (methanol:water = 5:1, 4:1, 
3:1, 2:1, 1:1, 1:2, 1:3, 1:4 or 1:5, volume ratio) at ambient temperature; after a few days, 
single crystals of the di-hydrate were obtained. 
The crystallization process to form anhydrous TMA2TBA1 involved dehydration 
of a sample of the di-hydrate in an oven at 100 °C for at least three days. This process 
produced a pure powder sample of anhydrous TMA2TBA1. 
The crystallization process to form the mono-hydrate TMA2TBA1·(H2O)1 
involved the dissolution of a sample of the anhydrous form in methanol and water 
(methanol:water = 1:1, volume ratio), followed by slow evaporation. After a few days, 
single crystals of the mono-hydrate were obtained. However, the process was quite 
difficult to reproduce. In the vast majority of cases, single crystals of the di-hydrate 
were obtained. 
The crystallization process to form the hemi-hydrate TMA4TBA2·(H2O)1 involved 
heating a sample of the di-hydrate from room temperature to 200 °C, then cooling down 
to room temperature. This process was carried out in the DSC instrument, with the 
sample in a sealed aluminium pan with heating and cooling rates of 10 °C/min–1. A 
powder sample of the hemi-hydrate was obtained. 
The crystallization processes to form the methanol solvate TMA2TBA1·(MeOH)1 
were as follows: (i) a solution containing TMA and TBA (TMA:TBA = 2:1, molar ratio) 
in methanol was allowed to evaporate slowly at room temperature; after a few days, 
single crystals of the methanol solvate were obtained; (ii) a hot methanol solution 
containing TMA and TBA (TMA: TBA = 2:1, molar ration) was prepared at 55 °C in a 
conical flask, followed by slow cooling from 55 °C to 25 °C in an incubator; single 
crystals of the methanol solvate were obtained. 
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All crystal structures (except the structures of the anhydrous form and the hemi-
hydrate) described in this chapter were determined by single-crystal XRD at 150 K on a 
Nonius Kappa CCD diffractometer equipped with a molybdenum tube source 
(λ = 0.71073 Å). The crystal structures were solved (by direct methods) by SHELXS 
and refined using SHELXL.[196] Refinement of non-hydrogen atoms was carried out 
using anisotropic displacement parameters. All hydrogen atoms were located in 
difference Fourier maps and were added to the structural model according to idealized 
geometries. Refinement of hydrogen atoms was carried out using a riding model, with 
isotropic displacement parameter equal to 1.2 or 1.5 times the equivalent isotropic 
displacement parameter of the atom to which the hydrogen atom is bonded. 
The crystal structures of the anhydrous form and the hemi-hydrate were 
determined directly from the powder XRD data. Firstly, high quality of powder X-ray 
diffraction pattern data were recorded for anhydrous form and hemi-hydrate sample at 
ambient temperature on a Bruker D8 instrument (CuKα1; Ge monochromated; 
transmission geometry) with a tape sample holder (2θ range, 4 – 50°; total time, 48 hrs). 
Secondly, the powder XRD patterns of anhydrous form and hemi-hydrate were indexed 
by using program CRYSTFIRE, combined with the program CHEKCELL. The Le 
Bailing fitting using GSAS gave a good quality of fits with space groups P21/a (for 
anhydrous form) and P1¯ (for hemi-hydrate), respectively (Figure 4.2a and 4.2b). For the 
anhydrous form, a = 22.743 Å, b = 7.512 Å, c = 14.992 Å, β = 114.159°, 
(V = 2336.82 Å3), Rwp = 2.17%, Rp = 1.69%. For the hemi-hydrate form, a = 15.071 Å, 
b = 21.503 Å, c = 7.391 Å, α = 90.319°, β = 89.99°, γ = 74.963°, (V = 2313.85 Å3), 
Rwp = 1.85%, Rp = 1.43%. 
Given the volume of the unit cell and consideration of density, for the anhydrous 
form, there are two TMA molecules and one TBA molecule in the asymmetric unit; for 
the hemi-hydrate form, there are four TMA molecules, two TBA molecules and one 
water molecule in the asymmetric unit. The refined unit cell and profile parameters 
obtained from the Le Bail fits were used in subsequent structure solution calculations. 
Structure solution was carried out using the direct-space genetic algorithm (GA) 
technique incorporated in the program EAGER[195] followed by Rietveld refinement[213]. 
In total, 16 independent GA calculations were carried out for each model and the GA 
calculation was allowed to evolve for 1000 generations for a population size of 100. In 
each generation, 10 mating operations and 50 mutation operations were carried out. The 
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results from all these structure solution calculations were assessed and evaluated to 
determine which model gives the best structure solution. In the Rietveld refinement, 
standard restraints were applied to bond lengths and bond angles, and planar restraints 
were applied to benzene rings and carboxylate groups. The structural model with lowest 
Rwp from GA calculation was used as the initial structural model for Rietveld refinement. 
The final Rietveld refinement gave good fits to the powder XRD data for both samples 
(for anhydrous form, Rwp = 2.34%, Rp = 1.81%; for hemi-hydrate, Rwp = 2.27%, 
Rp = 1.73%; Figure 4.2c and 4.2d), with the following refined parameters: for the 
anhydrous form, a = 22.7418 (6) Å, b = 7.5122 (1) Å, c = 14.9901 (4) Å, 
β = 114.1589 (20)°, (V = 2336.61 (10) Å3); for the hemi-hydrate form, 
a = 15.0729 (4) Å, b = 21.5029 (6) Å, c = 7.3900 (1) Å, α = 90.336 (4)°, β = 90.021 (4)°, 
γ = 74.9580 (31)°, (V = 2313.08 Å3). The details of the process for determination of 
crystal structures from powder XRD data are described in more detail in Chapters 5 and 
6. 
 
Figure 4.2. Le Bail fits of anhydrous form (a) and hemi-hydrate (b) of co-crystal of 
TMA2TBA1; Rietveld Refinement of anhydrous form (c) and hemi-hydrate (d) of co-
crystal of TMA2TBA1. 
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4.2.2 Structural Summary of Co-Crystals of TMA2TBA1 
The relationships between these materials are summarized in Figure 4.2e. As 
shown in Figure 4.2, the di-hydrate TMA2TBA1·(H2O)2 is stable at room temperature in 
the open air. The other solvate co-crystals slowly transformed to the di-hydrate 
TMA2TBA1·(H2O)2 at room temperature. The crystallographic parameters of the six 
structures are summarized in Table 4.1 and the crystal structures are shown in Figures 
4.3 to 4.12. 
Table 4.1 Crystallographic parameters of co-crystals of TMA2TBA1. 
 Tri-Hydrate Di-Hydrate Mono-Hydrate 
Space group P21/n P21/n P21/n 
a/Å 6.7390(2) 15.2910(3) 15.2931(3) 
b/Å 41.3370(12) 9.5020(2) 7.2592(1) 
c/Å 9.5880(3) 16.9010(5) 21.5708(4) 
α/° 90 90 90 
β/° 106.763(1) 102.065(1) 104.885(2) 
γ/° 90 90 90 
V(Å3) 2557.43(13) 2401.39(10) 2314.34 
Z 4 4 4 
Calculated Density 
(g/cm3) 
1.422 1.464 1.468 
R1/(%) 8.76 5.76 3.83 
Rw2/(%) 17.27 13.37 10.62 
 
 Hemi-Hydrate Methanol Solvate Anhydrous Form 
Space group P1¯ P1¯ P21/a 
a/Å 15.0729(4) 6.8545(2) 22.7418(6) 
b/Å 21.5029(6) 8.8246(2) 7.5122(1) 
c/Å 7.3900(1) 20.0279(7) 14.9901(4) 
α/° 90.336(4) 90.994(2) 90 
β/° 90.021(4) 96.235(2) 114.1589(20) 
γ/° 74.9580(31) 94.409(2) 90 
V(Å3) 2313.08 1200.32(6) 2336.61(10) 
Z 2 2 4 
Calculated 
Density (g/cm3) 
1.443 1.451 1.403 
R1/(%) / 3.83 / 
Rw2/(%) / 10.62 / 
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Figure 4.2e. The relationships between solvatomorphs of co-crystals of TMA2TBA1. In 
this figure, DVS stands for dynamic vapor sorption. RH stands for relative humilities. 
These six crystal structures can be classified into three categories in accordance 
with their structural features. Thus, the structure of the di-hydrate comprises double-
layered sheets without interpenetration (Figure 4.3), the structures of the tri-hydrate and 
methanol solvate are interpenetrated by two different sets of ribbons (Figure 4.6) and 
the remaining three structures are self-interpenetrated by one set of ribbons (Figure 
4.10). 
4.2.3 Structural Analysis of the Di-Hydrate of TMA2TBA1 
The crystal structure of the di-hydrate TMA2TBA1·(H2O)2 is monoclinic with 
space group P21/n and the asymmetric unit is composed of five independent molecules: 
one H3TMA molecule, one H2TMA
– anion, one HTBA+ cation and two water molecules. 
The structure (Figure 4.3) does not form the typical honeycomb network but, instead 
comprises double-layered sheets which are linked by intervening water molecules and 
HTBA+ cations via hydrogen bonding. The distance between two adjacent sheets is 
about 3.5 Å and the distance between adjacent HTBA+ cations is about 10.4 Å. The 
double-layered sheets are stacked in an offset manner. 
 73 
In Figure 4.4, the two types of sheet are shown. One sheet is formed by H2TMA
– 
anions (denoted as the anionic sheet) and the other sheet is formed by H3TMA 
molecules (denoted as the molecular sheet). Both sheets are not exactly flat. The anionic 
and molecular sheets both comprise hydrogen-bonded ribbon motifs (ribbons parallel to 
the b-axis). These ribbons are indicated by the region between the two dashed lines in 
Figure 4.4. We note that adjacent H2TMA
– anionic ribbons do not lie in the same plane 
but are slightly offset (the offset between adjacent anionic ribbons is 0.40 Å). It is for 
this reason that the anionic sheet is not entirely flat (Figure 4.3). The same situation 
exists for the molecular sheets (the offset between adjacent molecular ribbons is 0.77 Å). 
The distance between a pair of anionic/molecular ribbons is 3.5 Å (Figure 4.3). 
From Figure 4.4a, we can see that, within an anionic ribbon, adjacent H2TMA
– 
anions are linked by a direct O–H···O hydrogen bond involving an OH group of one 
H2TMA
– anion and an O atom of one –COO– group of another H2TMA– anion, and the 
other two O atoms of these groups are bridged by an O···H–O–H···O hydrogen-
bonding arrangement with an intervening water molecule, resulting in the cyclic graph 
set  1033R . In this hydrogen-bonding arrangement, the water molecule provides two 
hydrogen bond donors within the sheet. Between two adjacent anionic ribbons, adjacent 
H2TMA
– anions from each ribbon are double-bridged by the intervening water molecule 
and an –N+H3 group, forming a cyclic hydrogen-bonding ring (graph set  1034R ). These 
two graph sets are marked in Figure 4.4a. 
 
Figure 4.3. Double-layered sheets in the crystal structure of the di-hydrate of 
TMA2TBA1·(H2O)2. 
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Within a molecular ribbon (Figure 4.4b), a slightly different cyclic hydrogen-
bonding arrangement (graph set  1033R ) is formed between –COOH groups of adjacent 
TMA molecules and an intervening water molecule, which acts as both hydrogen bond 
acceptor and donor. Thus, the functionalities of the water molecules in the anionic and 
molecular sheets are not the same. Between adjacent molecular ribbons, an OH group of 
–COOH of a TMA molecule (denoted TMA1) of one ribbon is linked to two other TMA 
molecules (denoted TMA2 and TMA3) of another ribbon via  
O–H(TMA1)···O–H (water)···O (TMA2) and O–H (TMA1)···O (water)···O–H (TMA3) 
hydrogen-bonding arrangements with no cyclic hydrogen-bonding ring formed, due to 
the intervening HTBA+ cation linking to only one adjacent TMA molecule through  
O···H–N+ hydrogen bonding. 
 
Figure 4.4. (a) Anionic sheet and (b) molecular sheet of the crystal structure of the 
di-hydrate. 
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As shown in Figure 4.5, within both anionic and molecular sheets, groups of three 
adjacent H2TMA
– anions and H3TMA molecules form a hydrogen-bonded triangular 
ring (graph set  2855R ) involving three intervening water molecules. The two triangular 
rings in adjacent sheets are parallel to each other but, slightly offset, and are linked to 
each other through the three intervening water molecules, which gives rise to a cavity. 
One HTBA+ cation occupies the centre of the cavity and the HTBA+ cation is linked to 
one H3TMA molecule through O···H–N+ hydrogen bonds and linked to two H2TMA– 
anions through another two O···H–N+ hydrogen bonds. In order to balance the charge of 
the H2TMA
– anions, the –N+H3 group of the HTBA+ cation is close to the anionic sheet. 
Thus, the distance from the N atom of the –N+H3 groups to the anionic sheet is slightly 
shorter than the distance to the molecular sheet. These three hydrogen bonds are marked 
in Figure 4.5 and the distances (H···O) are 1.94 Å, 1.92 Å and 2.11 Å. In this structure, 
all water molecules act as bridges, providing two hydrogen bond donors and two 
hydrogen bond acceptors to link H2TMA
– anions and H3TMA molecules together to 
form a 3D network. 
4.2.4 Structural Comparison Between the Tri-Hydrate and the Methanol Solvate of 
TMA2TBA1. 
 
Figure 4.5. Cavity formed by double-layered anionic (purple) and molecular (cyan) 
sheets in the structure of the di-hydrate. 
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The tri-hydrate TMA2TBA1·(H2O)3 is monoclinic with space group P21/n and the 
asymmetric unit is composed of one neutral H3TMA molecule, one H2TMA
– anion, one 
HTBA+ cation and three water molecules. The methanol solvate TMA2TBA1·(MeOH)1 
is triclinic with space group P1¯ and the asymmetric unit is composed of one neutral 
H3TMA molecule, one H2TMA
– anion, one HTBA+ cation and one methanol molecule. 
These two crystal structures (Figures 4.6a and 4.6b) are both constructed from two 
sets of parallel ribbons which interpenetrate each other at angles of 43.66° (tri-hydrate) 
and 54.50° (methanol solvate). In both structures (Figure 4.7), HTBA+ cations and 
solvent molecules occupy the space between ribbons and act as a “glue” to link these 
ribbons together to form three-dimensional networks. In both structures (Figures 4.8 and 
4.9), one ribbon is formed by H2TMA
– anions (denoted ribbon I, Figures 4.8a and 4.9a) 
and the other ribbon is formed by H3TMA molecules (denoted ribbon II, Figures 4.8b 
and 4.9b). In the structure of the tri-hydrate (Figure 4.8a), within ribbon I, adjacent 
H2TMA
– anions are linked directly on one side by the typical carboxylic acid dimer 
head-to-head hydrogen-bonding motif (graph set  822R ), whilst on the other side, the  
–COO– group and the second –COOH group of each H2TMA– anion link to each other 
via two intervening water molecules to form a large hydrogen-bonding ring, with graph 
set  2044R . In the structure of the methanol solvate (Figure 4.9a), two adjacent H2TMA– 
anions are linked directly not only by the head-to-head carboxylic acid dimer motif but 
also by direct hydrogen bonding between the –COO– group of one H2TMA– anion and 
the second –COOH group of the other H2TMA– anion, forming graph set  1622R . 
 
Figure 4.6. Interpenetrated structures of (a) the tri-hydrate and (b) the methanol 
solvate. For clarity, the blue & green lines represent two different sets of ribbons. 
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Figure 4.8. Two types of ribbon, (a) type I and (b) type II in the crystal structure of the 
tri-hydrate and (c) the hydrogen-bonding patterns formed between these two ribbons. 
 
Figure 4.7. Structures of (a) the tri-hydrate and (b) the methanol solvate. 
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In the case of ribbon II for the tri-hydrate (Figure 4.8b), one H3TMA molecule is 
linked to an adjacent H3TMA molecule by a direct O–H···O hydrogen bond and by an 
intervening water molecule, giving rise to the cyclic graph set  1033R . As discussed 
above (section 4.2.3), this hydrogen-bonding motif is also observed in the structure of 
the di-hydrate (Figure 4.4b). However, in the structure of the methanol solvate (Figure 
4.9b), the ribbons formed by H3TMA molecules are different. Adjacent H3TMA 
molecules are linked directly only by a single O···H–O hydrogen bond and no cyclic 
hydrogen- bonding arrangement is formed. 
In the crystal structure of the tri-hydrate (Figure 4.8c), the two types of ribbon are 
linked together by a direct O···H–O hydrogen bond and via two intervening water 
 
Figure 4.9. Two types of ribbon (a) type I and (b) type II in the methanol solvate and (c) 
the hydrogen-bonding patterns formed between these two ribbons. 
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molecules and the –N+H3 group of the HTBA+ cation, giving rise to two graph sets 
 1034R . This situation is quite different from the two graph sets  10
3
4R  and  10
3
3R  
observed in the structure of the di-hydrate (Figure 4.4a). By comparison, in the 
methanol solvate (Figure 4.9c), the two sets of ribbons are linked directly by an  
O···H–O hydrogen bond and are bridged by the –N+H3 group of one HTBA+ cation, 
forming a cyclic hydrogen-bonding arrangements with graph set  1033R . 
In both structures, all three N–H bonds of the HTBA+ cation act as hydrogen bond 
donors and each methanol molecule in the methanol solvate acts both as a hydrogen 
bond donor (bonding to one H2TMA
– anion) and as a hydrogen bond acceptor (bonding 
to one H3TMA molecule). However, the methanol molecule is not involved in any 
cyclic hydrogen-bonding arrangement. In the structure of the tri-hydrate, there are three 
independent water molecules. The functionality of each water molecule is quite 
different. One water molecule (Figure 4.8a) is hydrogen bonded to two H2TMA
– anions 
to form graph set  2044R . The second water molecule (Figure 4.8b) is hydrogen bonded 
to two H3TMA molecules to form graph set  1033R . The third water molecule (Figure 
4.8c) is hydrogen bonded to a HTBA+ cation and a H2TMA
– anion to form graph set 
 1034R , with the intervention also of the first water molecule. 
4.2.5 Structural Comparison Between the Mono-Hydrate, Hemi-Hydrate and Anhydrous 
Form of TMA2TBA1 
The mono-hydrate and the anhydrous form are monoclinic with space groups 
P21/n and P21/a, respectively. The asymmetric unit of the mono-hydrate and the 
anhydrous form comprise one neutral H3TMA molecule, one H2TMA
– anion, one 
HTBA+ cation and, in the mono-hydrate, one water molecule. The hemi-hydrate is 
triclinic with space group P1¯ and the asymmetric unit is composed of two neutral 
H3TMA molecules, two H2TMA
– anions, two HTBA+ cations and one water molecule. 
All three crystal structures (Figure 4.10) are constructed from sheets of parallel ribbons 
which interpenetrate with symmetry copies at angles of 51.96° (mono-hydrate), 52.45° 
(hemi-hydrate) and 53.97° (anhydrous form). Furthermore, the TMA ribbons in each 
structure are essentially the same (Figure 4.11). 
 80 
 
Figure 4.10. Self-interpenetrated structures of (a) the mono-hydrate, (b) the 
hemi-hydrate and (c) anhydrous TMA2TBA1. For clarity, the blue & green lines 
represent two different sets of ribbons. 
 
 
Figure 4.11. The common ribbon motif in the structures of (a) the mono-hydrate (b) the 
hemi-hydrate and (c) anhydrous TMA2TBA1. For clarity, the blue & green lines are 
represent two different sets of ribbons. 
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As shown in Figure 4.11, the common ribbon in each structure involves an 
alternation of H2TMA
– anions and H3TMA molecules. Within the common ribbon, one 
H2TMA
–/H3TMA pair is linked on one side directly by the typical carboxylic acid dimer 
head-to-head hydrogen-bonding motif (graph set  822R ), whilst on the other side, the  
–COO– group of one H2TMA– anion and the –COOH group of the H3TMA molecule are 
linked directly, giving rise to the graph set  1622R . As shown in Figure 4.12, in all three 
structures, adjacent interpenetrated ribbons are linked together by a direct O···H–O 
hydrogen bond. The major difference between the three structures is that, in the 
mono-hydrate (Figure 4.12a), adjacent interpenetrated ribbons are also linked by an 
intervening HTBA+ anion to form a cyclic hydrogen-bonded ring, described by graph 
set  1244R . The water molecule acts as a hydrogen bond acceptor, linked to the adjacent 
HTBA+ anion through O···H–N hydrogen bonding. In the structure of the hemi-hydrate 
and the anhydrous form (Figure 4.12b and 4.12c), there is no cyclic hydrogen bonding 
formed between the two interpenetrated ribbons. 
4.2.6 Summary 
When the stoichiometric ratio between TMA and TBA is 2:1, we obtained six 
different co-crystals. The crystal structures exhibit aspects of structural similarity as 
 
Figure 4.12. The hydrogen-bonding patterns formed between two interpenetrated 
ribbons in the structures of (a) the mono-hydrate (b) the hemi-hydrate and (c) 
anhydrous TMA2TBA1. 
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well as significant structural diversity. Thus, one structure comprises double-layered 
sheets and the other five structures comprise single hydrogen-bonded ribbons with 
interpenetration. With the participation of HTBA+ cations and solvent molecules, the  
–COOH and –COO– groups of adjacent H3TMA molecules and H2TMA– anions form 
different types of extended hydrogen-bonding patterns (Figure 4.13). Specifically, 
between adjacent TMA molecules, apart from the typical carboxylic acid dimer head-to-
head hydrogen-bonding motif (graph set  822R ), three different single-bridged cyclic 
hydrogen-bonding motifs  1033R , one single-bridged cyclic hydrogen-bonding motif 
 1034R  and one double-bridged cyclic hydrogen-bonding motif  10
3
4R  are observed in 
this family of co-crystals of TMA and TBA. 
4.3 Solvatomorphs of TMA1TBA1 
When the stoichiometric ratio between TMA and TBA is 1:1, we obtained three 
different crystal structures, comprising one non-solvated material, one methanol solvate 
and one ethanol solvate, by using different crystallization conditions and methods. All 
three crystal structures may be described in terms of non-interpenetrated brick-wall 
networks. To the best of our knowledge, TMA has been used extensively to form 
honeycomb networks in organic co-crystals, while brick-wall networks of TMA 
molecules in organic co-crystals are not common[245]. 
 
Figure 4.13. The hydrogen-bonding motifs exhibit in the family of co-crystals of 
TMA2TBA1 
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4.3.1 Synthesis and Structure Determination 
The crystallization processes to form the methanol solvate TMA2TBA2·(MeOH)1 
were as follows: (1) a solution containing TMA and TBA (TMA:TBA = 1:1, molar ratio) 
in methanol was allowed to evaporate slowly at room temperature. After a few days, the 
solution dried out in air, and no large single crystals were formed (just microcrystalline 
materials of the methanol solvate were formed). By recrystallization from methanol and 
water and allowing it evaporate slowly at room temperature (1:1, volume ratio), after a 
few days, single crystals of the methanol solvate were obtained. (2) Crystallization was 
carried out by vapour diffusion of acetone (or acetonitrile) into a solution of TMA and 
TBA (TMA:TBA = 1:1, molar ratio) in methanol at room temperature; after a few days, 
single crystals of the methanol solvate were obtained. 
The crystallization process to form the ethanol solvate TMA1TBA1·(EtOH)0.25 
involved vapour diffusion of hexane, acetone or acetonitrile into an ethanol solution 
containing TMA and TBA (TMA:TBA = 2:1) at ambient temperature. After a few days, 
single crystals of the ethanol solvate were obtained. 
The crystallization process to form the non-solvated material TMA1TBA1 
involved vapour diffusion of acetonitrile into a methanol and iso-propanol (7:1, volume 
ratio) solution of TMA and TBA (4:3, molar ratio) at room temperature. After a few 
days, needle crystals were formed (a mixture of the methanol solvate and the non-
solvated material). These crystals were left in the open air for a few days. The methanol 
solvate became a white powder. However, some crystals were still transparent and these 
crystals were the non-solvated material. Since the morphologies of the methanol solvate 
and non-solvated material are both needles, we could not distinguish them by their 
morphology. 
Single-crystal X-ray diffraction data for these three structures were collected at 
150 K on a Nonius Kappa CCD diffractometer equipped with a molybdenum tube 
source (λ = 0.71073 Å). The crystal structures were solved (by direct methods) by 
SHELXS and refined using SHELXL. Refinement of non-hydrogen atoms was carried 
out using anisotropic displacement parameters. All hydrogen atoms were located in 
difference Fourier maps and were added to the structural model according to idealized 
geometries. Refinement of hydrogen atoms was carried out using a riding model, with 
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isotropic displacement parameter equal to 1.2 or 1.5 times the equivalent isotropic 
displacement parameter of the atom to which the hydrogen atom is bonded. 
4.3.2 Structural Analysis and Discussion 
The crystallographic parameters of these three structures are summarized in 
Table 4.2 and the crystal structures are shown in Figures 4.14 and 4.15. 
Table 4.2 Crystallographic parameters of three co-crystals of TMA1TBA1. 
 Non-Solvate Methanol Solvate Ethanol Solvate 
Asymmetric unit TMA1TBA1 TMA2TBA2·(MeOH)1 TMA1TBA1·(EtOH)0.25 
Crystal system Orthorhombic Orthorhombic Orthorhombic 
Space group Pnma Pn21a Pnma 
a/Å 6.7096(2) 6.6455(2) 6.7024(2) 
b/Å 18.4261(4) 18.4347(5) 18.4663(4) 
c/Å 24.8287(5) 24.7661(5) 24.8273(6) 
V(Å3) 3036.62(13) 3034.04(14) 3072.84(14) 
Z 8 4 8 
Calculated 
Density (g/cm3) 
1.226 1.310 1.266 
R1/(%) 4.63 5.85 9.60 
Rw2/(%) 13.58 14.48 28.37 
 
Figure 4.14. The crystal structures of (a) the non-solvated material (b) the ethanol 
solvate and (c) the methanol solvate. 
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From Figure 4.14 and Table 4.2, we can see that all three co-crystal structures are 
very similar. Firstly (Table 4.2), all of these materials are orthorhombic although with 
different space groups (for the non-solvated material and ethanol solvate, the space 
group is Pnma; for the methanol solvate, the space group is Pn21a) and the unit cell 
parameters and volumes are quite similar. In addition, all of these structures comprise 
HTBA+ cations and H2TMA
– anions. Secondly (Figure 4.14), all of these structures are 
composed of two-dimensional, brick-wall networks instead of hexagonal network sheets, 
which are generated by six adjacent H2TMA
– anions through –COOH···–COO– 
hydrogen bonding. This hydrogen-bonding arrangement creates almost the same size of 
cavities with dimensions of 16.2 × 11.1 Å in each structure, which is comparable with 
the cavities observed in the crystal structure of pure α-trimesic acid (14 × 14 Å). Third, 
in every cavity in all three structures, there are four HTBA+ cations and, due to the 
symmetry of each structure, the positions of all four HTBA+ cations are symmetry 
related. 
We note that, in all three structures, some of the H atoms of the carboxylic acid 
groups of the H2TMA
– anions are partially deprotonated, representing disorder in the 
hydrogen-bonding arrangement (with partial occupancy of certain H sites). Part of the 
reason for the disorder of the H atoms over two sites with the same occupancies is a 
consequence of the high symmetry of the space group. In every brick-wall network ring 
(Figure 4.14), two typical carboxylic acid dimer head-to-head hydrogen-bonding motifs 
(graph set  822R ) remain intact through hydrogen bonding involving these disordered H 
atoms of one carboxylic group of adjacent TMA molecules. 
Investigating these three structures in more detail, we can see that, in each 
structure (Figure 4.15a to c), adjacent brick-wall network sheets pack with a small offset 
to produce a channel along the a-axis, which runs through the brick-wall cavities. The 
distance between adjacent sheets is 3.35 Å (for the non-solvated structure), 3.32 Å (for 
the methanol solvate structure) and 3.35 Å (for the ethanol solvate structure). In each 
structure, the channel is occupied by four symmetrically arranged HTBA+ cations. Two 
N–H groups of each HTBA+ cation are linked to adjacent brick-wall network sheets 
through N–H···O hydrogen bonds. The distances between pairs of N atoms in every 
cavity are slightly different (Figure 4.15). For example, for all three structures, viewing 
along the b-axis, the distances between pairs of N atoms are 8.10 Å, 8.13 Å and 8.20 Å, 
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Figure 4.15. The brick-wall network motifs in the crystal structures of (a) the non-
solvated material, (b) the ethanol solvate and (c) the methanol solvate. 
respectively; viewing along the c-axis, the distances between pairs of N atoms are 
8.27 Å, 8.19 Å and 8.30 Å, respectively. In the case of the ethanol solvate (Figure 
4.15c), apart from four HTBA+ cations, disordered ethanol molecules are also trapped in 
the centre of the channel, filling the void space not occupied by the HTBA+ cations. The 
ethanol molecule is disordered over four positions with the same occupancies 
(0.25:0.25:0.25:0.25). The ethanol molecule is linked to an adjacent H2TMA
– anion 
through an O (TMA)···H–O (ethanol) hydrogen bond, with an O···H distance of 1.91 Å 
and an O···O distance of 2.74 Å. In the case of the methanol solvate (Figure 4.15b), in 
addition to the HTBA+ cations, there are two ordered methanol molecules (symmetry 
related) trapped in the centre of the channel and the methanol molecule is linked to an 
adjacent TMA molecule through an O (TMA)···H–O (methanol) hydrogen bond and the 
O···H distance is 2.01 Å. In the structure of the non-solvated material, the cavities of 
the channels are empty (apart from HTBA+ cations). 
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4.3.3 Summary 
When the stoichiometric ratio between TMA and TBA is 1:1, we obtained three 
different co-crystals and each structure comprises non-interpenetrated brick-wall 
networks. Apart from the typical carboxylic acid dimer head-to-head hydrogen-bonding 
motif (graph set  822R ), there is no new cyclic hydrogen-bonding motif formed in this 
family of co-crystals. 
4.4 Solvatomorphs of TMA1TBA2 
In the course of studying co-crystals of TMA and TBA, when the stoichiometric 
ratio of TMA to TBA is 1:2, we obtained six solvated co-crystals by using different 
solvents and different crystallization methods. The co-crystals contain the following 
solvents: methanol, ethanol, iso-propanol, iso-butanol, 2-methyl-2-butanol (TAA) and 
1,4-butanediol (BDO), and the ratio of TMA:TBA:solvent is 1:2:1 in each case except 
the BDO solvate (in the BDO solvate, the ratio of TMA:TBA:BDO is 4:8:3.5). Initially, 
we attempted to crystallize co-crystals without solvent at this stoichiometric ratio 
between TMA and TBA by using different types of alcohol. However, it turned out that 
incorporating alcohol molecules into the structure is a key factor in the formation of the 
structures reported here. 
4.4.1 Synthesis and Structure Determination 
The crystallization process to form the methanol solvate TMA1TBA2·(MeOH)1 
involved dissolving TMA and TBA (1:2, molar ratio) in methanol, followed by stirring 
for 1 hour, then vapour diffusion of hexane into this solution at room temperature. After 
a few days, single crystals were obtained. 
The crystallization processes to form the ethanol solvate TMA1TBA2·(EtOH)1 
were as follows: (1) Vapour diffusion of acetone into an ethanol solution containing 
TMA and TBA (2:1) at ambient temperature; after a few days, single crystals of the 
ethanol solvate were obtained. (2) A solution of TMA and TBA (1:2, molar ratio) in 
ethanol and methanol (4:1, volume ratio) was evaporated slowly at ambient temperature; 
after a few days, single crystals were obtained. 
The crystallization process to form the iso-propanol solvate 
TMA1TBA2·(iso-propanol)1 involved slow evaporation of a solution of TMA and TBA 
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(1:2, molar ratio) in methanol and iso-propanol (1:1, volume ratio) at ambient 
temperature. After a few days, single crystals were obtained. 
The crystallization process to form the iso-butanol solvate 
TMA1TBA2·(iso-butanol)1 involved slow evaporation of a solution of TMA and TBA 
(1:2, molar ratio) in methanol and iso-butanol (1:1, volume ratio) at room temperature. 
After a few days, single crystals were obtained. 
The crystallization process to form the TAA solvate TMA1TBA2·(TAA)1 
involved slow evaporation of a solution of TMA and TBA (1:2, molar ratio) in 
methanol and TAA (1:1, volume ratio) at ambient temperature. After a few days, single 
crystals were obtained. 
The crystallization process to form the BDO solvate TMA4TBA8·(BDO)3.5 
involved slow evaporation of a solution of TMA and TBA (1:2, molar ratio) in 
methanol and BDO (6:1, volume ratio) at room temperature. After a few days, single 
crystals were obtained. 
Single-crystal X-ray diffraction data for these three structures were collected at 
150 K on a Nonius Kappa CCD diffractometer equipped with a molybdenum tube 
source (λ = 0.71073 Å). The crystal structures were solved (by direct methods) by 
SHELXS and refined using SHELXL. Refinement of non-hydrogen atoms was carried 
out using anisotropic displacement parameters. All hydrogen atoms were located in 
difference Fourier maps and were added to the structural model according to idealized 
geometries. Refinement of hydrogen atoms was carried out using a riding model, with 
isotropic displacement parameter equal to 1.2 or 1.5 times the equivalent isotropic 
displacement parameter of the atom to which the hydrogen atom is bonded. 
4.4.2 Structural Summary of the Co-Crystals of TMA1TBA2 
The relationships between these solvated co-crystals are summarized in Figure 
4.16. As shown in Figure 4.16, all these solvates are unstable at room temperature in the 
open air, the process of desolvation would give rise to the mixed sample of TMA2TBA3 
and TMA1TBA3·(H2O)4.5.The crystallographic parameters of the six solvate structures 
are summarized in Table 4.3 and the crystal structures are shown in Figures 4.17 to 4.23. 
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Figure 4.16. The relationships between solvatomorphs of co-crystals of TMA1TBA2. 
Table 4.3 The crystallographic parameters for solvates of TMA1TBA2 
 Methanol Solvate Ethanol Solvate iso-Propanol Solvate 
Space group P21/c Pbca Pbca 
a/Å 8.6137(3) 12.9364(2) 13.1597(2) 
b/Å 15.4335(3) 17.8528(5) 18.0482(5) 
c/Å 16.9968(6) 20.2683(5) 20.1787(5) 
α/° 90 90 90 
β/° 104.108(1) 90 90 
γ/° 90 90 90 
V(Å3) 2191.39(12) 4680.98(19) 4792.62(19) 
Z 4 8 8 
Calculated Density 
(g/cm3) 
1.177 1.142 1.154 
R1/(%) 8.07 6.41 6.03 
Rw2/(%) 20.66 14.99 14.24 
 
 iso-Butanol Solvate TAA Solvate BDO Solvate 
Space group Pna21 Pna21 P21/c 
a/Å 12.1189(4) 12.2728(3) 16.4207(4) 
b/Å 12.6727(4) 12.4920(3) 21.8182(6) 
c/Å 16.4727(3) 16.5334(5) 27.9872(6) 
α/° 90 90 90 
β/° 90 90 101.187(2) 
γ/° 90 90 90 
V (Å3) 2529.86(12) 2534.77(12) 9836.46(42) 
Z 4 4 4 
Density (g/cm3) 1.130 1.165 1.206 
R1/(%) 6.83 7.54 9.69 
Rw2/(%) 17.98 15.42 24.94 
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From Table 4.3, we can see that these six structures can be classified into three 
categories according to their space groups. The ethanol and iso-propanol solvates are 
orthorhombic with space group Pbca. The iso-butanol and TAA solvates are 
orthorhombic with space group Pna21. The methanol and BDO solvates are monoclinic 
with space group P21/c. In the structures of the methanol, ethanol, iso-propanol, 
iso-butanol and TAA solvates, the asymmetric unit comprises four independent 
molecules: one HTMA2– anion, two HTBA+ cations and one solvent molecule. However, 
in the structure of the BDO solvate, the asymmetric unit comprises of four HTMA2– 
 
Figure 4.17. (a) Hydrogen-bonding patterns in the corrugated sheets and (b) the 
complete crystal structure of the methanol solvate. 
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anions, eight HTBA+ cations and three and a half independent solvent molecules (three 
independent whole molecules of BDO and a half independent molecule of BDO). 
In addition, from Figures 4.17b to 4.22b, we can see that these six structures can 
be classified into three categories according to their structural features. For the methanol, 
ethanol and iso-propanol solvates, the crystal structures comprise similar, single 
hydrogen-bonded corrugated sheets. For the iso-butanol and TAA solvates, the crystal 
 
Figure 4.18. (a) Hydrogen-bonding patterns in the corrugated sheets and (b) the 
complete crystal structure of the ethanol solvate. 
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structures comprise single hydrogen-bonded flat sheets. For the BDO solvate, the 
crystal structure also comprises single hydrogen-bonded sheets, which are almost but 
not exactly flat, as the planes of all the HTMA2– anions do not lie exactly in the same 
plane. These sheets actually give rise to channels, containing the BDO solvent 
molecules. In all six structures, the –N+H3 groups of the HTBA+ cations and the OH 
groups of the solvent molecules lie close to the sheets of HTMA2– anions, and are 
engaged in hydrogen bonding. The tert-butyl groups (TBA) and alkyl groups of the 
solvents project outwards from the sheets. For clarity, the three methyl groups of the 
tert-butyl groups are omitted in the figures. 
 
Figure 4.19. (a) Hydrogen-bonding patterns in the corrugated sheet in the crystal 
structure of the iso-propanol solvate TMA1TBA2·(iso-propanol), and (b) the complete 
crystal structure of iso-propanol solvate. 
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4.4.3 Structural Comparison Between the Methanol Solvate, the Ethanol Solvate and 
the iso-Propanol Solvate of TMA1TBA2 
As shown in Figures 4.17 to 4.19, within the corrugated sheet, each structure has a 
similar hydrogen-bonded ribbon motif, which runs parallel to the b-axis in each case. 
These ribbons are indicated as the region between the two dashed lines. 
For the ethanol and iso-propanol solvates (Figures 4.18a and 4.19a), within the 
ribbon motif, adjacent HTMA2– anions are linked by a direct O–H···O hydrogen bond 
and are bridged by an intervening –N+H3 group, forming a common cyclic hydrogen-
bonding motif with graph set  1033R . Furthermore, these two HTMA
2– anions are also 
linked to each other by an intervening –N+H3 group and the OH group of a solvent 
molecule to form a large common cyclic hydrogen-bonding motif with graph set 
 2044R . In the ribbon motif of the methanol solvate (Figure 4.17a), adjacent HTMA2– 
anions are linked by a direct O–H···O hydrogen bond but, there is no cyclic hydrogen-
bonding motif involving these two groups. Instead, a large cyclic hydrogen-bonding 
motif with graph set  1833R  forms between these two HTMA
2– anions and an 
intervening –N+H3 group. 
For the ethanol and iso-propanol solvates (Figures 4.18a and 4.19a), adjacent 
ribbons are linked by two common cyclic hydrogen-bonded rings, described by graph 
sets  1034R  and  16
4
5R . However, the methanol solvate (Figure 4.17a) has a different 
arrangement. Between two adjacent ribbons, three new cyclic hydrogen-bonded rings, 
described as  1244R ,  12
4
5R  and  16
4
6R , are formed. 
4.4.4. Structural Comparison Between the iso-Butanol and the 2-Methyl-2-Butanol 
Solvates of TMA1TBA2 
As shown in Figures 4.20a and 4.21a, these two solvates possess flat hydrogen-
bonded sheets and their structures are quite similar. Specifically, within the sheet, both 
structures have almost the same hydrogen-bonded zigzag ribbons, which run along the 
c-axis and are indicated as the region between the two dashed zigzag lines. The 
hydrogen-bonded sheets are stacked in a very similar manner (Figures 4.20b and 4.21b) 
that causes the tert-butyl groups and the alkyl groups of the solvent to come together at 
the interface between adjacent sheets, with a similar perpendicular distance (6.34 Å and 
6.26 Å) between the sheets in each structure. 
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In both structures (Figures 4.20a and 4.21a), within the zigzag ribbon, adjacent 
HTMA2– anions are linked together by a direct O–H···O hydrogen bond and by an 
intervening –N+H3 groups of HTBA+ cation to form the cyclic graph set  1033R , as in the 
structures of the ethanol and iso-propanol solvates. Adjacent zigzag ribbons are linked 
by the interaction of one –COO– group from each of HTMA2– anion with two 
intervening –N+H3 groups, which gives rise to the same cyclic graph set  1034R  as that 
observed in the ethanol and iso-propanol solvates. 
 
Figure 4.20. (a) Hydrogen-bonding patterns of zigzag ribbon in the sheet s and (b) the 
complete crystal structure of the iso-butanol solvate. 
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In addition, within every sheet, three adjacent HTMA2– anions are linked together 
via two intervening –N+H3 groups forming a large cyclic hydrogen-bonding motif 
(graph set  2465R ). One solvent molecule (iso-butanol or TAA) occupies the centre of 
this hydrogen-bonded ring. The solvent molecule is linked to one HTMA2– anion 
through an O (HTMA2–)···H–O (solvent) hydrogen bond and linked to one –N+H3 
group of a HTBA+ anion through an O (solvent)···H–N (HTBA+) hydrogen bond. 
4.4.5. Structural Analysis of the 1,4-Butanediol Solvate of TMA1TBA2 
From Figure 4.22, we can see that, in the structure of BDO solvate, the HTMA2– 
anions form approximately flat sheets. These sheets and BDO solvent molecules form 
two types of channel with cavities of dimensions ca. 7.4 Å × 9.3 Å and ca.7.0 Å × 5.5 Å, 
and the HTBA+ cations occupy these channels. 
 
Figure 4.21. (a) Hydrogen-bonding patterns of zigzag ribbon in the sheet in the crystal 
structure of the TAA solvate and (b) the complete crystal structure. 
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The BDO solvate is monoclinic with space group P21/c and the asymmetric unit 
comprises four independent HTMA2– anions (denoted A1 to A4), eight independent 
HTBA+ cations (denoted N1 to N8) and three and a half independent solvent molecules 
(denoted S1 to S4). As the solvent molecule has two OH groups, the OH groups of each 
solvent molecule are denoted Sia and Sib, i = 1 to 4. 
As shown in Figure 4.23, within each sheet, there are two types of zigzag ribbons 
(denoted ribbons I and II), which run along the a-axis. The ribbon I motif involves an 
alternation of the A2 and A1 anions in a zigzag and the ribbon II motif involves an 
alternation of the A3 and A4 anions in a zigzag. Within ribbon I, each A2/A1 anion pair 
is linked by a direct O–H···O hydrogen bond and forms a cyclic hydrogen-bonding ring 
through an intervening –N+H3 group of the N4 cation, which gives rise to graph set 
 823R . The A2 anion and the A1 anion are also bridged by an intervening –N
+H3 group 
of the N3 cation and OH bond S1b of the molecule to form a cyclic hydrogen-bonded 
ring with graph set )16(44R . On the other side, the A1 anion and another A2 anion are 
bridged by an intervening –N+H3 group of the N7 cation and OH bond S4b of the solvent, 
forming another cyclic hydrogen-bonded motif with graph set  1644R . 
 
Figure 4.22. (a) Crystal structure of the BDO solvate TMA4TBA8·(BDO)3.5 and (b) two 
types of channel formed by HTMA2– anions and solvent molecules. 
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Within ribbon II, the same graph set  823R  is formed between each A3/A4 anion 
pair, involving the intervening –N+H3 group of the N2 cation. In addition, as for each 
A2/A1 anion pair, two hydrogen-bonded rings with graph sets  1644R  are also formed 
for each A3/A4 anion pair. One ring involves an A3/A4 anion pair and the intervening  
–N+H3 group of the N6 cation and the OH group S3a of the solvent and the other 
involves an A3/A4 anion pair with the intervening –N+H3 group of the N5 cation and the 
OH group S2a of the solvent. 
Between these two types of ribbons, seven different cyclic hydrogen-bonded rings 
arise. The graph set descriptors for all these rings are marked in Figure 4.23 and are 
described as follows: (i)  1855R , involving the A1 and A3 anions, the N2 and N7 cations 
and the S4b solvent molecule; (ii) another  1855R , involving the A1 anion, another A3 
anion, the N4 and N6 cations and the S3a solvent molecule; (iii)  1434R , involving the A1 
and A4 anions, the N2 and N6 cations; (iv) another  1434R  involving the A2 and A3 
cations, the N4 and N7 cations; (v)  1245R , involving the A2 and A4 anions, the N5 and 
N8 cations and the S2a solvent molecule; (vi)  2056R , involving the A1, A2 and A4 
anions, the N3 and N8 cations and the S3b solvent molecule; (vii)  2056R , involving the 
A2, A4 and A5 anions, the N1 and N5 cations and the S3b solvent molecule. 
 
Figure 4.23. The hydrogen-bonding patterns of ribbon I (cyan) and ribbon II (purple) 
in the BDO solvate TMA4TBA8·(BDO)3.5. 
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In terms of the HTBA+ cations, for all six solvates, all three N–H bonds in each 
independent HTBA+ cation are engaged as donors in N–H···O hydrogen bonds to O 
atoms of the HTMA2– anion or a solvent molecule. In terms of the solvent molecules, 
the O–H bond of each independent solvent molecule is used both (i) as the donor in an  
O–H···O hydrogen bond with an O atom of the HTMA2– anion as the acceptor, and (ii) 
as the acceptor in an N–H···O hydrogen bond with an N–H bond of an HTBA+ cation as 
the donor. 
4.4.6 Summary 
When the stoichiometric ratio between TMA and TBA is 1:2, we obtained six 
solvate co-crystals, with each structure comprising hydrogen-bonded sheets. Analysis of 
these six crystal structures indicates that the specific hydrogen-bonding motifs formed 
are quite sensitive to the crystallization solvent. In these six solvate structures, the 
typical carboxylic acid dimer head-to-head hydrogen-bonding motif (graph set  822R ) 
does not appear between carboxylic acid groups of the H2TMA
– anions. However, 
several new hydrogen-bonding patterns are observed (Figure 4.24). Specifically, in 
addition to graph set  1033R  (a common cyclic hydrogen-bonding motif already 
observed in the family of co-crystals of TMA2TBA1), one new single-bridged cyclic 
 
Figure 4.24. The hydrogen-bonding motifs observed in the family of co-crystals of 
TMA1TBA2 (I) single-bridged graph sets  1033R  and  8
2
3R ; (II) double-bridged graph 
sets  1034R ,  12
4
4R  and  12
4
5R . 
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hydrogen-bonding motif  823R  and three new double-bridged cyclic hydrogen-bonding 
motifs  1034R ,  12
4
4R  and  12
4
5R  are formed in this family of co-crystals. 
4.5 Solvatomorphs of TMA1TBA3 
When the stoichiometric ratio of TMA to TBA is 1:3, we obtained five different 
co-crystals of TMA1TBA3 by using different crystallization conditions and different 
crystallization methods. Clearly, the H3TMA molecules are totally deprotonated (i.e., 
TMA3–) in these co-crystals, and thus the resulting crystal structures are devoid of any 
type of acid-acid hydrogen bonding. In these structures, the carboxylate groups of the 
TMA3– anions are bridged by the OH groups of the solvent molecules or the N+H3 
groups of the HTBA+ cations. 
4.5.1 Synthesis and Structure Determination 
The crystallization process to form the mixed di-methanol/mono-hydrate 
TMA1TBA3·(MeOH)2(H2O)1 involved slow evaporation of a methanol solution 
containing TMA and TBA (1:3 molar ratio). After a few days, single crystals were 
obtained. 
The crystallization process to form the methanol solvate TMA1TBA3·(MeOH)2 
involved vapour diffusion of ethanol into a methanol solution containing TMA and 
TBA (1:3, molar ratio) at ambient temperature. After a few days, single crystals were 
obtained. 
The crystallization process to form the BDO solvate TMA1TBA3·(BDO)1 
involved slow evaporation of a methanol and BDO (9:1, volume ratio) solution 
containing TMA and TBA (1:3, molar ratio). After a few days, single crystals were 
obtained. 
The crystallization process to form the di-hydrate TMA1TBA3·(H2O)2 involved 
slow evaporation of a solution of TMA and TBA (1:3, molar ratio) in ethanol and 
methanol (2:1, volume ratio) at ambient temperature. After a few days, single crystals 
were obtained. 
The crystallization processes to form the sesquin-hydrate TMA1TBA3·(H2O)4.5 
were as follows: (i) a water solution containing TMA and TBA (1:3, molar ratio) at 
ambient temperature was allowed to evaporate slowly at ambient temperature; after a 
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few weeks, single crystals were obtained; (ii) a solution of TMA and TBA (1:3, molar 
ratio) in methanol and ethanol (1:1, volume ratio) at ambient temperature was allowed 
to evaporate slowly at ambient temperature; after a few weeks, single crystals were 
obtained; (iii) an experiment was carried out involving vapour diffusion of acetone into 
a solution of TMA and TBA (1:3, molar ratio) in ethanol and water (5:1, volume ratio) 
at ambient temperature; after a few days, single crystals were obtained. 
Single-crystal X-ray diffraction data were collected at 150 K on a Nonius Kappa 
CCD diffractometer equipped with a molybdenum tube source (λ = 0.71073 Å). The 
crystal structures were solved (by direct methods) by SHELXS and refined using 
SHELXL.[196] Refinement of non-hydrogen atoms was carried out using anisotropic 
displacement parameters. All hydrogen atoms were located in difference Fourier maps 
and were added to the structural model according to idealized geometries. Refinement 
of hydrogen atoms was carried out using a riding model, with isotropic displacement 
parameter equal to 1.2 or 1.5 times the equivalent isotropic displacement parameter of 
the atom to which the hydrogen atom is bonded. 
4.5.2 Structural Summary of Co-Crystals of TMA1TBA3 
The relationships between these five solvated co-crystals are summarized in 
Figure 4.25. As shown in Figure 4.25, the sesquin-hydrate TMA1TBA3·(H2O)4.5 is the 
most stable material at room temperature in the open air, the other four solvates would 
slowly lose solvent molecules (methanol or BDO molecules) which were incorporated 
into their structures (desolvation) and absorb water molecules from the atmosphere, 
transforming to the sesquin-hydrate TMA1TBA3·(H2O)4.5. The crystallographic 
parameters are summarized in Table 4.4 and the crystal structures are shown in Figures 
4.26 to 4.32. 
From Table 4.4 and Figures 4.26 to 4.32, we can see that these five structures can 
be classified into three categories according to the types of solvent molecules. If only 
alcohol molecules (methanol or BDO, Figures 4.26 and 4.27) are incorporated into the 
structure, the crystal structure comprises single hydrogen-bonded corrugated sheets. If 
both alcohol and water molecules (Figure 4.28) are incorporated into the structure, the 
crystal structure comprises single hydrogen-bonded sheets that are approximately flat. If
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Figure 4.25. The relationships between solvatomorphs of co-crystals of TMA1TBA3. 
Table 4.4 The crystallographic parameters of solvates of TMA1TBA3 
 Mixed Solvate Sesquin-Hydrate Methanol Solvate 
Space group P 1  Pbca P21/n 
a/Å 12.4168(3) 14.2800(2) 9.0451(2) 
b/Å 14.7844(4) 21.5449(4) 19.4603(6) 
c/Å 17.3285(5) 38.2318(7) 17.2206(5) 
α/° 84.555(2) 90 90 
β/° 88.500(2) 90 100.029(2) 
γ/° 69.781(2) 90 90 
V(Å3) 2971.51(14) 11762.44(35) 2984.86(14) 
Z 2 8 4 
Calculated Density 
(g/cm3) 
1.142 1.153 1.098 
R1/(%) / 6.52 8.46 
Rw2/(%) 16.1 15.26 20.98 
 
 Di-Hydrate BDO Solvate 
Space group P21 P21/n 
a/Å 8.9845(2) 9.1626(3) 
b/Å 20.9121(6) 19.3079(11) 
c/Å 14.1487(4) 17.4446(8) 
α/° 90 90 
β/° 97.894(2) 98.561(2) 
γ/° 90 90 
V(Å3) 2633.13(12) 3051.75(25) 
Z 2 4 
Calculated Density 
(g/cm3) 
1.174 1.131 
R1/(%) 9.62 9.69 
Rw2/(%) 15.43 24.94 
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only water molecules (Figures 4.29 and 4.31) are incorporated into the structure, the 
crystal structure comprises single hydrogen-bonded flat ribbons that are stacked 
alternately in a slightly offset manner. In all five structures, the –N+H3 groups of the 
HTBA+ cations and the OH groups of the alcohol solvent molecules or water molecules 
lie close to the TMA3– sheets or ribbons due to hydrogen bonding. The tert-butyl groups 
of the HTBA+ cations and the alkyl groups of the alcohol solvent molecules project 
outward from the sheets. 
4.5.3 Structural Comparison Between the Methanol, Mixed Methanol/Water and 1,4-
Butanediol Solvates of TMA1TBA3 
The methanol and BDO solvates are monoclinic and have the same space group, 
P21/n. In the crystal structure of the methanol solvate, the asymmetric unit comprises 
one TMA3– anion, three HTBA+ cations and two methanol molecules. One methanol 
 
Figure 4.26. (a) Crystal structure of the methanol solvate and (b) the hydrogen-
bonding pattern in a single sheet. 
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molecule is disordered over two sites with occupancies 0.49 and 0.51. In the crystal 
structure of the BDO solvate, the asymmetric unit comprises one TMA3– anion, three 
HTBA+ cations and two half solvent units (due to the two half solvent units on special 
positions, the other two half solvent units can be created by symmetry operation 
(inversion centre). For the mixed solvate, the asymmetric unit comprises 12 independent 
molecules: two TMA3– anions, six HTBA+ cations, four methanol molecules and two 
water molecules. The structure is triclinic with space group P1¯. The crystal structures of 
these three solvates (Figures 4.26 to 4.28) have both similarities and differences, which 
are explained below. In the crystal structure of each of these solvates, the sheets contain 
a single hydrogen-bonded ribbon motif, which runs parallel to the c-axis in each case. 
These ribbons are indicated as the region between the two dashed lines in each case. 
 
Figure 4.27. (a) Crystal structure of the BDO solvate TMA1TBA3·(BDO)1 and (b) the 
hydrogen-bonding patterns of the corrugated sheet. 
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For all three structures, pairs of adjacent TMA3– anions are not linked to each 
other directly (as a consequence of total deprotonation, the TMA3– anion has no 
hydrogen bond donors) but are double-bridged by intervening –N+H3 groups of HTBA+ 
cations and O–H bonds of solvent molecules. For both single-component solvates 
(Figures 4.26b and 4.27b), within each ribbon, one –COO– group of TMA3– anion is 
linked to the –COO– group of an adjacent TMA3- anion by two O···H–N–H···O 
hydrogen-bonding arrangements, giving rise to a cyclic hydrogen-bonding ring with 
graph set  1034R . For one of the –COO– groups, each O atom receives one N–H···O 
hydrogen bond whereas for the other –COO– group, one O atom receives two N–H···O 
hydrogen bonds. These two anions are also double-bridged by two  
O···H–N–H···O–H···O hydrogen-bonding arrangements involving an intervening  
 
Figure 4.28. (a) Crystal structure of the mixed solvate TMA1TBA3·(H2O)2(MeOH)1 and 
(b) the hydrogen-bonding patterns of the corrugated sheets 
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–N+H3 group and an intervening OH group of a methanol (or BDO) molecule, 
corresponding to graph set  1246R . 
In the structure of the mixed solvate (methanol hydrate, Figure 4.28b), within the 
hydrogen-bonded ribbon, the hydrogen-bonding arrangements are totally different and 
more complicated. All the hydrogen-bonding patterns within this structure are marked 
in Figure 4.28b. Adjacent TMA3– anions are double-bridged by three different cyclic 
hydrogen-bonding rings: (i) an  1035R cyclic arrangement, involving one –COO
– group 
of each TMA3– anion, one intervening –N+H3 group, the OH group of one methanol 
molecule and both OH groups of one water molecule; (ii) another  1035R  cyclic 
arrangement, involving one –COO– group of each TMA3– anion, two intervening –N+H3 
groups and the OH bond of one methanol molecule; and (iii) an  1245R  cyclic 
arrangement involving one –COO– group of each TMA3– anion, two intervening –N+H3 
groups and the OH bond of one methanol molecule. 
For the solvates containing only methanol and BDO as the solvent component 
(Figures 4.26b and 4.27b), adjacent ribbons are linked indirectly by three different 
cyclic hydrogen-bonding arrangements: (i) an  1244R  ring, involving  one –COO– group 
of each TMA3– anion and two intervening –N+H3 groups; (ii) an  2044R  ring, involving 
two –COO– groups of each TMA3– anion and two intervening –N+H3 groups on one side; 
(iii) an  2466R  ring, involving two –COO
– groups of each TMA3– anion and two 
intervening –N+H3 groups on the other side. It is interesting to note that either two 
methanol molecules (one of which is disordered) or one BDO molecule occupy the 
cavities formed by the cyclic graph set  2466R , while the cavities formed by cyclic 
graph set  2044R  are empty. For the mixed solvate (methanol hydrate, Figure 4.28b), 
adjacent ribbons are linked indirectly by three cyclic hydrogen-bonding arrangements: (i) 
an  1244R  ring, comprising the same hydrogen-bonding arrangement discussed above 
for the pure solvate; (ii) an  1034R  ring, involving one –COO– group of each TMA3– 
anion and two intervening–N+H3 groups, and (iii) an  2066R  ring, involving one –COO
– 
group of one TMA3– anion, two –COO– groups of another TMA3– anion, two 
intervening –N+H3 groups and the OH bonds of two methanol molecules. 
4.5.4. Structural Comparison Between the Di-Hydrate and Sesquin-Hydrate of 
TMA1TBA3 
For the di-hydrate and the sesquin-hydrate TMA1TBA3·(H2O)4.5, the asymmetric 
unit is composed of two TMA3– anions, six HTBA+ cations and four or nine water 
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molecules, respectively. Although the structures of these two hydrates are described by 
different crystal systems (the di-hydrate is monoclinic with space group P21 and the 
sesquin-hydrate TMA1TBA3·(H2O)4.5 is orthorhombic with space group Pbca), the 
crystal structures of these two hydrates share several similar aspects (Figures 4.29 to 
4.32). 
Both structures (Figures 4.29 and Figure 4.31) comprise one-dimensional 
hydrogen-bonded ribbons, which are stacked parallel to the a-axis in each case (the 
distances between adjacent parallel ribbons along the a-axis are 8.98 Å (di-hydrate, 
Figure 4.29b) and 7.21 Å (the sesquin-hydrate TMA1TBA3·(H2O)4.5), Figure 4.31b) and 
adjacent ribbons are linked together by HTBA+ cations and water molecules with a 
slight offset along the a-axis (the offset is about 1.89 Å (di-hydrate, Figure 4.29b) and 
1.81 Å (the sesquin-hydrate TMA1TBA3·(H2O)4.5), Figure 4.31b). In both structures 
(Figures 4.29b and 4.31b), water molecules act as both hydrogen bond acceptors and 
donors to link all TMA3– anions together to form a channel, which is occupied by 
HTBA+ cations. From Figures 4.29 and 4.31, we can see that the ribbons run 
horizontally along the c-axis. 
In the crystal structure of the di-hydrate (Figure 4.30), the ribbons are zigzag and 
there are four different cyclic hydrogen-bonded rings between adjacent TMA3– anions 
within the ribbon: (i) an  824R  cyclic arrangement involving one –COO– group from 
each of two adjacent TMA3– anions and two intervening –N+H3 groups; (ii) another 
 824R  cyclic arrangement involving one –COO– group from each of two adjacent 
 
Figure 4.29. (a) Crystal structure of the di-hydrate and (b) channel formed by TMA and 
water molecules. 
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TMA3– anions, one intervening –N+H3 group and the OH bond of one water molecule. 
These two cyclic hydrogen-bonding arrangements are also observed in the crystal 
structure of the sesquin-hydrate TMA1TBA3·(H2O)4.5 (Figure 4.32); (iii) a double-
bridged cyclic arrangement with graph set  1666R , involving two intervening –N
+H3 
groups and two water molecules. 
This hydrogen-bonding ring is very rare in the structures studied here. On one side, 
an intervening –N+H3 group acts as a bridge to link two O atoms of adjacent TMA3– 
anions through O···H–N–H···O hydrogen bonds; however, on the other side, one 
 
Figure 4.30. Hydrogen-bonding patterns of the zigzag ribbons in the crystal structure 
of the di-hydrate TMA1TBA3·(H2O)2. 
 
Figure 4.31. (a) Crystal structure of the sesquin-hydrate TMA1TBA3·(H2O)4.5 and (b) 
the channel formed by TMA molecules and water molecules. 
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intervening–N+H3 group and two water molecules are linked together to act as another 
bridge to link another two O atoms of adjacent TMA3– anions through an O···H–N–
H···O–H···O–H···O hydrogen-bonding arrangement; and (iv) an  2044R  cyclic 
arrangement involving two –COO– groups of each two adjacent TMA3– anions and two 
intervening –N+H3 groups. 
In the structure of the sesquin-hydrate TMA1TBA3·(H2O)4.5, (Figure 4.32), within 
the zigzag ribbon, there are five different cyclic hydrogen-bonding rings formed 
between pairs of adjacent TMA3– anions. (i) and (ii) are the common arrangement with 
graph sets  824R  discussed above for the di-hydrate. (iii) an  10
3
4R  cyclic arrangement 
involving one –COO– group of each two adjacent TMA3– anions and two intervening  
–N+H3 groups; (iv) an  1245R  cyclic arrangement involving one –COO
– group of each 
two adjacent TMA3– anions, one intervening –N+H3 group and two water molecules. 
In this double-bridged hydrogen-bonding arrangement, one bridge is an 
intervening –N+H3 group, while the other bridge comprises two water molecules which 
are linked together through O (TMA3–)···H–O–H (water)···O–H (water)···O (TMA3–) 
hydrogen-bond arrangement; (v) a double-bridged cyclic arrangement with graph set 
 1457R . In this complicated hydrogen-bonding arrangement, one bridge involves 
O (TMA3–)···H–N–H (HTBA+)···O–H (water)···O (TMA3–) hydrogen bonds and the 
other bridge involves O (TMA3–)···H–O (water)···H–N–H (HTBA+)···O–
H (water)···O (TMA3–) hydrogen bonds. In these two structures, we can see that the 
water molecules participate actively in the cyclic hydrogen-bonding arrangements. 
For the di-hydrate (Figure 4.30), adjacent ribbons are double-bridged by three 
different cyclic hydrogen-bonding arrangements: (i)  824R , (ii)  12
4
4R , and (iii)  16
4
4R . 
For the sesquin-hydrate TMA1TBA3·(H2O)4.5 (Figure 4.32), adjacent ribbons are 
bridged by four different cyclic hydrogen-bonding arrangements: (i)  1034R , (ii)  12
4
4R , 
(iii) a double-bridged arrangement with graph set  1645R  involving one intervening  
–N+H3 group and two water molecules acting as bridges. In this double-bridged 
hydrogen-bonding arrangement, one bridge involves O···H–O–H···O hydrogen bonds 
and the other involves O (TMA3–)···H–N–H (HTBA+)···O–H (water)···O (TMA3–) 
hydrogen bonds. (iv) A double-bridged graph set  1846R  involves four water molecules 
acting as bridges; one bridge involves O (TMA3–)···H–O–H (water)···O (TMA3–) 
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hydrogen bonds and the other more complicated and longer bridge involves  
O (TMA3–)···H–O–H (water)···O (water)···O–H (water)···O (TMA3–) hydrogen bonds. 
The latter bridge involving three water molecules is quite uncommon in organic hydrate 
structures. Comparing the cyclic hydrogen-bonding arrangements observed in the di-
hydrate and sesquin-hydrate, it is clear that there are four common cyclic graph sets: 
two different cyclic graph sets  824R  arrangements, one  10
3
4R  arrangement and one 
 1244R  arrangement which exist in both structures. 
For all five structures, all three N–H bonds in each HTBA+ cation are used as 
donors in N–H···O hydrogen bonding to O atoms of the TMA3–anions or solvent 
molecules as hydrogen bond acceptors. The O–H group in each solvent molecule is 
used both (i) as the donor in an O–H (solvent)···O (TMA3–) hydrogen bond, and (ii) as 
the acceptor in an N+–H (HTBA+)···O (solvent) hydrogen bond. 
4.5.5 Summary 
When the stoichiometric ratio between TMA and TBA is 1:3, we obtained five co-
crystals of TMA and TBA. In these five crystal structures, due to the TMA molecules 
being fully deprotonated, there is no direct hydrogen bonding between adjacent TMA3– 
anions. Pairs of adjacent carboxylate groups are double-bridged by OH groups of 
solvent molecules and/or by –N+H3 groups of HTBA+ cations. The specific hydrogen-
bonding motifs formed are quite sensitive to the particular solvents incorporated into the 
structure (methanol and BDO) and the number of water molecules. Apart from double-
bridged graph sets  1034R ,  12
4
4R  and  12
4
5R , there are another nine new double-
 
Figure 4.32. Hydrogen-bonding patterns of the two zigzag ribbons in the crystal 
structure of the hydrate TMA1TBA3·(H2O)4.5. 
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bridged cyclic graph sets (Figure 4.33) observed in this family of co-crystals of TMA 
and TBA. 
4.6 Summary 
In conclusion, the range and diversity of structures and compositions of co-
 
Figure 4.33. Double-bridged hydrogen-bonding motifs observed in the family of co-
crystals of TMA1TBA3. 
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crystals of TMA and TBA is very uncommon. Adjusting the stoichiometric ratio 
between TMA and TBA and the types of solvent used gives rise to a broad range of 
totally different crystal structures, such as a structure comprising double-layered sheets 
TMA2TBA1·(H2O)2, single hydrogen-bonded flat sheets TMA1TBA2·(iso-butanol)1, 
single hydrogen-bonded corrugated sheets TMA1TBA2·(MeOH)1), a structure with 
interpenetration TMA2TBA1·(H2O)3 and a structure comprising brick-wall networks 
TMA2TBA2·(MeOH)1. Furthermore, the formation of hydrogen-bonding motifs are 
quite sensitive to the stoichiometric ratio between TMA and TBA and the crystallization 
solvents. In general, we have observed several recurrent “supramolecular synthons” in 
the family of co-crystals of TMA and TBA (see Figures 4.13, 4.24 and 4.33). 
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Chapter 5 Co-Crystals of ʟ-Arginine and Trimesic Acid, 
with Structure Determination Directly from Powder 
X-Ray Diffraction Data 
5.1 Introduction 
Amino acids are a class of materials containing not only a proton donor group  
(–COOH) but also a proton acceptor group (–NH2). Designing and preparing new 
organic nonlinear optical (NLO) materials involving amino acids with low cost and high 
efficiency is a hot issue for scientists.[253,254] ʟ-arginine (Figure 5.1) (ʟ-Arg) is one of the 
20 genetically encoded amino acids and is the most basic amino acid. Due to its basic 
nature, it can form co-crystals with many different types of acids. The discovery of a 
mono-hydrate co-crystal of ʟ-arginine and phosphoric acid[255], which showed high 
nonlinear optical (NLO) properties, has attracted a great deal of attention and led to 
significant interest in co-crystals containing ʟ-arginine molecules. Due to its potential 
applications for NLO materials, a series of co-crystals of ʟ-arginine with different types 
of inorganic or organic acids[256-262] have been prepared and their structural, physical 
and optical properties have been investigated. 
ʟ-Arginine is a chiral molecule with several conformational degrees of freedom 
and may be prone to exhibiting polymorphism when co-crystallized with other 
molecules. Therefore, in the course of studying the co-crystallization of TMA and 
ʟ-arginine, we expected that polymorphic co-crystals might appear as in the case of the 
co-crystals of TMA and TBA. We attempted to prepare single crystals of TMA and 
ʟ-arginine by different co-crystallization methods. However, no large single crystals 
were prepared successfully. Instead, four types of microcrystalline TMA and ʟ-arginine 
co-crystals have been discovered, which are designated as phase 1 to phase 4. The 
powder XRD patterns are shown in Figure 5.2. 
 
Figure 5.1. Molecular structure of ʟ-arginine. 
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Figure 5.2. The powder XRD patterns of Phase 1 to Phase 4 of co-crystal of TMA and 
ʟ-arginine. 
We could not determine the crystal structures of these materials by single-crystal 
XRD methods because no large single crystals of these samples were produced. 
However, due to the recent advances in structure determination from PXRD data, 
especially the development of the direct-space strategy, researchers are able to 
determine the structures of organic materials (microcrystalline) with moderate 
complexity (small molecules) from PXRD data, sometimes in conjunction with other 
techniques.[263-268] In this chapter, the crystal structures of two co-crystals of TMA and 
ʟ-arginine (phase 1 and phase 2) are determined directly from PXRD data, while the 
structure determination of the other two phases is currently in progress. We present the 
results from structure determination of phases 1 and 2 from PXRD data, and analyse the 
structures of these co-crystals of TMA and ʟ-arginine. 
5.2 Synthesis 
In the course of studying organic co-crystals of TMA and ʟ-arginine, we prepared 
four distinct microcrystalline phases from this family of co-crystals. Each powder 
sample can be produced by several different methods and the processes are as follows. 
The crystallization processes to form phase 1 were as follows: (1) TMA (1 mmol) 
was dissolved in iso-propanol (5 ml) and water (5 ml). Separately, ʟ-arginine (1.5 mmol) 
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was dissolved in water (2 ml). These two solutions were then mixed together, stirring 
for 15 minutes, then the solution was allowed to slowly evaporate at room temperature. 
After about two weeks, a white precipitate appeared in the solution. The solution was 
filtered and the precipitates were allowed to dry out, producing a microcrystalline 
sample of phase 1. (2) TMA (1 mmol) was dissolved in ethanol (10 ml) and water 
(2 ml). Separately, ʟ-arginine (1 mmol) was dissolved in water (2 ml). These two 
solutions were then mixed together, stirring for about 15 minutes, then the solution was 
allowed to slowly evaporate at room temperature. After a few weeks, a microcrystalline 
sample of phase 1 was obtained. 
The crystallization processes to form phase 2 were as follows: (1) TMA (1 mmol) 
was dissolved in ethanol (10 ml) and water (5 ml). Separately, ʟ-arginine (1 mmol) was 
dissolved in water (5 ml) and 1,4-dioxane (5 ml). These two solutions were then mixed 
together, stirring for 15 minutes, then the solution was allowed to slowly evaporate at 
room temperature. After about two weeks, a microcrystalline sample of phase 2 was 
obtained. (2) ʟ-arginine (0.5 mmol) and TMA (1 mmol) was dissolved in DMSO (2 ml), 
ethanol (4 ml) and water (3 ml), stirring for 15 minutes, then the solution was allowed 
to slowly evaporate at room temperature. After a few weeks, a microcrystalline sample 
of phase 2 was obtained. (3) ʟ-arginine (1.5 mmol) was dissolved in ethanol (2 ml) and 
water (2 ml). Separately, TMA (1 mmol) was dissolved in water (2 ml) and ethanol 
(4 ml). These solutions were then mixed together in a conical flask and the solution was 
heated to 55 °C, followed by placing the conical flask into an incubator and slowly 
cooling from 55 °C to 20 °C. A microcrystalline sample of phase 2 was obtained. 
The crystallization processes to form phase 3 were as follows: (1) ʟ-arginine 
(0.5 mmol) was dissolved in methanol (1 ml) in a small glass bottle, then a solution of 
1,4-dioxane (2 ml) and water (0.5 ml) containing TMA (0.5 mmol) was slowly added 
into the glass bottle and sealed with a cap. After a few weeks, a microcrystalline sample 
of phase 3 was obtained. (2) ʟ-arginine (2 mmol) was dissolved in water (6 ml). 
Separately, TMA (1 mmol) was dissolved in ethanol (4 ml). These two solutions were 
then mixed together, with stirring for 15 minutes, then the solution was allowed to 
slowly evaporate at room temperature. After about two weeks, a microcrystalline 
sample of phase 3 was obtained. (3) ʟ-arginine (2 mmol) was dissolved in water (3 ml). 
Separately, TMA (1 mmol) was dissolved in iso-propanol (5 ml) and water (7 ml). 
These two solutions were then mixed together, with stirring for 15 minutes, then the 
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solution was allowed to slowly evaporate at room temperature. After about two weeks, a 
microcrystalline sample of phase 3 was obtained. (4) TMA (0.5 mmol) was dissolved in 
methanol (1 ml) and THF (1 ml) in a small glass bottle, then a solution of water (1 ml) 
containing ʟ-arginine (0.5 mmol) was slowly added to this glass bottle and sealed with a 
cap. After a few weeks, a microcrystalline sample of phase 3 was obtained. 
The crystallization processes to form phase 4: (1) TMA (1 mmol) was dissolved 
in iso-propanol (5 ml) and water (7 ml). Separately, ʟ-arginine (0.5 mmol) was 
dissolved in water (3 ml). These two solutions were then mixed together, with stirring 
for 15 minutes, then the solution was allowed to slowly evaporate at room temperature. 
After about two weeks, a microcrystalline sample of phase 4 was obtained. (2) TMA 
(1 mmol) and ʟ-arginine (2 mmol) were dissolved in water (5 ml), then the solution was 
allowed to slowly evaporate at room temperature. After a few weeks, a microcrystalline 
sample of phase 4 was obtained. 
5.3 Structure Determination 
The powder XRD data for phase 1 to phase 4 were recorded on a Bruker D8 
instrument in transmission mode using Ge-monochromated CuKα1 radiation. (2θ: 4–50, 
total time 48 hrs). Samples were mixed with starch (2:1, mass ratio) and contained 
within glass capillaries to reduce the effects of preferred orientation in each case. 
5.3.1 Structure Determination of Phase 1 
For phase 1, the powder XRD pattern was indexed successfully by using the 
TREOR[202] and ITO[203] codes, which are incorporated into the program CRYSFIRE[205], 
combined with the program CHEKCELL[207]. The Le Bailing fitting[208] using GSAS[209] 
software and its graphical user interface editor EXPGUI[210] gave a good quality of fit 
with space groups P21 and P2 (Figure 5.3a, space group: P21, a = 26.8480(11) Å, 
b = 13.3480(5) Å, c = 3.7442(2) Å, β = 88.8447(16)°, V = 1341.53(17) Å3, Rwp = 1.30%, 
Rp = 0.98%. Figure 5.3b, space group P2: a = 26.8492(10) Å, b = 13.3484(5) Å, 
c = 3.7444(2) Å, β = 88.8419(15)°, V = 1341.69(14) Å3, Rwp = 1.30%, Rp = 0.98%). 
Thus, both space groups are possible, and the true space group cannot be assigned 
uniquely at this stage. Therefore, structure solution calculations were carried out in 
parallel using these two possible space groups in the next stage. 
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Figure 5.3. Le Bail profile fitting for phase 1 with (a) P21 and (b) P2. 
From the solution 1H NMR spectrum, we know that the molar ratio of ʟ-arginine 
to TMA in this sample is 1:2. Given the volume of the unit cell and consideration of the 
density of the sample, we infer that there are four TMA molecules and two ʟ-arginine 
molecules in the unit cell and the calculated density is 1.47 g cm–3. Therefore, for space 
groups P2 and P21, there are two TMA molecules and one ʟ-arginine molecule in the 
asymmetric unit. The refined unit cell parameters and profile parameters obtained from 
the Le Bail fits and space groups P2 and P21 were used in the structure solution 
calculations. 
Structure solution was carried out using the direct-space genetic algorithm[191] 
(GA) technique incorporated in the program EAGER[195]. Two input models were used 
in the structure solution calculations, representing the two different space groups P21 
and P2. For each input model, there are three fragments: two fragments are TMA 
molecules and the third fragment is the ʟ-arginine molecule. In each fragment, the TMA 
molecule was defined by a total of nine structural variables (three positional variables, 
three orientational variables and three torsion angle variables) and the ʟ-arginine 
molecule was defined by a total of twelve structural variables (three positional variables, 
three orientational variables and six torsion angles). Hence, each model is represented 
by a total of 30 structural variables. In total, 16 independent GA calculations were 
carried out for each model and the GA calculation was allowed to evolve for 1000 
generations for a population size of 100. In each generation, 10 mating operations and 
50 mutation operations were carried out. The results from all these structure solution 
calculations were assessed and evaluated to determine which model gives the best 
structure solution. 
 117 
The results from the structure solution calculations show that, for space group P2, 
one structural model has lowest Rwp but this structural model is unreasonable, because 
all molecules are linked together (in fact, all structural models with space group P2 
obtained from the GA calculations are unreasonable). For space group P21, the 
structural models obtained from the GA calculations are reasonable. Therefore, the 
structural model with lowest Rwp for space group P21 was used as the initial structural 
model for Rietveld refinement[213], which was carried out using the GSAS program. In 
the Rietveld refinement, initially, the TMA molecule was modelled as H2TMA
– anions 
and the carboxylic acid group of the ʟ-arginine molecule was modelled as deprotonated 
(carboxylate group) and the –NH2 of the ʟ-arginine molecule was modelled as 
protonated (–N+H3 group). Standard restraints were applied to bond lengths and bond 
angles, and planar restraints were applied to benzene rings, carboxylate groups, 
carboxylic acid groups and guanidinium groups. As the refinement progressed, these 
restraints were gradually relaxed. In the process of refinement, the isotropic 
displacement parameters were refined as a common value for all atoms within the same 
molecule. The value of isotropic displacement parameter for all hydrogen atoms were 
set to 1.2 times that of the non-H atoms in the same molecule. After the initial Rietveld 
refinement, the calculated powder XRD pattern did not fit the experimental powder 
pattern satisfactorily with Rwp = 3.67% (Figure 5.4a). 
With the help of difference Fourier maps, we could see that some electron density 
in the crystal had not been included in the structural model. Considering the solvent 
(water) and the density of the sample, we concluded that there are one or two water 
molecules in the asymmetric unit (corresponding to calculated densities of 1.51 g cm–3 
and 1.56 g cm–3, respectively). Therefore, the initial input models as discussed above for 
structure solution are not correct, and these input models were modified by adding one 
more or two water molecules in the asymmetric unit, representing two new input 
models for structure solution calculations. In these two input models, one or two more 
fragments, which represent one or two water molecules, were introduced and the other 
conditions were kept the same as those discussed above. The structure solution 
calculations using the program EAGER were then carried out again. 
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Figure 5.4. Rietveld refinements for phase 1 for the models with (a) no water, (b) one 
water molecule and (c) two water molecules in the asymmetric unit. 
The results from structure solution indicated that the model with two water 
molecules in the asymmetric unit had the lowest Rwp and the structural model was 
reasonable. We performed Rietveld refinement with this model, exploring the process as 
described above. This refinement led to a good fit with the experimental powder XRD 
data (Rwp = 1.78%, Rp = 1.27%, Figure 5.4c). In addition, in order to make sure that the 
model with one water molecule in the asymmetric unit does not lead to a superior final 
refinement, we also performed Rietveld refinement with the structural model containing 
one water molecule in the asymmetric unit. As expected, this model did not give as 
good a fit to the experimental powder XRD data (Rwp = 2.41%, Rp = 1.68%, Figure 
5.4b). The final Rietveld refinement for the structural model containing two water 
molecules gave the following data: P21; a = 26.8430(21) Å, b = 13.3445(9) Å, 
c = 3.7441(3) Å, β = 88.8585(24)°; V = 1340.91(30) Å3, Rwp = 1.78%, Rp = 1.27%. 
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Figure 5.5. Le Bail profile fitting for phase 2 with (a) P2221 and (b) P222. 
5.3.2 Structure Determination of Phase 2 
The powder XRD pattern of phase 2 was indexed by using program CRYSFIRE, 
giving the following unit cell parameters in an orthorhombic system: a = 16.84 Å, 
b = 13.34 Å, c = 11.06 Å (V = 2484.7 Å3), with P2221 as the best estimated space group. 
However, profile-fitting did not give a good quality of fit (Figure 5.5a). We then used 
the simplest space group in the orthorhombic system, P222, for Le Bail fitting. The 
resulting fit was still not good (Figure 5.5b). Therefore, we lowered the symmetry to 
monoclinic (The powder pattern of phase 2 was indexed again by using program 
CRYSFIRE and combined with the program CHEKCELL). When the space group was 
assigned as P2 and P21 with the unit cell parameters: a = 13.342 Å, b = 11.057 Å, 
c = 16.844 Å, β = 90.133° (V = 2484.7 Å3), Le Bail fitting gave a good quality of fit 
(Figure 5.6a, space group P2, a = 13.3277(3) Å, b = 11.0393(2) Å, c = 16.8182(4) Å, 
β = 90.1354(17)°, V = 2474.43(13) Å3, Rwp = 1.55%, Rp = 1.17%. Figure 5.6b, space 
group P21, a = 13.3299(3) Å, b = 11.0393(2) Å, c = 16.8175(4) Å, β = 90.1388(18)°, 
V = 2474.74(13) Å3, Rwp = 1.58%, Rp = 1.18%). 
From the solution 1H NMR spectrum, we determined the molar ratio between 
ʟ-arginine and TMA is 1:1. Thus, we deduced that there are six TMA molecules and six 
ʟ-arginine molecules in the unit cell and the calculated density is 1.54 g cm–3. Thus, 
there are three TMA molecules and three ʟ-arginine molecules in the asymmetric unit 
for space group P2 and P21. The refined unit cell parameters and profile parameters 
obtained from the Le Bail fits and space groups P2 and P21 were used in the structure 
solution calculation. 
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Figure 5.6. Le Bail profile fitting for phase 2 with (a) P2 and (b) P21. 
Structure solution calculations were carried out using the program EAGER. Two 
input models were used in the structure solution calculations. For each input model, 
there were six fragments: three fragments were TMA molecules and the remaining three 
fragments were ʟ-arginine molecules. In each fragment, the TMA molecule was defined 
by a total of nine structural variables and the ʟ-arginine molecule was defined by a total 
of twelve structural variables. Hence, each model was represented by a total of 63 
structural variables. The other conditions were kept the same as phase 1. 
From the structure solution calculations, the lowest Rwp was obtained for space 
group P21, and the structural model is reasonable. When the space group is P2, the 
structural model has the second lowest Rwp and is also reasonable. First, the structural 
model with lowest Rwp with space group P21 was used as the initial structural model for 
Rietveld refinement. This refinement led to a good fit with the experimental powder 
XRD data (Rwp = 2.42%, Rp = 1.71%, Figure 5.7a). In order to make sure that the model 
with space group P2 is not correct, we also performed Rietveld refinement with the 
structural model for this space group. As expected, this model did not give as good a fit 
to experimental powder XRD data (Rwp = 3.47%, Rp = 2.30%, Figure 5.7b). The final 
Rietveld refinement for the structural model with space group P21 gave the following 
data: a = 13.3271(4) Å, b = 11.0393(3) Å, c = 16.8183(6) Å, β = 90.1491(27)°, 
V = 2474.34(20) Å3, Rwp = 2.42%, Rp = 1.71%. 
5.3.3 Structure Determination of Phases 3 and 4 
The powder XRD pattern of phase 3 was indexed successfully by using program 
CRYSFIRE and combined with the program CHEKCELL, giving the following unit 
cell parameters in an monoclinic system: a = 17.17 Å, b = 3.81 Å, c = 13.34 Å, 
β = 104.7°, with P2 and P21 as the best estimated space group. The Le Bail fitting gave 
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a good quality of fit for space groups P2 and P21 (Figures 5.8a: P2, a = 17.1675(7) Å, 
b = 3.8101(5) Å, c = 13.3367(5) Å, β = 104.7039(18)°, V = 843.77(8) Å3, Rwp = 2.12%, 
Rp = 1.60%. Figure 5.8b: P21, a = 17.1672(6) Å, b = 3.8099(2) Å, c = 13.3370(6) Å, 
β = 104.7035(19)°, V = 843.75(9) Å3, Rwp = 2.13%, Rp = 1.61%). 
From the solution 1H NMR spectrum, the molar ratio of ʟ-arginine to TMA is 1:1 
was established. With two TMA molecules and two ʟ-arginine molecules in the unit cell, 
the calculated density is 1.51 g cm–3. Thus, there is one TMA molecule and one 
ʟ-arginine molecule in the asymmetric unit for space groups P2 and P21. Structure 
solution calculations were carried out using the program EAGER. Two input models 
were used in the structure solution calculations. For each input model, there were two 
fragments: one fragment was the TMA molecule and the other fragment was the 
ʟ-arginine molecule. The TMA molecule was defined by nine structural variables and 
the ʟ-arginine molecule was defined by twelve structural variables. Hence, each model 
was represented by a total of 21 structural variables. The other conditions were kept the 
same as phase 1. 
 
Figure 5.8. Le Bail profile fitting for phase 3 with (a) P2 and (b) P21. 
 
Figure 5.7. Rietveld refinement for phase 2 with (a) P21 and (b) P2. 
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Figure 5.9. Rietveld refinement for phase 3 with (a) P2 and (b) P21. 
Using the structural models giving the structure solution with lowest Rwp for space 
groups P2 and P21, the Rietveld refinement did not lead to a good fit (space group P2: 
Rwp = 4.58%, Rp = 2.97%, Figure 5.9a; space group P21: Rwp = 4.34%, Rp = 2.87%, 
Figure 5.9b). Therefore, we lowered the symmetry to triclinic. (The powder pattern of 
phase 3 was indexed again by using program CRYSFIRE and combined with the 
program CHEKCELL). Since ʟ-arginine is a chiral molecule, the achiral space group P1¯ 
is ruled out, thus the space group was assigned as P1 with the unit cell parameters: 
a = 3.81 Å, b = 13.34 Å, c = 17.17 Å, α = 104.70°, β = 90.13°, γ = 90.04°, V = 843.9 Å3. 
Le Bail fitting gave a good quality of fit (Figure 5.10a, space group P1, a = 3.8104(1) Å, 
b = 13.3370(4) Å, c = 17.1673(5) Å, α = 104.7018(18)°, β = 89.9990(31)°, 
γ = 90.037(4)°, V = 843.87(6) Å3, Rwp = 2.15%, Rp = 1.61%). 
Structure solution calculations were carried out in the program EAGER again. For 
this input model, there were four fragments: two fragments were TMA molecules and 
the other two fragments were ʟ-arginine molecules. The TMA molecule was defined by 
a total of nine structural variables and the ʟ-arginine molecule was defined by a total of 
twelve structural variables. Hence, this model was represented by a total of 42 structural 
variables. The other conditions were kept the same as discussed above. The structural 
model with lowest Rwp was used as the initial model for Rietveld refinement. However, 
this refinement did not lead to an acceptable fit (Rwp = 4.51%, Rp = 2.96%, Figure 
5.10b). The structure determination of this phase is currently in progress. 
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For phase 4, it was quite difficult to reproduce this sample and the quality of 
powder XRD pattern was not good enough (due to peak overlap), we could not index 
this powder XRD pattern at this stage. Thus, we could not carry out structure solution 
calculation in the program EAGER and could not determine the structure of phase 4 
from PXRD data. 
5.4 Results and Discussion 
5.4.1 Structural Analysis of Phase 1 
As mentioned above, there are two TMA molecules (denoted as TMA1 and 
TMA2), one ʟ-arginine molecule and two water molecules in the asymmetric unit of 
phase 1. Thus, the formula of phase 1 is (TMA)2 (ʟ-Arg)1·(H2O)2. The structure of 
phase 1 is shown in Figure 5.11. In the crystal structure, all TMA molecules are present 
as H2TMA
2– anions and the carboxylic acid group of ʟ-arginine molecule is not 
deprotonated (present as the –COOH group)and the –NH2 group is protonated (i.e., the  
–N+H3 group). Viewed along the c-axis, the crystal structure comprises two types of 
TMA ribbons, which lie parallel to the b-axis (these two ribbons are denoted as ribbon I 
and ribbon II, indicated within a green rectangle in Figure 5.11). Ribbon I is formed by 
TMA1 molecules and ribbon II is formed by TMA2 molecules. The ʟ-arginine 
molecules line up to occupy the space between these two types of TMA ribbons and are 
linked to adjacent TMA ribbons directly through  
O (TMA)···H–O (ʟ-Arg) hydrogen bonds and N–H (ʟ-Arg)···O (TMA) hydrogen bonds 
or indirectly via intervening water molecules. 
 
Figure 5.10.(a) Le Bail profile fitting and (b) Rietveld refinement for phase 3. 
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Viewed along the a-axis separately (Figures 5.12a and 5.12b), we can see that 
these two types of TMA ribbons are almost the same and both are corrugated instead of 
flat. For both types of ribbons (Figures 5.12a and 5.12b), each TMA molecule in one 
ribbon is linked to an adjacent TMA molecule directly by an  
O···H–O hydrogen bond (in ribbon I, the distance of O···H and O···O is 1.72 Å and 
2.71 Å and in ribbon II, the distance of O···H and O···O is 1.57 Å and 2.51 Å). 
Adjacent ribbons are also linked together through an O···H–O hydrogen bond (in 
ribbon I, the distance of O···H and O···O is 1.57 Å and 2.51 Å and in ribbon II, the 
distance of O···H and O···O is 1.58 Å and 2.51 Å). Thus, all ribbons I are linked 
together and there are no cyclic hydrogen-bonding arrangements observed in ribbon I 
(the same situation for ribbon II). 
 
 
Figure 5.11. Two types of TMA ribbons (ribbon I and ribbon II) in the crystal structure 
of phase 1, viewed along the c-axis. 
 
Figure 5.12. Two types of TMA ribbons (a) ribbon I and (b) ribbon II in the crystal 
structure of phase 1, viewed along the a-axis. 
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In terms of the ʟ-arginine molecule, as shown in Figure 5.13, for each ʟ-arginine 
molecule, on one side, the –COOH group of the ʟ-arginine molecule is linked to one 
TMA1 molecule directly through an O–H···O hydrogen bond (the distance of H···O 
and O···O in this hydrogen bond is 2.26 Å and 3.12 Å) and one –NH2 group of the 
guanidinium group is linked to another TMA1 molecule through an  
N–H···O–H (water)···O hydrogen-bonding arrangement involving one intervening 
water molecule. On the other side of the ʟ-arginine molecule, the –N+H3 group of the 
ʟ-arginine is linked to two TMA2 molecules through two N–H···O hydrogen bonds (in 
these two hydrogen bonds, the distances of N···O is 2.96 Å and 2.68 Å and a cyclic 
hydrogen-bonding  823R  arrangement forms between them. Another –NH2 group of the 
 
Figure 5.13. Hydrogen-bonding arrangements between ʟ-Arg molecules and TMA 
molecules in the structure of phase 1. 
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guanidinium group is linked to one TMA2 molecule involving one intervening water 
molecule, which give rise to graph set  1233R . In this cyclic hydrogen-bonding 
arrangement, on one side, the –NH2 group of the guanidinium group is linked to a 
TMA2 molecule directly through an N–H···O hydrogen bond, on other side, the –NH2 
group is linked to a TMA2 molecule via an intervening water molecule through an N–
H···O–H···O hydrogen bond. In addition, it is noted that there is a large cyclic 
hydrogen-bonding ring, which involves two TMA1 molecules, two water molecules, 
two ʟ-arginine molecules and one TMA2 molecule, giving rise to graph set  2257R . 
 
Figure 5.14. (a) The complete crystal structure of phase 2, viewed along the b-axis. 
(b) Two types of TMA pillars and (c) Three types of strands of ʟ-arginine molecule in 
the crystal structure of phase 2, viewed along the c-axis. 
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5.4.2 Structural Analysis of Phase 2 
In the structure of phase 2, there are three independent TMA molecules (A1, A2, 
and A3) and three independent ʟ-arginine molecules (B1, B2 and B3) in the asymmetric 
unit. Thus, the formula of phase 2 is (TMA)1 (ʟ-Arg)1. The structure of phase 2 is 
shown in Figure 5.14, in the crystal structure, all TMA molecules are present as 
H2TMA
2– anions and the carboxylic acid group of ʟ-arginine molecule is deprotonated 
and present as the –COO– group and the –NH2 group is protonated and present as the 
–N+H3 group. 
As show in Figure 5.14a, viewed along the b-axis, there are two types of TMA 
pillars and three types of ʟ-arginine strands. The TMA molecules are stacked in the 
sequence A1, A2, A3, A1, A2, A3,… with two different dispositions to form two types of 
TMA pillars, which both lie parallel to the b-axis (Figure 5.14b, viewing along the c-
axis). Next to the TMA pillars, there are three lined different types of ʟ-arginine strand 
(Figure 5.14c, strand B1, B2 and B3) in turn. These three strands are also parallel to the 
b-axis (viewing along the c-axis). Within the strand B1, adjacent B1 molecules are 
linked together by two N–H···O hydrogen-bonding arrangements involving two –NH2 
groups of the guanidinium group of one B1 molecule and the –COO– group of another 
B1 molecule, which gives rise to a hydrogen-bonding arrangement with graph set  822R . 
The distances (hydrogen bond lengths) between these two H···O hydrogen bonds within 
this strand are 1.948 Å and 1.985 Å, and the distance of N···O are 2.867 Å and 2.719 Å. 
Within each of the strands B2 and B3, there is only one N–H···O hydrogen bond 
involving one –NH2 of the guanidinium group of one B2 (or B3) molecule and the –
COO– group of another B2 (or B3) molecule, and the distance (hydrogen bond lengths) 
between H···O hydrogen bonds is 1.846 Å (or 2.295 Å) and the distances of N···O are 
2.811 Å or (2.859 Å). 
The hydrogen-bonding arrangements between TMA molecules and ʟ-arginine 
molecules in the crystal structure of phase 2 are shown in Figure 5.15 (viewed along (-5 
2 0)), i.e. firstly, view along the a-axis, then rotate the structure with about 26° along the 
a-axis in order to show the TMA molecules clearly). One A2 molecule is linked to an A1 
molecule and an A3 molecule through two O (A2)···H–O (A1 or A3) hydrogen bonds to 
form a short TMA ribbon. On one side, one B1 molecule of the B1 strand is linked to an 
A2 molecule through an N–H···O hydrogen bond and the distance (hydrogen bond 
length) of H···O is 1.967 Å and the distance of N···O is 2.70 Å. On the other side, one 
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B2 molecule of the B2 strand is linked to the A1 molecule through two N–H···O 
hydrogen bonds, forming a hydrogen-bonding arrangement with graph set  612R . The 
distance (hydrogen bond lengths) of these two H···O hydrogen bonds are 1.934 Å and 
2.109 Å and the distances of N···O are 2.758 Å and 2.885 Å. The B3 molecules in the 
strand B3 is not linked to any TMA molecules. 
5.5 Summary 
In conclusion, in the course of studying co-crystals of TMA and ʟ-arginine, we 
obtained four new solid phases and the structures of two co-crystals of TMA and  
ʟ-arginine have been determined directly from powder XRD data. One co-crystal is 
composed of two TMA molecules, one ʟ-arginine molecule and two water molecules in 
the asymmetric unit, whereas the co-crystal is composed of three TMA molecules and 
three ʟ-arginine molecules in the asymmetric unit. The process of structure 
determination from powder XRD data is presented in this chapter, demonstrating that 
PXRD analysis is a reliable alternative for structural analysis when the single-crystal 
XRD method cannot be used. 
 
Figure 5.15. Hydrogen-bonding arrangements between TMA molecules and ʟ-arginine 
molecules of phase 2, viewed towards plane (5¯20). 
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Chapter 6 Co-Crystal of Pillar[5]quinone and 
1,1,2,2,-Tetrachloroethane, with Structure 
Determination Directly from Powder X-Ray Diffraction 
Data 
6.1 Introduction 
Pillar[n]arenes[269-272] are a new class of macrocyclic molecular compound 
composed of hydroquinone units linked by methylene groups at the para positions 
(Figure 6.1a). Due to their symmetrical, pillar-like structures and potential applications 
in host-guest chemistry, pillar[n]arenes and their derivatives have attracted considerable 
attention.[273,274] To date, pillar[n]arenes (n = 5 - 10) have been synthesized. However, 
due to the low yields (1 - 2%) of pillar[n]arenes (n = 7 - 10), currently most research 
involving pillar[n]arenes has been focused on pillar[5]arene and pillar[6]arene and their 
derivatives, especially pillar[5]arene and its derivatives.[275-279] It has been reported that 
partial or full functionalization of pillar[5]arenes with different functional groups can 
change their physicochemical properties (such as solubility), leading to different 
potential applications in various areas.[280-283] 
Pillar[5]quinone (P[5]Q), the oxidation product of pillar[5]arene, was synthesized 
for the first time in 2009.[271] P[5]Q is composed of five p-benzoquinones linked by 
methylene groups at the para positions (Figure 6.1b). In theory, the structure of the 
P[5]Q molecule should have a symmetrical pillar-shaped framework with two equally 
sized cavity portals. These features make P[5]Q interesting and useful in host-guest 
chemistry. Therefore, understanding the detailed crystal structure properties of P[5]Q is 
very important. Lao and Yu[284] investigated the thermodynamic properties and 
electronic structure of P[5]Q by computational studies and the results of their 
calculations suggested that P[5]Q undergoes significant intramolecular charge transfer 
upon the electronic excitation from the HOMO to the LUMO, owing to the large 
difference in electron distributions between the HOMO to the LUMO. 
Furthermore, they also suggested that P[5]Q is a promising material for trapping 
anionic halogens through anion-π interactions[285] in the interior cavity of P[5]Q. 
Significantly, π-π interactions and cation-π interactions are well known to play a key 
role in chemistry and biological sciences, such as crystal engineering, protein structures 
and DNA structures. However, non-covalent interactions between π-acidic aromatic 
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systems and anions, namely anion-π interactions, have been largely ignored by scientists 
due to their seemingly counterintuitive nature. In 2002, scientists[286] established that 
anion-π interactions really exist and are energetically favourable, and subsequently 
anion-π interactions have attracted much attention.[287-290] It has been reported[291,292] 
that 1,4-benzoquinone has a large electron affinity, which makes 1,4-benzoquinone very 
efficient as an electron acceptor. Therefore, as P[5]Q is composed of five 
1,4-benzoquinone moieties, it is anticipated that P[5]Q can interact with anions in the 
interior cavity through anion-π interactions. In order to understand the structural 
properties of P[5]Q in more detail and to confirm the expectations inferred from 
computational studies, chemists attempted to prepare P[5]Q in the form of a crystalline 
solid. However, to date, large single crystals of P[5]Q have not been prepared, and the 
structural properties of P[5]Q have not been determined by single-crystal X-ray 
diffraction techniques. Fortunately, using powder X-ray diffraction for structure 
solution (the direct-space strategy), we can carry out the structure determination of 
P[5]Q instead by powder X-ray diffraction data, combined with other techniques such 
as high-resolution solid-state NMR. Given the importance of P[5]Q in host-guest 
chemistry, the aim of this chapter is to determine the co-crystal structure of P[5]Q with 
1,1,2,2-tetrachloroethane directly from powder X-ray diffraction data. 
6.2 Experimental 
A yellow-coloured, fluffy, microcrystalline sample of co-crystals of P[5]Q with 
1,1,2,2-tetrachloroethane (TCE) was produced by our collaborators in India (Gangadhar 
J. Sanjayan, CSIR-National Chemical Laboratory). A high-quality powder XRD pattern 
of this sample was recorded on a Bruker D8 instrument (Ge-monochromated CuKα1 
 
Figure 6.1. (a) Molecular structure of pillar[n]arenes. (b) Molecular structure of 
pillar[5]quinone. 
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radiation) using a tape sample holder. The powder XRD data were recorded in 
transmission mode (2θ range: 4 - 50°, total time: 48 h). Differential scanning 
calorimetry (DSC) data were measured on a TA Instruments Q100 using sealed 
aluminium pans and cooling rates between 1 and 20 °C min–1. Variable-temperature 
powder XRD data were recorded from 90 K to 300 K (90 K, 100 K, 150 K, 200 K, 
250 K, 295 K and 300 K) using synchrotron X-ray powder diffraction at the Diamond 
Light Source. (Beam-line I11, High resolution powder diffraction, λ = 0.826607(2) Å). 
The sample was loaded within a capillary sample holder and step-scanned in 2 steps of 
0.001° with total scan time of 1800 s for each experiment). High-resolution solid-state 
13C NMR experiments were carried out at the EPSRC UK National Solid-State NMR 
Service at the University of Durham. Spectra were recorded at ambient temperature on a 
spectrometer operating at a 13C Larmor frequency of 100.562 MHz, with MAS at 8 kHz. 
Spectra were recorded both using the standard 1H→13C CPMAS pulse sequence and 
using the 1H→13C CPMAS pulse sequence with a dipolar dephasing delay of 50 s 
between the 1H excitation pulse and CP. 
6.3 Structure Determination from Powder XRD Data 
The powder XRD pattern was indexed by using the TREOR[202] and ITO[203] 
codes, which are incorporated into the program CRYSFIRE.[205] Combined with the 
program CHEKCELL[207], the following unit cell in an orthorhombic system was 
obtained: a = 18.794 Å, b = 15.258 Å, c = 6.914 Å (V = 1982.8 Å3), and the best 
estimated space groups given by program CHEKCELL were I222 and Immm. Le Bail 
fitting[208] was then used to check these space groups using the GSAS[209] software and 
the graphical user interface editor EXPGUI.[210] However, a good quality of Le Bail fit 
was not obtained for either of these space groups (Figure 6.2a and 6.2b). We then used 
the simplest space group in the orthorhombic system, P222, for Le Bail fitting. The 
resulting fit was still not good quality (Figure 6.2c), suggesting that the orthorhombic 
system is not correct. Therefore, we lowered the symmetry to monoclinic. The space 
group was assigned as P2, P21, Pm, P2/m, P2/n, P21/m or P21/n, with the unit cell 
parameters: a = 18.771 Å, b = 15.250 Å, c = 6.905 Å, β = 89.736° (V = 1976.6 Å3). Le 
Bail fitting gave a good quality of fit for all these space groups (Figure 6.3a - 6.3g). 
Thus, the space group could not be assigned uniquely on the basis of systematic 
absences alone at this stage and, all these seven possible space groups were considered 
in parallel for structure solution in the next stage. 
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Given the volume of the unit cell and consideration of the density of the material, 
there are two P[5]Q molecules and four TCE molecules in the unit cell and the 
calculated density is 1.57 g cm–3. Therefore, if the space groups is P2, P21 or Pm, there 
is one P[5]Q molecule and two TCE molecules in the asymmetric unit; if the space 
group is P2/m, P2/n, P21/m or P21/n, there is one half a P[5]Q molecule and one TCE 
molecule in the asymmetric unit. The refined unit cell parameters and profile parameters 
obtained from the Le Bail fits for space groups P2, P21, Pm, P2/m, P2/n, P21/m and 
P21/n were used in the structure solution calculations. 
Structure solution calculations were carried out using the direct-space genetic 
algorithm (GA)[191] technique incorporated in the program EAGER.[195] A total of seven 
input models were used in the structure solution calculations, representing the seven 
different space group. For space groups P2, P21 and Pm, the input model comprised four 
fragments: two half P[5]Q molecules and two TCE molecules. The reason for two half 
P[5]Q molecules rather than one independent P[5]Q molecule were used in these cases 
was to confirm whether the P[5]Q molecule can form a pentagonal ring and whether the 
five 1,4-benzoquinone moieties can link each other by methylene groups at the para 
 
Figure 6.2. Le Bail profile fitting for space groups (a) I222, (b) Immm and (c) P222. 
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positons. Each half P[5]Q molecule was defined by a total of six structural variables 
(three positional variables and three orientational variables) and each TCE molecule 
was defined by a total of seven structural variables: three positional variables, three 
orientational variables and one torsional angle variable. Hence, these structure solution 
calculations involved a total of 26 structural variables. For P2/m, P2/n, P21/m and P21/n, 
each input model comprised three fragments: one fragment was a half P[5]Q molecule 
and each of the other two fragments was a half TCE molecule. The half P[5]Q molecule 
was defined by six structural variables and each half TCE molecule was defined by six 
structural variables. Hence, these structure solution calculations involved a total of 18 
structural variables. In total, 16 independent GA calculations were carried out for each 
space group and the GA calculation was allowed to evolve for 1000 generations with a 
population size of 100. In each generation, 10 mating operations and 50 mutation 
operations were carried out. The results from all these structure solution calculations 
were assessed and evaluated to determine which space group gives the best structure 
solution. 
The results from the structure solution calculations indicated that the lowest Rwp 
was obtained for space group P21, and this best structure solution was structurally 
reasonable. In this model, the two half P[5]Q molecules formed into one complete 
P[5]Q molecule. For space group P2/n, the structure solution with the second lowest Rwp 
is obtained, with two half P[5]Q molecules (related to each other by the 2-fold axis) 
forming into one complete P[5]Q molecule. However, one of TCE molecules is not 
formed correctly in this space group. In the remaining five space groups, the two half 
P[5]Q molecules do not form a complete P[5]Q molecule correctly. Therefore, the 
structure solution with lowest Rwp obtained in the GA calculations with space group P21 
was used as the initial structural model for Rietveld refinement,[213] which was carried 
out using the GSAS program. In the Rietveld refinement, standard restraints were 
applied to bond lengths and bond angles, and planar restraints were applied to each 
quinone ring. As the refinement progressed, these restraints were gradually relaxed. In 
the process of refinement, the isotropic displacement parameters were refined. The 
value of Uiso for all atoms within the same molecule were set to the same value. All 
hydrogen atoms were set to a value of 1.2 times that of the non-H atoms. However, the 
initial Rietveld refinement did not lead to an acceptable quality of fit, with acceptable 
discrepancies between the experimental and calculated powder XRD patterns 
(Rwp = 1.82%, Figure 6.4a). 
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Figure 6.3. Le Bail profile fitting for space groups (a) P2, (b) P21, (c) Pm, (d) P2/m,  
(e) P2/n, (f) P21/m and (g) P21/n.
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Figure 6.4. Rietveld refinements for the models with (a) two ordered solvent molecules 
and (b) one ordered and one disordered solvent molecule. 
With the help of difference Fourier maps, we noticed that there were significant 
discrepancies in electron density associated with one of the TCE molecule, suggesting 
that this molecule may be disordered. To confirm this suggestion, we performed a 
CP/MAS 13C SSNMR experiment with dipolar dephasing to investigate the possible 
motion of the TCE molecules. The solid-state 13C NMR spectra are shown in Figure 6.5. 
In the solid-state 13C NMR spectrum recorded without a dephasing delay (Figure 6.5a), 
we can see two isotropic peaks at 75.14 ppm and 73.53 ppm assigned to the carbon 
atoms of TCE. Thus, there are two different types of TCE molecules in the solid state. 
Then we performed the solid-state 13C NMR experiment with a dephasing delay of 
50.0 μs. The peak at 75.14 ppm is missing from the resulting spectrum (Figure 6.5b), 
with just one peak at 73.62 ppm. Comparing these two spectra, we conclude that the 
peak at 75.14 ppm corresponds to a static TCE molecule and the peak at 73.53 ppm 
(present in the spectrum recorded without a dephasing delay) or 73.62 ppm (present in 
the spectrum recorded with a dephasing delay of 50.0 μs) corresponds to a mobile TCE 
molecule. These results indicate that one TCE molecule in the asymmetric unit is 
mobile, representing dynamic disorder. From these solid-state 13C NMR spectra, we can 
conclude that there are two TCE molecules in the asymmetric unit and one molecule is 
dynamic and the other molecule is static. 
Therefore, the initial input models as discussed above for structure solution are 
not optimal, and modifications to the input model are required to enable one of  
TCE molecules to be disordered. Thus, we set up a new input model with space group 
P21 for structure solution calculations. In this input models, one  
TCE molecule is now represented by two components each with occupancy of a half. 
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Other conditions were kept the same as discussed above. The structure solution 
calculations in the program EAGER were carried out again. 
The results from structure solution indicated that the best structure solution with 
the lowest Rwp was structurally reasonable. In this model, the two half P[5]Q molecules 
formed into one complete P[5]Q. We performed Rietveld refinement for the new 
structure solution with the lowest Rwp, and the occupancies for the two TCE molecules 
with partial occupancies were allowed to refine, subject to the total occupancy being 
equal to 1. This time the refinement led to a good fit with the experimental powder 
XRD data (Rwp = 1.29%, Figure 6.4b). The final Rietveld refinement gave the following 
data: P21; a = 18.7699(5) Å, b = 15.2490(5) Å, c = 6.9056(2) Å, β = 89.7436(19)°, 
V = 1976.52(15) Å3, Rwp = 1.29%, Rp = 0.99%; the two TCE are disordered over two 
sites with occupancies 0.577(18):0.423(18). 
6.4 Results and Discussion 
From the structure of P[5]Q·TCE2 (Figure 6.6b, viewed along the c-axis) we can 
see that, due to the packing arrangement of P[5]Q molecules, there are two types of 
channel along the c-axis: pentagonal channels formed by the internal cavities of each 
P[5]Q molecule (denoted by channel I) and channels formed by the region of space 
between groups of four adjacent P[5]Q molecules (denoted by channel II). The ordered 
TCE molecules occupy channel II and the disordered TCE molecules occupy channel I. 
From Figure 6.6a (view along the b-axis), we can see that, in channel I, the disordered 
TCE molecules occupy the space between two adjacent P[5]Q molecules, instead of the 
internal cavities of the P[5]Q molecules. This is because the volume of one TCE 
 
Figure 6.5. Solid-state 13C NMR spectrum of P[5]Q·TCE2 (a) without dephasing delay 
and (b) with a dephasing delay of 50.0 μs. 
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molecule is larger than the volume of the cavity inside the P[5]Q molecule. The ordered 
TCE molecules filled the void formed by groups of four P[5]Q molecules. 
Investigating the crystal structure in more detail, we note that each P[5]Q 
molecule is not based on a perfect pentagonal ring, as the five angles (the angle refers to 
the dihedral angle between two adjacent 1,4-benzoquinone moieties) and the lengths of 
 
Figure 6.6. (a) Two types of channels (channel I and channel II) in the crystal structure 
of P[5]Q·TCE2, and (b) the complete crystal structure of P[5]Q·TCE2. 
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the five sides (the length refers to the distance between two adjacent methylene groups) 
in the pentagon are not the same. Specifically, the five angles are 113.6°, 108.6°, 117.8°, 
110.4° and 106.3°, and the lengths of the five sides are 5.96 Å, 5.88 Å, 5.93 Å, 6.00 Å 
and 5.99 Å. 
In addition, due to the lack of hydrogen bond donors, there is no hydrogen 
bonding between P[5]Q molecules and TCE molecules. However, as mentioned above, 
from computational studies, researchers have inferred that P[5]Q can interact with 
anions (e.g. Cl–) in the interior cavity through anion-π interactions. From the crystal 
structure of the cocrystal of P[5]Q with TCE, we can see that, in channel I, due to the 
volume of TCE being larger than the internal cavity of P[5]Q, the whole TCE molecule 
cannot be located within the cavity of P[5]Q (Figure 6.7a). However, one Cl atom of 
each disordered TCE molecule does penetrate within the internal cavity of P[5]Q 
(Figure 6.7b). 
As shown in Figure 6.6b, the shortest distances between the two “included” Cl 
atoms (Cl79 and Cl87) and the C atoms (C27 and C53) of adjacent 1,4-benzoquinone are 
3.14 Å (Cl87···C53) and 3.35 Å (Cl79···C27), respectively. The shortest distances from 
these two “included” Cl atoms to the plane of the adjacent 1,4-benzoquinone moiety are 
3.35 Å and 3.10 Å. According to the criterion of anion-π interactions[285] (the distance 
from anion to carbon atom distances is less than or equal to the sum of van der Waals 
radii plus 0.8 Å), the sum of van der Waals radii of C and Cl is 3.45 Å, so the distance 
between the “included” Cl atoms and the C atom of P[5]Q (3.14 Å and 3.35 Å) should 
be less than 4.25 Å. Thus, the two Cl atoms of the disordered TCE molecules in channel 
I can be considered to be bound to the P[5]Q molecules through anion-π type 
interactions. In channel II, the shortest distance between the Cl (Cl67) atom of the 
ordered TCE molecule and the C (C27) atom of the adjacent 1,4,-benzoquinone moiety 
is 3.41 Å and the distance of Cl67 to the plane of this 1,4-benzoquione moiety is 3.21 Å. 
Therefore, there is also an anion-π type interaction between them. 
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Since two TCE molecules in the asymmetric unit are disordered over two sites at 
room temperature, we expected that, at lower temperatures, the disordered molecules 
might become ordered. Therefore, we investigated the thermal properties of this sample 
by using DSC and variable-temperature powder XRD. However, even when we cooled 
the sample slowly from room temperature down to –160 °C (113 K) with different 
cooling rates (cooling rates between 1 and 20 °C min–1) by DSC, no phase transition 
was observed. Likewise, the powder XRD patterns (synchrotron data) recorded at 295 K, 
250 K, 200 K, 150 K, 100 K and 90 K showed no evidence for a phase transition. 
6.5 Summary 
In conclusion, we have determined the crystal structure of P[5]Q·TCE2 directly 
from powder XRD data. In the asymmetric unit, there is one P[5]Q molecule, one 
ordered TCE molecule and one disordered TCE molecule (disordered over two sites 
with occupancies 0.577(18):0.423(18). The final refined parameters are as follows: P21; 
a = 18.7699 (5) Å, b = 15.2490 (5) Å, c = 6.9056 (2) Å, β = 89.7436 (19)°; 
V = 1976.52 (15) Å3, Rwp = 1.29%, Rp = 0.99%. One Cl atom of each TCE molecule 
may be considered to be bound to an adjacent P[5]Q molecule through an anion-π type 
interaction. 
 
Figure 6.7. (a) Space-filling structure of one TCE molecule in front of a P[5]Q 
molecule. (b) One Cl atom of each dynamically disordered TCE molecule penetrates 
the internal cavity of a P[5]Q molecule. 
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Chapter 7 Conclusions and Future Work 
7.1 Conclusions 
Due to the importance of organic co-crystals in the pharmaceutical industry, in 
this thesis we focused on the preparation and investigations of two types of co-crystal 
system. One system comprises organic co-crystals of TMA and TBA, which exhibits 
astonishing structural diversity based on the stoichiometric ratios between TMA and 
TBA, particularly with regard to the phenomenon of polymorphism. The other system 
comprises co-crystals of TMA and ʟ-arginine. 
In the course of study of co-crystals of TMA and TBA, we discovered that they 
form a series of co-crystals with different molar ratios, by using a series of solvents 
combined with different crystallization methods and different ratios of TMA and TBA 
in the crystallization solution. The structural diversity observed for the co-crystals in 
this system is quite uncommon. In chapter 3, we reported two novel polymorphic co-
crystal systems of TMA and TBA. One is a solvated polymorphic system (with 2:5:3 
ratio of TMA, TBA and methanol), which is particularly novel in having a large number 
of independent components in the asymmetric unit in each of the polymorphs. The other 
is a polymorphic co-crystal system with a 2:3 ratio of TMA and TBA. In the case of co-
crystals of TMA2TBA5·(MeOH)3, the crystal structures of the two polymorphs both 
have quite similar parallel 2D sheets but the hydrogen-bonding pattern within these 
sheets shows subtle (but significant) differences. In the case of co-crystals of 
TMA2TBA3, despite the TMA molecules being partially deprotonated, both polymorphs 
still retain hexagonal networks and, due to the presence of TBA molecules, the 
hexagonal networks within both polymorphs are non-interpenetrated. However, the 
network in form I is planar while the network in form II is corrugated. 
In addition to the phenomenon of polymorphism of co-crystals of TMA and TBA, 
the structural diversity of other co-crystals of TMA and TBA is discussed in chapter 4. 
In this chapter, all co-crystals of TMA and TBA are classified into four families based 
on the stoichiometric ratio between TMA and TBA, and the structural features of each 
family are investigated from the viewpoint of hydrogen bonding. Adjusting the 
stoichiometric ratio between TMA and TBA and the types of solvent used gives rise to a 
broad range of totally different crystal structures, such as a structure comprising double-
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layered sheets (TMA2TBA1·(H2O)2), single hydrogen-bonded flat sheets 
(TMA1TBA2·(iso-Butanol)1), single hydrogen-bonded corrugated sheets 
(TMA1TBA2·(MeOH)1), a structure with interpenetration (TMA2TBA1·(H2O)3) and a 
structure comprising brick-wall networks (TMA2TBA2·(MeOH)1). That is to say, the 
hydrogen-bonding motifs formed in these co-crystals are quite sensitive to the 
stoichiometric ratios between TMA, TBA and the crystallization solvents used in each 
co-crystal. 
In the course of studying co-crystals of TMA and ʟ-arginine, we attempted to 
prepare single crystals of TMA and ʟ-arginine by different co-crystallization methods. 
However, no large single crystals were prepared successfully. Instead, four types of 
microcrystalline co-crystals materials containing TMA and ʟ-arginine were discovered. 
Since determining crystal structures directly from powder X-ray diffraction data has 
become an increasingly important technique for characterization of co-crystals, in 
chapters 5 and 6 we demonstrate the processes of structure determination of co-crystals 
of TMA and ʟ-arginine (chapter 5) and the co-crystal of pillar[5]quinone and 1,1,2,2-
tetrachloroethane (chapter 6) from powder X-ray diffraction data. The process of 
structure determination from powder X-ray diffraction data is presented in these two 
chapters, demonstrating that powder X-ray diffraction analysis is a reliable alternative 
for structural analysis when single-crystal X-ray diffraction cannot be used. 
7.2 Future Work 
In the course of studying the co-crystals of TMA and ʟ-arginine, we discovered 
four different phases and the structures of only two phases were determined from 
powder X-ray diffraction data. In the future, we could focus on the other two phases. In 
addition, in order to obtain good quality powder X-ray diffraction data for structure 
determination, which cannot obtained easily from solution crystallization or to obtain 
new phases of co-crystals of TMA and ʟ-arginine, we could use solid-state grinding 
methods to prepare co-crystals of TMA and ʟ-arginine. 
In the course of studying polymorphic co-crystals of TMA2TBA5·(MeOH)3, we 
discovered that, under an ambient atmosphere, both polymorphs were highly susceptible 
to loss of methanol, resulting in the same crystalline phase in each case. In the future, 
we could try to determine the structure of this new desolvated phase from powder X-ray 
diffraction data. 
 142 
References 
[1] G. R. Desiraju, CrystEngComm, 5, 466-467 (2003) 
[2] J. D. Dunitz, CrystEngComm, 5, 506-506 (2003) 
[3] C. B. Aakeroy and D. J. Salmon, CrystEngComm, 7, 439-448 (2005) 
[4] M. J. Zaworotko, Cryst. Growth Des., 7, 4-9 (2007) 
[5] N. Shan and M. J. Zaworotko, Drug Discov. Today, 13, 440-446 (2008) 
[6] J. Lu, Y.-P. Li, J. Wang, Z. Li, S. Rohani and C.-B. Ching, J. Cryst. Growth, 335, 
110-114 (2011) 
[7] H. G. Brittain, Cryst. Growth Des., 12, 1046-1054 (2011) 
[8] A. D. Bond, CrystEngComm, 9, 833-834 (2007) 
[9] L. Kux, Federal Register, 75551-75552 (2011) 
[10] S. Aitipamula, R. Banerjee, A. K. Bansal, K. Biradha, M. L. Cheney, A. R. 
Choudhury, G. R. Desiraju, A. G. Dikundwar, R. Dubey, N. Duggirala, P. P. 
Ghogale, S. Ghosh, P. K. Goswami, N. R. Goud, R. K. R. Jetti, P. Karpinski, P. 
Kaushik, D. Kumar, V. Kumar, B. Moulton, A. Mukherjee, G. Mukherjee, A. S. 
Myerson, V. Puri, A. Ramanan, T. Rajamannar, C. M. Reddy, N. Rodriguez-
Hornedo, R. D. Rogers, T. N. G. Row, P. Sanphui, N. Shan, G. Shete, A. Singh, 
C. C. Sun, J. A. Swift, R. Thaimattam, T. S. Thakur, R. K. Thaper, S. P. Thomas, 
S. Tothadi, V. R. Vangala, P. Vishweshwar, D. R. Weyna and M. J. Zaworotko, 
Cryst. Growth Des., 12, 4290-4291 (2012) 
[11] Guidance for Industry: Regulatory Classification of Pharmaceutical Co-Crystals, 
U.S. Department of Health and Human Services - Food and Drug Administration, 
Silver Spring, MD, 2013. 
[12] B. R. Bhogala, S. Basavoju and A. Nangia, CrystEngComm, 7, 551-562 (2005) 
[13] D. A. Haynes, W. Jones and W. D. S. Motherwell, CrystEngComm, 8, 830-840 
(2006) 
[14] S. L. Childs, G. P. Stahly and A. Park, Mol. Pharm., 4, 323-338 (2007) 
[15] M. K. Stanton and A. Bak, Cryst. Growth Des., 8, 3856-3862 (2008) 
[16] S. Mohamed, D. A. Tocher, M. Vickers, P. G. Karamertzanis and S. L. Price, 
Cryst. Growth Des., 9, 2881-2889 (2009) 
[17] C. B. Aakeroy, M. E. Fasulo and J. Desper, Mol. Pharm., 4, 317-322 (2007) 
[18] J. Kastelic, Z. Hodnik, P. Sket, J. Plavec, N. Lah, I. Leban, M. Pajk, O. Planinsek 
and D. Kikelj, Cryst. Growth Des., 10, 4943-4953 (2010) 
[19] G. P. Stahly, Cryst. Growth Des., 9, 4212-4229 (2009) 
[20] A. Gavezzotti, Curr. Opin. Solid State Mater. Sci., 1, 501-505 (1996) 
[21] H. Thakuria, B. M. Borah, A. Pramanik and G. Das, J. Chem. Cryst., 37, 807-
816 (2007) 
[22] H. G. Brittain, Cryst. Growth Des., 12, 5823-5832 (2012) 
[23] J. Geng, T. Tao, S.-J. Fu, W. You and W. Huang, Dyes and Pigments, 90, 65-70 
(2011) 
 143 
[24] D.-K. Bucar, S. Filip, M. Arhangelskis, G. O. Lloyd and W. Jones, 
CrystEngComm, 15, 6289-6291 (2013) 
[25] F. Pan, M. S. Wong, V. Gramlich, C. Bosshard and P. Gunter, J. Am. Chem. Soc., 
118, 6315-6316 (1996) 
[26] K. S. Huang, D. Britton, M. C. Etter and S. R. Byrn, J. Mater. Chem., 7, 713-720 
(1997) 
[27] C. A. Ellis, E. R. T. Tiekink and J. Zukerman-Schpector, J. Chem. Cryst., 38, 
513-517 (2008) 
[28] S.-J. Kwon, O. P. Kwon, M. Jazbinsek, V. Gramlich and P. Guenter, Chem. 
Comm., 3729-3731 (2006) 
[29] V. Krishnakumar, M. Rajaboopathi and R. Nagalakshmi, Physica B, 407, 1119-
1123 (2012) 
[30] H. M. Ratajczak, I. Bryndal, I. Ledoux-Rak and A. J. Barnes, J. Mol. Struct., 
1047, 310-316 (2013) 
[31] K. Hoogsteen, Acta Cryst., 16, 907-916 (1963) 
[32] S. Shavitt and R. H. Fazio, Pers. Soc. Psychol. B, 17, 507-516 (1991) 
[33] A. K. H. Hirsch, M. S. Alphey, S. Lauw, M. Seet, L. Barandun, W. Eisenreich, F. 
Rohdich, W. N. Hunter, A. Bacherc and F. Diederich, Org. Biomol. Chem., 6, 
2719-2730 (2008) 
[34] D. M. Bender, J. Q. Bao, A. H. Dantzig, W. D. Diseroad, K. L. Law, N. A. 
Magnus, J. A. Peterson, E. J. Perkins, Y. W. J. Pu, S. M. Reutzel-Edens, D. M. 
Remick, J. J. Starling, G. A. Stephenson, R. K. Vaid, D. Y. Zhang and J. R. 
McCarthy, J. Med. Chem., 52, 6958-6961 (2009) 
[35] A. Bak, A. Gore, E. Yanez, M. Stanton, S. Tufekcic, R. Syed, A. Akrami, M. 
Rose, S. Surapaneni, T. Bostick, A. King, S. Neervannan, D. Ostovic and A. 
Koparkar, J. Pharm. Sci., 97, 3942-3956 (2008) 
[36] K. Shiraki, N. Takata, R. Takano, Y. Hayashi and K. Terada, Pharm. Res., 25, 
2581-2592 (2008) 
[37] G. Bruni, M. Maietta, L. Maggi, P. Mustarelli, C. Ferrara, V. Berbenni, C. 
Milanese, A. Girella and A. Marini, J. Pharm. Sci., 102, 4079-4086 (2013) 
[38] N. Schultheiss and A. Newman, Cryst. Growth Des., 9, 2950-2967 (2009) 
[39] A. V. Trask, W. D. S. Motherwell and W. Jones, Cryst. Growth Des., 5, 1013-
1021 (2005) 
[40] S. Jung, J. Lee and I. W. Kim, J. Cryst. Growth, 373, 59-63 (2013) 
[41] R. Thakuria, A. Delori, W. Jones, M. P. Lipert, L. Roy and N. Rodriguez-
Hornedo, Int. J. Pharm., 453, 101-125 (2013) 
[42] M. B. Hickey, M. L. Peterson, L. A. Scoppettuolo, S. L. Morrisette, A. Vetter, H. 
Guzmán, J. F. Remenar, Z. Zhang, M. D. Tawa, S. Haley, M. J. Zaworotko and 
Ö. Almarsson, Eur. J. Pharm. Biopharm., 67, 112-119 (2007) 
[43] P. Vishweshwar, J. A. McMahon, J. A. Bis and M. J. Zaworotko, J. Pharm. Sci., 
95, 499-516 (2006) 
[44] N. Blagden, M. de Matas, P. T. Gavan and P. York, Adv. Drug. Deliver. Rev., 59, 
617-630 (2007) 
 144 
[45] S. Mirza, J. Heinamaki, I. Miroshnyk and J. Yliruusi, Eur. J. Pharm. Sci., 34, 
S16-S17 (2008) 
[46] T. Friščič and W. Jones, J. Pharm. Pharmacol., 62, 1547-1559 (2010) 
[47] N. Qiao, M. Li, W. Schlindwein, N. Malek, A. Davies and G. Trappitt, Int. J. 
Pharm., 419, 1-11 (2011) 
[48] D. P. Elder, R. Holm and H. L. de Diego, Int. J. Pharm., 453, 88-100 (2013) 
[49] H. G. Brittain, J. Pharm. Sci., 102, 311-317 (2013) 
[50] A. Delori, T. Friščič and W. Jones, CrystEngComm, 14, 2350-2362 (2012) 
[51] E. Arunan, G. R. Desiraju, R. A. Klein, J. Sadlej, S. Scheiner, I. Alkorta, D. C. 
Clary, R. H. Crabtree, J. J. Dannenberg, P. Hobza, H. G. Kjaergaard, A. C. 
Legon, B. Mennucci and D. J. Nesbitt, Pure Appl. Chem., 83, 1637-1641 (2011) 
[52] T. Steiner, Angew. Chem. Int. Ed., 41, 48-76 (2002) 
[53] G. R. Desiraju, Acc. Chem. Res., 24, 290-296 (1991) 
[54] H. Adams, K. D. M. Harris, G. A. Hembury, C. A. Hunter, D. Livingstone and J. 
F. McCabe, Chem. Comm., 2531-2532 (1996) 
[55] M. C. Etter, J. C. Macdonald and J. Bernstein, Acta Cryst. B, 46, 256-262 (1990) 
[56] M. C. Etter, Acc. Chem. Res., 23, 120-126 (1990) 
[57] T. Sugiyama, J. B. Meng and T. Matsuura, J. Mol. Struct., 611, 53-64 (2002) 
[58] R. D. B. Walsh, M. W. Bradner, S. Fleischman, L. A. Morales, B. Moulton, N. 
Rodriguez-Hornedo and M. J. Zaworotko, Chem. Comm., 186-187 (2003) 
[59] C. B. Aakeroy, A. M. Beatty and B. A. Helfrich, J. Am. Chem. Soc., 124, 14425-
14432 (2002) 
[60] S. Jin, W. Zhang, L. Liu, D. Wang, H. He, T. Shi and F. Lin, J. Mol. Struct., 991, 
1-11 (2011) 
[61] S. Jin, L. Liu, D. Wang and J. Guo, J. Mol. Struct., 1005, 59-69 (2011) 
[62] P. Vishweshwar, A. Nangia and V. M. Lynch, Cryst. Growth Des., 3, 783-790 
(2003) 
[63] H. Y. Ando, L. Dehaspe, W. Luyten, E. Van Craenenbroeck, H. Vandecasteele 
and L. Van Meervelt, Mol. Pharm., 3, 665-674 (2006) 
[64] P. T. A. Galek, L. Fabian, W. D. S. Motherwell, F. H. Allen and N. Feeder, Acta 
Cryst. B, 63, 768-782 (2007) 
[65] A. Delori, P. T. A. Galek, E. Pidcock, M. Patni and W. Jones, CrystEngComm, 
15, 2916-2928 (2013) 
[66] G. M. Day, T. G. Cooper, A. J. Cruz-Cabeza, K. E. Hejczyk, H. L. Ammon, S. X. 
M. Boerrigter, J. S. Tan, R. G. Della Valle, E. Venuti, J. Jose, S. R. Gadre, G. R. 
Desiraju, T. S. Thakur, B. P. van Eijck, J. C. Facelli, V. E. Bazterra, M. B. 
Ferraro, D. W. M. Hofmann, M. A. Neumann, F. J. J. Leusen, J. Kendrick, S. L. 
Price, A. J. Misquitta, P. G. Karamertzanis, G. W. A. Welch, H. A. Scheraga, Y. 
A. Arnautova, M. U. Schmidt, J. van de Streek, A. K. Wolf and B. Schweizer, 
Acta Cryst. B, 65, 107-125 (2009) 
[67] T. S. Thakur and G. R. Desiraju, Cryst. Growth Des., 8, 4031-4044 (2008) 
 145 
[68] A. J. Cruz-Cabeza, G. M. Day and W. Jones, Chem. Eur. J., 14, 8830-8836 
(2008) 
[69] D. W. M. Hofmann and T. Lengauer, J. Mol. Struct., 474, 13-23 (1999) 
[70] J. Kendrick, F. J. J. Leusen, M. A. Neumann and J. van de Streek, Chem. Eur. J., 
17, 10736-10744 (2011) 
[71] K. B. Landenberger and A. J. Matzger, Cryst. Growth Des., 10, 5341-5347 (2010) 
[72] C. A. Hunter and J. K. M. Sanders, J. Am. Chem. Soc., 112, 5525-5534 (1990) 
[73] M. L. Waters, Curr. Opin. Chem. Biol., 6, 736-741 (2002) 
[74] C. A. Hunter, K. R. Lawson, J. Perkins and C. J. Urch, J. Chem. Soc., Perkin 
Trans. 2, 651-669 (2001) 
[75] A. K. Tewari and R. Dubey, Bioorg. Med. Chem., 16, 126-143 (2008) 
[76] B. Sarma, L. S. Reddy and A. Nangia, Cryst. Growth Des., 8, 4546-4552 (2008) 
[77] C. R. P. G. S. Prosser, Nature, 187, 1021-1021 (1960) 
[78] A. P. West, S. Mecozzi and D. A. Dougherty, J. Phys. Org. Chem., 10, 347-350 
(1997) 
[79] J. H. Williams, Acc. Chem. Res., 26, 593-598 (1993) 
[80] M. Baldrighi, G. Cavallo, M. R. Chierotti, R. Gobetto, P. Metrangolo, T. Pilati, 
G. Resnati and G. Terraneo, Mol. Pharm., 10, 1760-1772 (2013) 
[81] D. Cincic, T. Friscic and W. Jones, Chem. Eur. J., 14, 747-753 (2008) 
[82] S. Tothadi and G. R. Desiraju, Chem. Comm., 49, 7791-7793 (2013) 
[83] F. Wöhler and V. Liebig, J. Ann. Pharm., 3, 249-282 (1832) 
[84] J. M. Robertson and A. R. Ubbelohde, Proc. Roy. Soc. London A, 167, 0122-
0135 (1938) 
[85] J. B. Nanubolu, B. Sridhar, V. S. P. Babu, B. Jagadeesh and K. Ravikumar, 
CrystEngComm, 14, 4677-4685 (2012) 
[86] A. R. Sheth, S. Bates, F. X. Muller and D. J. W. Grant, Cryst. Growth Des., 4, 
1091-1098 (2004) 
[87] P. Sanphui, N. R. Goud, U. B. R. Khandavilli, S. Bhanoth and A. Nangia, Chem. 
Comm., 47, 5013-5015 (2011) 
[88] J. Y. Khoo, U. V. Shah, M. Schaepertoens, D. R. Williams and J. Y. Y. Heng, 
Powder Technol., 236, 114-121 (2013) 
[89] J. Lu, X.-J. Wang, X. Yang and C.-B. Ching, Cryst. Growth Des., 7, 1590-1598 
(2007) 
[90] T. Gelbrich, D. E. Braun, A. Ellern and U. J. Griesser, Cryst. Growth Des., 13, 
1206-1217 (2013) 
[91] K. M. Lutker, R. Quinones, J. Xu, A. Ramamoorthy and A. J. Matzger, J. Pharm. 
Sci., 100, 949-963 (2010) 
[92] P. J. Wheatley, J. Chem. Soc., S, 6036-6048 (1964) 
[93] P. Vishweshwar, J. A. McMahon, M. Oliveira, M. L. Peterson and M. J. 
Zaworotko, J. Am. Chem. Soc., 127, 16802-16803 (2005) 
 146 
[94] M. R. Hauser, L. Zhakarov, K. M. Doxsee and T. Li, Cryst. Growth Des., 8, 
4428-4431 (2008) 
[95] S. Long, S. Parkin, M. Siegler, C. P. Brock, A. Cammers and T. Li, Cryst. 
Growth Des., 8, 3137-3140 (2008) 
[96] I. Barsky and J. Bernstein, CrystEngComm, 10, 669-674 (2008) 
[97] B. D. Sharma, J. Chem. Educ., 64, 404-407 (1987) 
[98] A. Gavezzotti, J. Pharm. Sci., 96, 2232-2241 (2007) 
[99] Guideline on Test Procedures and Acceptance Criteria for New Veterianary Drug 
Substances and New Medicinal Products: Chemical Substances, European 
Medicines Agency, London, 2005. 
[100] B. R. Jali and J. B. Baruah, Cryst. Growth Des., 12, 3114-3122 (2012) 
[101] K. R. Back, R. J. Davey, T. Grecu, C. A. Hunter and L. S. Taylor, Cryst. Growth 
Des., 12, 6110-6117 (2012) 
[102] S. Long, S. Parkin, M. A. Siegler, A. Cammers and T. Li, Cryst. Growth Des., 8, 
4006-4013 (2008) 
[103] A. Nangia, Acc. Chem. Res., 41, 595-604 (2008) 
[104] G. R. Desiraju, Cryst. Growth Des., 8, 3-5 (2008) 
[105] M. Haisa, S. Kashino, R. Kawai and H. Maeda, Acta Cryst. B, 32, 1283-1285 
(1976) 
[106] T. N. Drebushchak and E. V. Boldyreva, Z. Kristallogr., 219, 506-512 (2004) 
[107] M.-A. Perrin, M. A. Neumann, H. Elmaleh and L. Zaske, Chem. Comm., 3181-
3183 (2009) 
[108] J. C. Burley, M. J. Duer, R. S. Stein and R. M. Vrcelj, Eur. J. Pharm. Sci., 31, 
271-276 (2007) 
[109] S. Gaisford, A. B. M. Buanz and N. Jethwa, J. Pharm. Biomed. Anal., 53, 366-
370 (2010) 
[110] M. Kitamura, J. Cryst. Growth, 237, 2205-2214 (2002) 
[111] A. Llinas and J. M. Goodman, Drug Discov. Today, 13, 198-210 (2008) 
[112] W. S. Wang, M. D. Aggarwal, J. Choi, T. Gebre, A. D. Shields, B. G. Penn and 
D. O. Frazier, J. Cryst. Growth, 198, 578-582 (1999) 
[113] R. C. Kelly and N. Rodriguez-Hornedo, Org. Process Res. Dev., 13, 1291-1300 
(2009) 
[114] M. Alleso, F. Van Den Berg, C. Cornett, F. S. Jorgensen, B. Halling-Sorensen, H. 
L. De Diego, L. Hovgaard, J. Aaltonen and J. Rantanen, J. Pharm. Sci., 97, 
2145-2159 (2008) 
[115] K. R. Prasad, A. Chandrakumar, A. G. Dikundwar and T. N. G. Row, 
CrystEngComm, 12, 3452-3454 (2010) 
[116] J. M. Rubin-Preminger and J. Bernstein, Cryst. Growth Des., 5, 1343- 1349 
(2005) 
[117] A. F. Fioritto, S. N. Bhattachar and J. A. Wesley, Int. J. Pharm., 330, 105- 113 
(2007) 
 147 
[118] D. Braga, G. Palladino, M. Polito, K. Rubini, F. Grepioni, M. R. Chierotti and R. 
Gobetto, Chem. Eur. J., 14, 10149-10159 (2008) 
[119] I. Halasz, M. Rubčić, K. Užarević, I. Dilović and E. Meštrović, New J. Chem., 
35, 24-27 (2011) 
[120] S. Aitipamula, P. S. Chow and R. B. H. Tan, CrystEngComm, 11, 1823-1827 
(2009) 
[121] S. Aitipamula, P. S. Chow and R. B. H. Tan, CrystEngComm, 11, 889-895 (2009) 
[122] S. Aitipamula, P. S. Chow and R. B. H. Tan, Cryst. Growth Des., 10, 2229-2238 
(2010) 
[123] S. Aitipamula, P. S. Chow and R. B. H. Tan, CrystEngComm, 12, 3691-3697 
(2010) 
[124] W. W. Porter, III, S. C. Elie and A. J. Matzger, Cryst. Growth Des., 8, 14-16 
(2008) 
[125] J. H. ter Horst and P. W. Cains, Cryst. Growth Des., 8, 2537-2542 (2008) 
[126] W. Limwikrant, A. Nagai, Y. Hagiwara, K. Higashi, K. Yamamoto and K. 
Moribe, Int. J. Pharm., 431, 237-240 (2012) 
[127] S. Aitipamula, A. B. H. Wong, P. S. Chow and R. B. H. Tan, CrystEngComm, 14, 
8193-8198 (2012) 
[128] M. D. Eddleston, S. Sivachelvam and W. Jones, CrystEngComm, 15, 175-181 
(2013) 
[129] N. Schultheiss, M. Roe and S. X. M. Boerrigter, CrystEngComm, 13, 611-619 
(2011) 
[130] A. V. Trask, W. D. S. Motherwell and W. Jones, Chem. Comm., 890-891 (2004) 
[131] A. Asmadi, J. Kendrick and F. J. J. Leusen, Phys. Chem. Chem. Phys., 12, 8571-
8579 (2010) 
[132] H. C. S. Chan, J. Kendrick and F. J. J. Leusen, Phys. Chem. Chem. Phys., 13, 
20361-20370 (2011) 
[133] M. D. Eddleston, K. E. Hejczyk, E. G. Bithell, G. M. Day and W. Jones, Chem. 
Eur. J., 19, 7874-7882 (2013) 
[134] J. Kendrick, G. A. Stephenson, M. A. Neumann and F. J. J. Leusen, Cryst. 
Growth Des., 13, 581-589 (2013) 
[135] A. Gavezzotti, CrystEngComm, 343-347 (2002) 
[136] R. G. Della Valle, E. Venuti, A. Brillante and A. Girlando, J. Phys. Chem. A, 112, 
6715-6722 (2008) 
[137] R. A. Chiarella, R. J. Davey and M. L. Peterson, Cryst. Growth Des., 7, 1223-
1226 (2007) 
[138] S. G. Fleischman, S. S. Kuduva, J. A. McMahon, B. Moulton, R. D. B. Walsh, N. 
Rodriguez-Hornedo and M. J. Zaworotko, Cryst. Growth Des., 3, 909-919 (2003) 
[139] T. Rager and R. Hilfiker, Cryst. Growth Des., 10, 3237-3241 (2010) 
[140] A. Jayasankar, L. S. Reddy, S. J. Bethune and N. Rodríguez-Hornedo, Cryst. 
Growth Des., 9, 889-897 (2009) 
 148 
[141] S. L. James, C. J. Adams, C. Bolm, D. Braga, P. Collier, T. Friščič, F. Grepioni, 
K. D. M. Harris, G. Hyett, W. Jones, A. Krebs, J. Mack, L. Maini, A. G. Orpen, I. 
P. Parkin, W. C. Shearouse, J. W. Steed and D. C. Waddell, Chem. Soc. Rev., 41, 
413-447 (2012) 
[142] S. Karki, T. Friščič, W. Jones and W. D. S. Motherwell, Mol. Pharm., 4, 347-354 
(2007) 
[143] A. O. Patil, D. Y. Curtin and I. C. Paul, J. Am. Chem. Soc., 106, 348-353 (1984) 
[144] W. Somphon and K. J. Haller, J. Cryst. Growth, 362, 252-258 (2013) 
[145] A. Shevchenko, I. Miroshnyk, L.-O. Pietilä, J. Haarala, J. Salmia, K. Sinervo, S. 
Mirza, B. van Veen, E. Kolehmainen, Nonappa and J. Yliruusi, Cryst. Growth 
Des., 13, 4877-4884 (2013) 
[146] J. Lu and S. Rohani, Org. Process Res. Dev., 13, 1269-1275 (2009) 
[147] M. C. Etter, S. M. Reutzel and C. G. Choo, J. Am. Chem. Soc., 115, 4411-4412 
(1993) 
[148] M. C. Etter and D. A. Adsmond, J. Chem. Soc. Chem. Comm., 589-591 (1990) 
[149] A. V. Trask, J. van de Streek, W. D. S. Motherwell and W. Jones, Cryst. Growth 
Des., 5, 2233-2241 (2005) 
[150] I.-C. Wang, M.-J. Lee, S.-J. Sim, W.-S. Kim, N.-H. Chun and G. J. Choi, Int. J. 
Pharm., 450, 311-322 (2013) 
[151] M.-J. Lee, N.-H. Chun, I.-C. Wang, J. J. Liu, M.-Y. Jeong and G. J. Choi, Cryst. 
Growth Des., 13, 2067-2074 (2013) 
[152] N. Rodríguez-Hornedo, S. J. Nehru, K. F. Seefeldt, Y. Pagan-Torres and C. J. 
Falkiewicz, Mol. Pharm., 3, 362-367 (2006) 
[153] T. Friščič, S. L. Childs, S. A. A. Rizvi and W. Jones, CrystEngComm, 11, 418-
426 (2009) 
[154] S. Aher, R. Dhumal, K. Mahadik, A. Paradkar and P. York, Eur. J. Pharm. Sci., 
41, 597-602 (2010) 
[155] L. Padrela, M. A. Rodrigues, S. P. Velaga, A. C. Fernandes, H. A. Matos and E. 
G. de Azevedo, J. Supercrit. Fluids, 53, 156-164 (2010) 
[156] L. Padrela, M. A. Rodrigues, S. R. Velaga, H. A. Matos and E. G. de Azevedo, 
Eur. J. Pharm. Sci., 38, 9-17 (2009) 
[157] N. Takata, K. Shiraki, R. Takano, Y. Hayashi and K. Terada, Cryst. Growth Des., 
8, 3032-3037 (2008) 
[158] F. L. F. Soares and R. L. Carneiro, Cryst. Growth Des., 13, 1510-1517 (2013) 
[159] E. Lu, N. Rodríguez-Hornedo and R. Suryanarayanan, CrystEngComm, 10, 665-
668 (2008) 
[160] R. S. Dhumal, A. L. Kelly, P. York, P. D. Coates and A. Paradkar, Pharm. Res., 
27, 2725-2733 (2010) 
[161] D. J. Berry, C. C. Seaton, W. Clegg, R. W. Harrington, S. J. Coles, P. N. Horton, 
M. B. Hursthouse, R. Storey, W. Jones, T. Friščič and N. Blagden, Cryst. 
Growth Des., 8, 1697-1712 (2008) 
[162] P. G. Vekilov, Nanoscale, 2, 2346-2357 (2010) 
[163] P. R. Unwin, Farad. Discuss., 136, 409-416 (2007) 
 149 
[164] Y.-H. Luo and B.-W. Sun, Cryst. Growth Des., 13, 2098-2106 (2013) 
[165] J. A. Bis, O. L. McLaughlin, P. Vishweshwar and M. J. Zaworotko, Cryst. 
Growth Des., 6, 2648-2650 (2006) 
[166] C. B. Aakeröy, I. Hussain and J. Desper, Cryst. Growth Des., 6, 474-480 (2006) 
[167] M. Wenger and J. Bernstein, Mol. Pharm., 4, 355-359 (2007) 
[168] P. K. Thallapally, R. K. R. Jetti, A. K. Katz, H. L. Carrell, K. Singh, K. Lahiri, S. 
Kotha, R. Boese and G. R. Desiraju, Angew. Chem. Int. Ed., 43, 1149-1155 
(2004) 
[169] C. C. Seaton, A. Parkin, C. C. Wilson and N. Blagden, Cryst. Growth Des., 9, 
47-56 (2009) 
[170] T. Leyssens, G. Springuel, R. Montis, N. Candoni and S. Veesler, Cryst. Growth 
Des., 12, 1520-1530 (2012) 
[171] S. Zhang and A. C. Rasmuson, CrystEngComm, 14, 4644-4655 (2012) 
[172] Z. Q. Yu, P. S. Chow and R. B. H. Tan, Cryst. Growth Des., 10, 2382-2387 
(2010) 
[173] D. M. Croker, R. J. Davey, A. C. Rasmuson and C. C. Seaton, Cryst. Growth 
Des., 13, 3754-3762 (2013) 
[174] K. Fucke, S. A. Myz, T. P. Shakhtshneider, E. V. Boldyreva and U. J. Griesser, 
New J. Chem., 36, 1969-1977 (2012) 
[175] S. J. Nehm, B. Rodríguez-Spong and N. Rodríguez-Hornedo, Cryst. Growth Des., 
6, 592-600 (2006) 
[176] A. Y. Sheikh, S. A. Rahim, R. B. Hammond and K. J. Roberts, CrystEngComm, 
11, 501-509 (2009) 
[177] F. Wöhler, Annalen Chem. Pharm., 51, 145-163 (1844) 
[178] A. Jayasankar, A. Somwangthanaroj, Z. J. Shao and N. Rodríguez-Hornedo, 
Pharm. Res., 23, 2381-2392 (2006) 
[179] M. R. Caira, L. R. Nassimbeni and A. F. Wildervanck, J. Chem. Soc., Perkin 
Trans. 2, 2213-2216 (1995) 
[180] T. Friščič and W. Jones, Cryst. Growth Des., 9, 1621-1637 (2009) 
[181] R. P. Rastogi, P. S. Bassi and S. L. Chadha, J. Phys. Chem., 67, 2569-2573 
(1963) 
[182] R. P. Rastogi and N. B. Singh, J. Phys. Chem., 72, 4446-4449 (1968) 
[183] R. P. Rastogi and N. B. Singh, J. Phys. Chem., 70, 3315-3324 (1966) 
[184] N. Shan, F. Toda and W. Jones, Chem. Comm., 2372-2373 (2002) 
[185] T. Friščič and W. Jones, Farad. Discuss., 136, 167-178 (2007) 
[186] S. A. Myz, T. P. Shakhtshneider, K. Fucke, A. P. Fedotov, E. V. Boldyreva, V. 
V. Boldyrev and N. I. Kuleshova, Mendeleev Commun., 19, 272-274 (2009) 
[187] E. Y. Cheung, S. J. Kitchin, K. D. M. Harris, Y. Imai, N. Tajima and R. Kuroda, 
J. Am. Chem. Soc., 125, 14658-14659 (2003) 
[188] B. M. Kariuki, P. Calcagno, K. D. M. Harris, D. Philp and R. L. Johnston, 
Angew. Chem. Int. Ed., 38, 831-835 (1999) 
 150 
[189] Y. Yan, C. E. Hughes, B. M. Kariuki and K. D. M. Harris, Cryst. Growth Des., 
13, 27-30 (2013) 
[190] F. G. Vogt, J. S. Clawson, M. Strohmeier, A. J. Edwards, T. N. Pham and S. A. 
Watson, Cryst. Growth Des., 9, 921-937 (2009) 
[191] K. D. M. Harris, M. Tremayne and B. M. Kariuki, Angew. Chem. Int. Ed., 40, 
1626-1651 (2001) 
[192] W. I. F. David, K. Shankland and N. Shankland, Chem. Comm., 931-932 (1998) 
[193] C. Hammond, The Basics of Crystallography and Diffraction, Oxford University 
Press, Oxford, 2009. 
[194] A. L. Patterson, Phys. Rev., 46, 0372-0376 (1934) 
[195] D. Albesa-Jové, B. M. Kariuki, S. J. Kitchin, L. Grice, E. Y. Cheung and K. D. 
M. Harris, ChemPhysChem, 5, 414-418 (2004) 
[196] G. Sheldrick, Acta Cryst. A, 64, 112-122 (2008) 
[197] L. Farrugia, J. Appl. Cryst., 32, 837-838 (1999) 
[198] M. Tremayne, B. M. Kariuki and K. D. M. Harris, Angew. Chem. Int. Ed., 36, 
770-772 (1997) 
[199] K. D. M. Harris and M. Tremayne, Chem. Mater., 8, 2554-2570 (1996) 
[200] K. D. M. Harris and E. Y. Cheung, Chem. Soc. Rev., 33, 526-538 (2004) 
[201] K. D. M. Harris, R. L. Johnston and B. M. Kariuki, Acta Cryst. A, 54, 632-645 
(1998) 
[202] P. E. Werner, L. Eriksson and M. Westdahl, J. Appl. Cryst., 18, 367-370 (1985) 
[203] J. W. Visser, J. Appl. Cryst., 2, 89-95 (1969) 
[204] A. Boultif and D. Louër, J. Appl. Cryst., 24, 987-993 (1991) 
[205] R. A. Shirley, CRYSFIRE, Suite of Programs for Indexing Powder Diffraction 
Patterns, University of Surrey, 2002. 
[206] B. M. Kariuki, S. A. Belmonte, M. I. McMahon, R. L. Johnston, K. D. M. Harris 
and R. J. Nelmes, J. Synchrotron Radiat., 6, 87-92 (1999) 
[207] J. Laugier and B. Bochu, CHEKCELL: A Powder Indexing Suite, Software 
Performing Automatic Cell/Space Group Determination, Collaborative 
Computational Project Number 14 (CCP14), Laboratoire des Materiaux et du 
Genie Physique de l'Ecole Superieure de Physique de Grenoble, France, 2000 
[208] A. Le Bail, H. Duroy and J. L. Fourquet, Mat. Res. Bull., 23, 447- 452 (1988) 
[209] A. C. Larson and R. B. V. Dreele, Los Alamos National Laboratory Report 
LAUR, 86-748 (2004) 
[210] B. H. Toby, J. Appl. Cryst., 34, 210-213 (2001) 
[211] B. M. Kariuki, H. Serrano-González, R. L. Johnston and K. D. M. Harris, Chem. 
Phys. Lett., 280, 189-195 (1997) 
[212] S. Habershon, E. Y. Cheung, K. D. M. Harris and R. L. Johnston, Chem. Phys. 
Lett., 390, 394-398 (2004) 
[213] R. A. Young, The Rietveld Method, Oxford University Press, Oxford, 1993. 
 151 
[214] E. Y. Cheung, K. D. M. Harris and B. M. Foxman, Cryst. Growth Des., 3, 705-
710 (2003) 
[215] D. Giron, J. Therm. Anal. Cal., 68, 335-357 (2002) 
[216] D. C. Apperley, R. K. Harris and P. Hodgkinson, Solid-State NMR: Basic 
Principles and Practice, Momentum Press, New York, 2012. 
[217] J. S. Clawson, F. G. Vogt, J. Brum, J. Sisko, D. B. Patience, W. Dai, S. Sharpe, 
A. D. Jones, T. N. Pham, M. N. Johnson and R. C. P. Copley, Cryst. Growth 
Des., 8, 4120-4131 (2008) 
[218] G. M. J. Schmidt, Pure Appl. Chem., 27, 647-678 (1971) 
[219] J. C. Macdonald and G. M. Whitesides, Chem. Rev., 94, 2383-2420 (1994) 
[220] K. Biradha, CrystEngComm, 5, 374-384 (2003) 
[221] S. L. James, C. J. Adams, C. Bolm, D. Braga, P. Collier, T. Friscic, F. Grepioni, 
K. D. M. Harris, G. Hyett, W. Jones, A. Krebs, J. Mack, L. Maini, A. G. Orpen, I. 
P. Parkin, W. C. Shearouse, J. W. Steed and D. C. Waddell, Chem. Soc. Rev., 41, 
413-447 (2012) 
[222] T. Steiner, Acta Cryst. B, 57, 103-106 (2001) 
[223] A. Ballabh, D. R. Trivedi and P. Dastidar, Cryst. Growth Des., 5, 1545-1553 
(2005) 
[224] A. Ballabh, T. K. Adalder and P. Dastidar, Cryst. Growth Des., 8, 4144-4149 
(2008) 
[225] I. Goldberg and J. Bernstein, Chem. Comm., 132-134 (2007) 
[226] R. E. Melendez, C. V. K. Sharma, M. J. Zaworotko, C. Bauer and R. D. Rogers, 
Angew. Chem. Int. Ed., 35, 2213-2215 (1996) 
[227] D. J. Duchamp and R. E. Marsh, Acta Cryst. B, 25, 5-19 (1969) 
[228] C. V. K. Sharma, C. B. Bauer, R. D. Rogers and M. J. Zaworotko, Chem. Comm., 
1559-1560 (1997) 
[229] T. R. Shattock, P. Vishweshwar, Z. Q. Wang and M. J. Zaworotko, Cryst. 
Growth Des., 5, 2046-2049 (2005) 
[230] F. A. A. Paz and J. Klinowski, CrystEngComm, 5, 238-244 (2003) 
[231] O. M. Yaghi, G. M. Li and H. L. Li, Nature, 378, 703-706 (1995) 
[232] O. M. Yaghi, H. L. Li and T. L. Groy, J. Am. Chem. Soc., 118, 9096-9101 (1996) 
[233] D. P. Cheng, M. A. Khan and R. P. Houser, Inorg. Chem., 40, 6858-6859 (2001) 
[234] J. W. Steed, CrystEngComm, 5, 169-179 (2003) 
[235] K. M. Anderson, M. R. Probert, A. E. Goeta and J. W. Steed, CrystEngComm, 
13, 83-87 (2011) 
[236] K. M. Anderson, A. E. Goeta and J. W. Steed, Cryst. Growth Des., 8, 2517-2524 
(2008) 
[237] H. S. Shieh, L. G. Hoard and C. E. Nordman, Acta Cryst. B, 38, 2411-2419 
(1982) 
[238] D. A. Parrish, J. R. Deschamps, R. D. Gilardi and R. J. Butcher, Cryst. Growth 
Des., 8, 57-62 (2008) 
 152 
[239] A. S. Batsanov, J. C. Collings, R. M. Ward, A. E. Goeta, L. Porres, A. Beeby, J. 
A. K. Howard, J. W. Steed and T. B. Marder, CrystEngComm, 8, 622-628 (2006) 
[240] C. V. K. Sharma and M. J. Zaworotko, Chem. Comm., 2655-2656 (1996) 
[241] P. Vishweshwar, D. A. Beauchamp and M. J. Zaworotko, Cryst. Growth Des., 6, 
2429-2431 (2006) 
[242] F. H. Herbstein, M. Kapon and G. M. Reisner, J. Incl. Phenom. Macro. Chem., 5, 
211-214 (1987) 
[243] S. V. Kolotuchin, P. A. Thiessen, E. E. Fenlon, S. R. Wilson, C. J. Loweth and S. 
C. Zimmerman, Chem. Eur. J., 5, 2537-2547 (1999) 
[244] O. Ermer and J. Neudorfl, Helv. Chim. Acta, 84, 1268-1313 (2001) 
[245] S. Bhattacharya and B. K. Saha, Cryst. Growth Des., 11, 2194-2204 (2011) 
[246] D. J. Duchamp and R. E. Marsh, Acta Cryst. B, B 25, 5-19 (1969) 
[247] S. H. Dale, M. R. J. Elsegood and S. J. Richards, Chem. Comm., 1278-1279 
(2004) 
[248] R. Santra, N. Ghosh and K. Biradha, New J. Chem., 32, 1673-1676 (2008) 
[249] D. J. Plaut, K. M. Lund and M. D. Ward, Chem. Comm., 769-770 (2000) 
[250] C. H. Gorbitz and H. P. Hersleth, Acta Cryst. B, 56, 526-534 (2000) 
[251] H. D. Clarke, K. K. Arora, H. Bass, P. Kavuru, T. T. Ong, T. Pujari, L. Wojtas 
and M. J. Zaworotko, Cryst. Growth Des., 10, 2152-2167 (2010) 
[252] L. Infantes, J. Chisholm and S. Motherwell, CrystEngComm, 5, 480-486 (2003) 
[253] G. Bhagavannarayana, B. Riscob and M. Shakir, Mater. Chem. Phys., 126, 20-23 
(2011) 
[254] M. Prakash, D. Geetha and M. L. Caroline, Physica B, 406, 2621-2625 (2011) 
[255] X. Dong, J. Minhua and T. Zhongke, Acta Chim. Sinica, 41, 570-573 (1983) 
[256] R. Ittyachan, P. Sagayaraj and B. Kothandapani, Acta Cryst. E, 59, o886-o888 
(2003) 
[257] S. B. Monaco, L. E. Davis, S. P. Velsko, F. T. Wang, D. Eimerl and A. Zalkin, J. 
Cryst. Growth, 85, 252-255 (1987) 
[258] D. Xu, X. Q. Wang, W. T. Yu, S. X. Xu and G. H. Zhang, J. Cryst. Growth, 253, 
481-487 (2003) 
[259] Z. H. Sun, W. M. Sun, C. T. Chen, G. H. Zhang, X. Q. Wang and D. Xu, 
Spectrochim. Acta A, 83, 39-45 (2011) 
[260] M. R. Silva, J. A. Paixao, A. M. Beja and L. A. da Veiga, J. Chem. Cryst., 30, 
411-414 (2000) 
[261] S. Roy, D. D. Singh and M. Vijayan, Acta Cryst. B, 61, 89-95 (2005) 
[262] M. Selvaraj, S. T. S. Roy and M. Vijayan, Acta Cryst. B, 63, 459-468 (2007) 
[263] S. Ahn, F. Guo, B. M. Kariuki and K. D. M. Harris, J. Am. Chem. Soc., 128, 
8441-8452 (2006) 
[264] Z. Pan, M. Xu, E. Y. Cheung, J. A. Platts, K. D. M. Harris, E. C. Constable and 
C. E. Housecroft, J. Solid State Chem., 179, 3214-3223 (2006) 
 153 
[265] Z. G. Pan, M. C. Xu, E. Y. Cheung, K. D. M. Harris, E. C. Constable and C. E. 
Housecroft, J. Phys. Chem. B, 110, 11620-11623 (2006) 
[266] E. Courvoisier, P. A. Williams, G. K. Lim, C. E. Hughes and K. D. M. Harris, 
Chem. Comm., 48, 2761-2763 (2012) 
[267] P. A. Williams, C. E. Hughes, G. K. Lim, B. M. Kariuki and K. D. M. Harris, 
Cryst. Growth Des., 12, 3104-3113 (2012) 
[268] D. A. Jove, E. Tedesco, K. D. M. Harris, R. L. Johnston and E. Y. Cheung, Cryst. 
Growth Des., 1, 425-428 (2001) 
[269] T. Ogoshi, S. Kanai, S. Fujinami, T. Yamagishi and Y. Nakamoto, J. Am. Chem. 
Soc., 130, 5022-5023 (2008) 
[270] Y. Chen, H. Q. Tao, Y. H. Kou, H. Meier, J. L. Fu and D. R. Cao, Chin. Chem. 
Lett., 23, 509-511 (2012) 
[271] D. Cao, Y. Kou, J. Liang, Z. Chen, L. Wang and H. Meier, Angew. Chem. Int. 
Ed., 48, 9721-9723 (2009) 
[272] X. Hu, Z. Chen, L. Chen, L. Zhang, J. Hou and Z. Li, Chem. Comm., 48, 10999-
11001 (2012) 
[273] T. Ogoshi and T. Yamagishi, Eur. J. Org. Chem., 2961-2975 (2013) 
[274] W. Si, X.-B. Hu, X.-H. Liu, R. Fan, Z. Chen, L. Weng and J.-L. Hou, Tet. Lett., 
52, 2484-2487 (2011) 
[275] T. Ogoshi, R. Shiga, M. Hashizume and T. Yamagishi, Chem. Comm., 47, 6927-
6929 (2011) 
[276] T. Ogoshi, R. Shiga, T. Yamagishi and Y. Nakamoto, J. Org. Chem., 76, 618-
622 (2011) 
[277] M. Pan and M. Xue, Eur. J. Org. Chem., 4787-4793 (2013) 
[278] C. Han, Z. Zhang, G. Yu and F. Huang, Chem. Comm., 48, 9876-9878 (2012) 
[279] M. Pan and M. Xue, Chin. J. Chem., 32, 128-132 (2014) 
[280] L. Wu, Y. Fang, Y. Jia, Y. Yang, J. Liao, N. Liu, X. Yang, W. Feng, J. Ming and 
L. Yuan, Dalton Trans., 43, 3835-3838 (2014) 
[281] M. Pan and M. Xue, RSC Adv., 3, 20287-20290 (2013) 
[282] Y. Fang, L. Wu, J. Liao, L. Chen, Y. Yang, N. Liu, L. He, S. Zou, W. Feng and 
L. Yuan, RSC Adv., 3, 12376-12383 (2013) 
[283] M. P. Sonawane, J. Jacobs, J. Thomas, L. Van Meervelt and W. Dehaen, Chem. 
Comm., 49, 6310-6312 (2013) 
[284] K. Lao and C. Yu, J. Comp. Chem., 32, 2716-2726 (2011) 
[285] H. T. Chifotides and K. R. Dunbar, Acc. Chem. Res., 46, 894-906 (2013) 
[286] D. Quinonero, C. Garau, C. Rotger, A. Frontera, P. Ballester, A. Costa and P. M. 
Deya, Angew. Chem. Int. Ed., 41, 3389-3392 (2002) 
[287] B. L. Schottel, H. T. Chifotides and K. R. Dunbar, Chem. Soc. Rev., 37, 68-83 
(2008) 
[288] P. Gamez, Inorg. Chem. Front., 1, 35-43 (2014) 
[289] D.-X. Wang and M.-X. Wang, J. Am. Chem. Soc., 135, 892-897 (2013) 
 154 
[290] A. Frontera, P. Gamez, M. Mascal, T. J. Mooibroek and J. Reedijk, Angew. 
Chem. Int. Ed., 50, 9564-9583 (2011) 
[291] T. Heinis, S. Chowdhury, S. L. Scott and P. Kebarle, J. Am. Chem. Soc., 110, 
400-407 (1988) 
[292] J. Schiedt and R. Weinkauf, J. Chem. Phys., 110, 304-314 (1999) 
 
